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SUMMARY.
Beta-adrenoceptor blockade has become an 
established method of treating both angina pectoris and 
hypertension. Among the beta-adrenoceptor antagonists 
available, are several with distinct pharmacological 
properties including cardioselectivity, membrane 
stabilising activity and intrinsic sympathomimetic or 
partial agonist activity. This thesis is concerned with 
the clinical evaluation of the latter property in the 
long-term treatment of chronic stable angina pectoris. 
Several reports have suggested that beta blockers with 
with this property confer certain advantages over pure 
beta blockers, but their long-term effects in chronic 
angina pectoris have not been clearly demonstrated.
There are five main objectives to this thesis:
1. To determine the effect of pure beta blockers 
on left ventricular function during long-term 
treatment of angina pectoris and the influence 
of ISA.
2. To assess the long-term effect of beta blockers 
and the influence of ISA on the plasma lipo­
protein profile.
3. To establish the efficacy of beta blockers 
with ISA in suppressing symptomatic and 
asymptomatic episodes of myocardial ischaemia
in chronic stable effort angina pectoris, in 
comparison to a ’p u r e ’ beta blocker.
4. To determine the effect of pure beta blockade 
on respiratory function during long-term 
treatment of angina pectoris in comparison to 
a beta blocker with ISA.
5. To assess the value of radionuclide ventricu­
lography in the detection of coronary artery 
disease in our laboratory and the role of 
cold pressor stress and isometric handgrip 
exercise. In these investigations, propranolol 
was used as a pure beta blocker, pindolol was 
used as a prototype of a beta blocker 
possessing ISA.
From the studies contained in this thesis I have 
obtained the following results and conclusions:
1. Despite the demonstration of improved or
sustained left ventricular function obtained 
with beta blockers possessing ISA, after single 
dose oral or intravenous administration, I 
failed to find any advantages using pindolol in 
chronic stable angina pectoris, when compared 
to propranolol. This conclusion is derived 
from the results of serial radionuclide 
ventriculography carried out at intervals 
during the course of a y e a r ’s treatment with
both drugs in a controlled study. Left 
ventricular function at rest failed to improve 
in those taking pindolol, but significantly 
improved in those taking propranolol. This 
observation held for those with subnormal basal 
left ventricular performance in whom one might 
expect a beta blocker with ISA to have the 
greatest effect. However the results of this 
thesis do not disprove the potential of drugs 
with ISA to protect or improve left ventricular 
performance in patients with severely compromised 
left ventricular function as this group was not 
included in my investigation. It is concluded 
that ISA is an unhelpful property in terms of 
left ventricular function during chronic therapy 
of stable angina pectoris, in patients with 
normal or moderately compromised left ventricular 
function. It should be pointed out that the 
beneficial changes in left ventricular function 
observed in those taking propranolol were within 
the variability (5%) of the technique used. This 
may be partially offset by the fact that the 
study was controlled, statistical analysis was by 
2-way analysis of variance and the variability of 
the technique was calculated using results from 
normal volunteers who are known to have greater 
variability of left ventricular performance.
A review of the literature shows little 
consistency in the plasma lipoprotein changes
in response to beta blockers. The most 
frequent changes noted by other investigators 
have been an elevation of total triglyceride 
with pure beta blockers and a fall in total 
high density lipoprotein. In comparing the 
effect of pindolol and propranolol in patients 
with chronic stable angina pectoris I found 
no significant change in total triglycerides 
with either drug and observed small falls in 
total HDL with both drugs although this was 
only significant for propranolol. Conversely 
H D L 2 , which has been shown to have a more 
strongly negative correlation with coronary 
artery disease rose with both drugs, but this 
was only significant in those treated with 
propranolol after 52 weeks treatment. For 
those 'with initially elevated total cholesterol, 
pindolol caused a significant reduction through­
out treatment, but this did not occur with 
propranolol.
Although pindolol was associated with more 
symptomatic and asymptomatic episodes of ST- 
segment depression than propranolol there was no 
significant difference between the two drugs. 
Propranolol resulted in a significantly lower 
heart rate, but was associated with a 
significantly higher hourly frequency of 
ventricular premature contractions. Thus, no 
significant difference could be demonstrated
in the efficacy of both drugs in suppressing 
myocardial ischaemia, although there was a 
trend in favour of propranolol.
4. Patients taking propranolol developed 
significantly increased airways obstruction 
throughout treatment and although this also 
occurred with pindolol, it was significantly 
less than that experienced with propranolol. 
These results suggest that deteriorating 
respiratory function was maintained through­
out treatment with propranolol, and pindolol 
conferred protection against this effect.
5. Radionuclide ventriculography is a reproducible
technique in our laboratory with cold pressor
stress and isometric handgrip exercise proving 
to be useful, easily applied and reproducible 
interventions when comparative assessments are 
being made within the individual. However, 
when used to enhance the ability of radio­
nuclide ventriculography to detect coronary 
artery disease they were insufficiently 
sensitive, although may be of use when the 
subject is incapable of dynamic exercise.
Thus, the long-term effects of beta blockers with 
and without ISA in patients with chronic stable angina 
pectoris differ from those observed in short-term studies. 
Although ISA has been shown to be a useful property in
many respects, some of the anticipated advantages could 
not be demonstrated by these experiments.
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1.1. PLAN AND AIM OF THESIS.
The studies which form the basis of this thesis 
were performed over the course of two and a half years 
from May 1982 until October 1984, during the tenure of my 
post of Research Fellow inCardiology at the Victoria 
Infirmary, Glasgow.
The main object has been to establish the clinical 
importance of intrinsic sympathomimetic activity possessed 
by beta blockers during the treatment of chronic stable 
angina pectoris. Despite their widespread use, the long­
term clinical effects of beta blockers with and without 
ISA are poorly documented. Thus, I have investigated 
the influence of beta blockers with and without this 
property on left ventricular performance, plasma lipo­
proteins, symptomatic and asymptomatic myocardial 
ischaemia, respiratory function and adverse effects.
In addition, the experiments involved presented an 
opportunity to evaluate the role of radionuclide ventricu­
lography in the detection of coronary artery disease, and 
an assessment of cold pressor stress and isometric hand­
grip exercise used in conjunction with this technique.
This thesis consists of eight sections of which 
Section 1 is the introduction. Sections 2-7 comprise 
the investigations conducted by the author and Section 8 
contains the final commentary and references. Where 
necessary each section has been divided into subsections 
covering particular topics or experiments. Each table or
figure is described by a section number and a number 
corresponding to i t ’s appearance in that section.
In the first section I have developed the concept 
of beta-adrenoceptor blockade and intrinsic sympathomimetic 
activity. In this introduction I have attempted to 
describe the current understanding of ISA and the known 
clinical effects and adverse reactions of beta blockers 
with this property in as brief a review as is commensurate 
with an understanding of the main topics of this thesis. 
This section lays the foundation for the following 
experiments and attempts to pinpoint important gaps in our 
knowledge of the clinical effects of these agents.
Section 2 describes briefly how patients with 
chronic stable angina were recruited for the experiments 
to follow and includes an assessment of patient compliance 
with the beta blockers used in each experiment and their 
adverse -reactions.
Sections 3 and 4 contain the results of investi­
gations using radionuclide ventriculography to determine 
left ventricular function. Section 3 investigates the 
role of ISA in the long-term treatment of chronic stable 
angina with beta blockers and Section 4 evaluates the 
reproducibility of radionuclide ventriculography in our 
laboratory and its use in the detection of coronary artery 
disease. In addition, the cardiovascular effects and 
application of cold pressor stress and isometric handgrip 
exercise are explored. All of the measurements of heart
rate and blood pressure in this thesis necessitated the 
use of a semi-automatic recorder, and the Hitachi HME-20 
pulse and blood pressure monitor was chosen for this 
purpose and it's evaluation is contained in Section 4.
Section 5 contains the results from a long-term 
investigation into the effects of pure beta blockers and 
one with ISA on plasma lipoproteins and contains an 
extensive review of the current literature.
The study contained in Section 6 was designed to 
evaluate the effect of beta blockers with and without ISA 
on the frequency of symptomatic and asymptomatic myocardial 
ischaemia in chronic stable angina pectoris and their 
effect on heart rate and rhythm. This was carried out 
using ambulatory ECG recorders designed for the purpose.
One of the long established concerns when using beta 
blockers is their effect on respiratory function. There 
is considerable evidence of increased airway narrowing 
following their administration. In Section 7, this is 
investigated with particular reference to the possible 
influence of ISA which may aleviate this effect.
In the final section (Section 8), I have attempted 
to construct a concise resume of my findings and place 
them in perspective to previous knowledge.
1.2. INTRODUCTION.
Beta-adrenoceptor blockade has become one of the 
mainstays in the therapy of ischaemic heart disease and 
hypertension in the last 15 years, and established use 
has clarified the efficacy and adverse effects of beta 
blockers. Despite this a number of misunderstandings 
regarding their properties have developed. Beta- 
adrenoceptor blockers or beta blockers can be classified 
according to their lipid solubility, cardioselectivity, 
possession of membrane stabilising activity (MSA) or 
intrinsic sympathomimetic activity (ISA) sometimes 
referred to as partial agonist activity. This thesis 
concerns this latter property and its possible clinical 
effects.
Several beta-adrenoceptors currently available 
exhibit ISA. These include pindolol, oxprenolol, 
acebutalol and alprenolol. As pindolol exerts the most 
potent "ISA effect", most of the current literature 
concerning ISA refers to this drug. In this introduction 
I have reviewed the current knowledge of beta blockade 
and ISA with special reference to pindolol.
The first beta blocker to be investigated in man - 
dichloroisoprenoline - was found to produce cardiac 
stimulation (1) causing a marked tachycardia (2). This 
effect was initially attributed, to stimulation of beta- 
adr enoceptor s and was termed ISA (3). Although this
early beta blocker was unsuitable for clinical use, beta 
blockers with less potent ISA were later introduced which 
did produce effective beta blockade, such as pindolol and 
oxprenolol (4).
The importance of ISA is controversial and has 
resulted in considerable debate in recent years (5,6). 
There is no contention regarding the pharmacological 
definition or physiological potential of this property - 
but it is still not universally accepted as being of 
clinical value. However, the theoretical possibilities 
are now supported by evidence suggesting that ISA may 
have important therapeutic implications.
Although it is possible that ISA could diminish 
the clinical efficacy of beta blockade (7), pindolol 
appears to be as effective as beta blockers without ISA 
in the treatment of angina (4,8,9), hypertension (4,10) 
and arrhythmias (11-13) and may be of particular use in 
patients with compromised myocardial function (8,14).
1.3. PURE BETA ADRENOCEPTOR BLOCKADE.
The sympathetic nervous system and circulating 
catecholamines exert their effects through receptors on 
the effector cell surface. These receptors can be 
divided into alpha-adrenoceptors and beta-adrenoceptors. 
Stimulation of alpha-adrenoceptors in the cardiovascular 
system leads to vasoconstriction, whereas stimulation of 
the beta receptors results in an increase in heart rate, 
atrio-ventricular conduction, myocardial contractility 
and peripheral vascular dilatation. Beta-adrenoceptor 
blockers were developed with the intention of attenuating 
the direct effects of sympathetic stimulation on the 
heart, particularly in the patient with ischaemic heart 
disease.
What is beta-adrenoceptor blockade? The beta- 
adrenoceptor is a localised region of the cell membrane 
which is sensitive to the effects of catecholamines.
This region has the ability to combine reversibly with 
extracellular catecholamines. Such a reaction triggers 
a complex series of intracellular events resulting in 
the characteristic response of the parent cell. The 
receptor region is accepted as being part of a macro- 
molecular complex which is able to interact specifically 
with catecholamines, or their analogues, to effect a 
response.
The molecular structure of Isoprenaline allows 
for its attachment at all major sites of a beta- 
adrenoceptor effecting maximum stimulation of the parent 
cell. Three components of the Isoprenaline molecule 
(Figure 1.1a) are important for its combination with the 
receptor (15). Modification of one of these sites of 
attachment results in a structure which is not optimal for 
occupation of the receptor, and thus activation of the 
receptor is slow and inefficient - in addition, the access 
of endogenous catecholamines is prevented, and therefore 
the beta-adrenoceptor has been blocked (competitive 
antag onism). Such an effect is schematically represented 
in Figure 1.1b which shows the combination of propranolol 
with the beta-adrenoceptor. Thus, beta blockers can be 
defined as chemical substances which specifically and 
competitively block the effects of catecholamines, and are 
structural modifications of the beta-adrenoceptor 
stimulant, isoprenaline. A pure beta blocker, like 
Propranolol, posesses an isoprenaline like side chain with 
an alternative aromatic nucleus (Figure 1.1b), and will 
compete with the endogenous agonist for the receptor site.
Beta-adrenoceptors occur in blood vessels, the 
heart, brain, kidneys, parts of the eye, lungs, uterus and 
insulin secreting cells of the pancreas and can be divided 
into Beta i or B e t a 2 receptors according to the proposal by 
Lands in 1967 (16). The distribution of beta adrenoceptors 
is represented in Table 1.1. Although the heart contains 
predominantly Beta i receptors, it also contains some Beta 2 
adrenoceptors. Therefore selectivity is not absolute.
ISOPRENALINE
Bonds formed rapidly, 
but are easily broken
Activity site Attachment site
PROPRANOLOL
PINDOLOL
HO
FIGURE 1.1
Schematic representation of the major points of .attachment 
for a pure agonist (a. Isoprenaline), a pure antagnoist 
(b. Propranolol) and a partial agonist (c. P i n d olol), to 
a beta—adrenoceptor site on a cell membrane. Such a 
combination of.receptor and agonist/antagonist is said 
to take place in ’stereo-specific fashion'.
TABLE 1.1 CLASSIFICATION OF TISSUE BETA ADRENOCEPTOR
TISSUE PREDOMINANT
Heart Bi
Lung B 2
Peripheral Blood Vessel B 2
Central Nervous System B 1B 2
Uterus B 2
Metabolic Receptors B 2
Some beta blockers have been developed which have a 
relative affinity for Betaj receptors more than B e t a 2 
receptors and these beta blockers have been termed 
CARDIOSELECTIVE. However, there is considerable evidence 
that the cardioselectivity of drugs such as practolol, 
atenolol or metoprolol is only a relative phenomena and 
may be lost or diminished with increasing dosage.(17)
1.4. BETA ADRENOCEPTOR BLOCKERS WITH INTRINSIC
SYMPATHOMIMETIC ACTIVITY.
Beta blockers can be classified according to three 
main pharmacological properties, one of these; cardio- 
selectivity, has already been discussed. The other 
properties are membrane stabilising action and intrinsic 
sympathomimetic activity. ISA beta blockers have a 
molecular structure similar to Isoprenaline, but not 
entirely optimal for full stimulation (Figure 1.1c). 
Nevertheless, partial stimulation does occur simultaneously 
with beta blockade, as endogenous catecholamines are denied 
access to the receptor sites. ISA beta blockers therefore 
act as competitive antagonists in the same manner as other 
beta blockers (18), but are capable of sub-optimal 
stimulation of the receptors (Figure 1.2). (15) The potential 
for partial stimulation can be altered by restructuring 
the molecular configuration of the antagonist.
Dichloroisoprenaline, the first beta blocker developed, 
had potent ISA and tended to increase resting heart rate 
and was not suitable for clinical use. (2) Of the beta 
blockers with ISA currently available pindolol has the 
most potent ISA, but does not have the pharmacological 
potency of adrenalin or isoprenaline. (7,15) Pindolol has 
up to 50% of the agonist activity of isoprenaline in 
laboratory animals, but this is probably an exagerated 
response when compared to humans. The relative ISA of the 
commercially available beta blockers is shown in Table 1.2.
It may be expected that any benefits which the property
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TABLE 1.2 RELATIVE DEGREE OF INTRINSIC SYMPATHOMIMETIC
ACTIVITY OF SEVERAL FREQUENTLY USED BETA 
ADRENOCEPTOR BLOCKING DRUGS.
DRUG RELATIVE DEGREE
OF ISA
Pindolol ++
Oxprenolol +
Alprenolol +
Acebutalol +
Practolol +
Propranolol 0
Timolol 0
Metoprolol 0
Atenolol 0
Nadolol 0
Sotalol 0
Labetalol 0
may acrue should be demonstrable with pindolol rather than 
those with weaker ISA.
The ISA of pindolol has been appreciated for many 
years and was investigated by Hill and Turner in 1969 who 
reported that in a dosage producing the same reduction in 
exercise induced tachycardia pindolol reduced heart rate 
to a lesser extent than did propranolol. (19) The degree 
of ISA in the individual beta blocker can be demonstrated 
in animals depleted of endogenous catecholamines by 
syrosingopine and adrenalectomy to abolish sympathetic 
activity. (20) In this situation, administration of 
propranolol will not affect heart rate as no endogenous 
catecholamines are present which can be "blocked".
Pindolol, however, increases resting heart rate because of 
its partial agonist effect. (21) Such demonstration of 
ISA in man is not possible, although in the intact human, 
Hill (19) and Svendson (22) have demonstrated a smaller 
reduction in resting heart rate compared with other beta 
blockers.
It has been argued that ISA reduces or dilutes the 
beta blocking capability of a drug, but this is not 
correct. As these drugs also act as beta blockers they 
can be expected to protect the heart from the deleterious 
effects of excessive adrenergic stimulation during 
exercise or emotional stress by decreasing myocardial 
oxygen requirements at any given level of activity. (4)
They will also block catecholamine induced increments in 
heart rate and the velocity and extent of myocardial
contraction. However, because of ISA the d r u g s 1 effect is 
most evident at times of low sympathetic drive eg. at rest 
or during sleep, whereas during periods of high 
sympathetic drive eg. during exercise or emotional stress, 
the effect of ISA is more difficult to discern. The 
inotropic action of these drugs is so weak that the nett 
result in man is to prevent the extreme effects of beta 
blockade, rather than to produce positive inotropic 
effects.
Theoretically, beta blockers with ISA would be 
expected to cause a smaller negative chronotropic and 
inotropic effect and reduce the tendency of the beta 
blocker to induce peripheral vasoconstriction and 
bronchoconstriction. However, beta blockers with ISA have 
different quantitative influences in different organs - 
the effects being greater in vascular smooth muscle than 
in cardiac or bronchial muscle. This may be due to 
variations in the number of beta-adrenoceptors available- 
for stimulation or distribution of beta-adrenoceptor 
subtypes in different tissues. In addition, because of 
constantly varying sympathetic activity it is extremely 
difficult to measure the effects of ISA in man. Thus, 
although the theoretical advantages or influences of ISA 
can be readily demonstrated in isolated tissues, or in the 
experimental animal, the clinical influence in man is a 
subject of debate. (5,6)
Possible Advantages of ISA Beta Blockers a r e :
1. Stimulation of the sinus node and atrio­
ventricular conduction during periods of low
sympathetic activity, thereby reducing the
liklihood of bradycardia and heart block 
during beta blockade, especially in the 
elderly.
2. Direct stimulation of contractile elements of 
the myocardium, and reduction in cardiac 
afterload because of vasodilation - resulting 
in a lesser reduction in myocardial 
contractility induced by beta blockade 
especially in the compromised heart.
3. Stimulation of Beta 2 bronchodilator receptors
offsetting some of the bronchoconstrictor 
effects of beta blockade.
4. Less tendency to develop peripheral vascular 
constriction through unopposed Alphai 
stimulation by partial stimulation of the Beta 
vasodilating adrenoceptors.
The overall effect is a probable increase in 
exercise capacity during beta blockade with a drug 
possessing ISA.
Membrane Stabilising Activity.
Although MSA is not a property covered in detail 
in this Thesis it is appropriate to distinguish this 
property from ISA. MSA will decrease the rate of rise and 
magnitude of the cardiac intracellular action potential 
and will prolong the refractory period of the myocardial 
cells. (23) Although both propranolol and pindolol (with 
ISA) exert weak MSA (24,25), this property is only 
apparent at doses far in excess of those necessary for 
beta blockade (26,27) and is probably of no therapeutic 
rel evance.
1.5. PINDOLOL: PHARMACODYNAMICS AND PHARMACOKINETICS.
Structure.
P indolol’s molecular structure differs from 
propranolol by the substitution of an indole for a benzene 
ring in the aromatic nucleus of the molecule (Figure 1.3), 
which is capable of reacting with the beta receptor, unlike 
the benzene ring which is biologically inert.
Pharmacokinetics.
Pindolol is rapidly and almost completely absorbed 
(95%) after oral ingestion and absorption is not influenced 
by the presence of food. (28,29) The drug is detectable 
in plasma within 30 minutes following ingestion, and peak 
levels are recorded between 1-2 hours post ingestion. 
(28,29) First pass metabolism by the liver is low with 
an oral bio-availability of approximately 90%. (28,29)
An increase in oral daily dosage of pindolol results in a 
proportional increase in concentration of the drug within 
the body (linear pharmacokinetics). (28,29) Although oral 
bioavailability is good, plasma drug concentrations may 
vary by as much as four fold after a single oral dose. 
(28-30) However, after multiple doses this falls to two 
fold. (29) The cause for this is not known although it 
has been suggested that it may be due to interindividual 
differences in the volume of distribution of the drug. 
Pindolol is only 40% bound to plasma proteins which is
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less than with other beta-blockers (28) and this may 
account for a relatively high level of beta blockade at 
comparatively low total plasma concentrations. It's 
volume of distribution in healthy subjects is about 2 
litres per kilogram of body weight. (28) An identical 
drug concentration does not guarantee an identical beta 
blocker response in different individuals. However, if 
the interindividual plasma drug concentration is the same, 
differences in degree of beta blockade will vary by only 
2-3 fold. Thus, like all beta blockers, plasma levels 
offer little as regards a therapeutic guide although they 
can be useful when assessing patient compliance. (7)
Plasma concentrations required to produce therapeutic 
beta blockade vary substantially between individuals (30) 
and therefore manipulation of the dose may be necessary 
for optimal beta blockade, although this need not present 
a greater problem with pindolol because of it's relatively 
low first pass hepatic metabolism when compared to other 
beta blockers (28,31), and consequent good bioavailability.
The drug is relatively lipophilic and as such, is 
able to cross the blood brain barrier and enter the central 
nervous system. It also crosses the placenta and is 
excreted in human milk.
Following oral administration the plasma 
concentration of pindolol declines monoexponentially in 
the normal subject, with a plasma half-life of 3-4 hours 
(29), although this can increase to about 7 hours in the 
elderly patient. (29) Despite a relatively short half-life
(similar to other beta blockers), the beta blocking effect 
persists for up to 9 hours, which can be demonstrated by a 
prevention of exercise induced tachycardia until this time. 
Approximately 60% of an oral dose is ultimately metabolised 
by the liver, with the remainder being eliminated unchanged 
in the urine. (28,29)
D o s a g e .
Previous work has confirmed adequate beta blockade 
with 15 mgs. pindolol per day - no haemodynamic benefit 
being observed with higher doses. (32) This implies that 
Pindolol is more potent per mg. than propranolol (by as 
much as 6-8 times) and this can be confirmed by comparing 
the ability of both drugs to inhibit isoprenaline induced 
tachycardia. (7) This difference in potency cannot be 
explained by differences in the side chain of the molecular 
structure - this being identical to propranolol (Figure 1.3), 
and is more likely to be the consequence of a lower 
percentage of the drug bound to plasma proteins (33) and 
superior bioavailability.
Unlike the relative cardioselectvity of alternative 
beta blockers such as atenolol or metoprolol, which is 
attenuated at high therapeutic doses (7,34,35), the ISA is 
not lost when higher doses are administered. (36) However, 
this activity occurs with low doses and has a flat dose 
response curve confirmed by studying the effect of the 
drug on resting heart rate throughout a wide range of 
therapeutic doses. (36,37) In common with other beta
blockers drug tolerance does not appear to develop with 
longterm use, this applying to both the beta blocking and 
ISA effect. (10,38)
Thus the pharmacodynamics and pharmacokinetics of 
pindolol are favourable in comparison to other beta 
blockers although it would appear that pindolol requires 
to be administered in a twice or thrice daily dose which 
may detract from i t ’s patient acceptability in comparison 
to other beta blockers such as atenolol which can be given 
in a single daily dose.
1.6. CONFIRMING THE PRESENCE OF INTRINSIC SYMPATHOMIMETIC
ACTIVITY.
Animal Studies.
Qualitative and quantitative demonstration of ISA 
can be performed in the animal model in whom the effect of 
reflex sympathetic nervous stimulation and the effects of 
endogenous catecholamines are abolished. This can be 
achieved by adrenalectomy, vagotomy and pretreatment with 
reserpine or syringoserpine. (20,39) In this situation 
there is an increase in heart'rate when a beta blocker with 
ISA is administered, but no change when a pure beta blocker 
is given (40) (Figure 1.4). As the increase in heart rate 
observed with the ISA blocker can be antagonised by 
propranolol, such an effect must be mediated through beta 
receptor stimulation. A similar change is observed in the 
contractile force of isolated strips of heart muscle (4), 
demonstrating a positive inotropic effect. Although these 
changes are observed in this artificial setting, it may not 
be appropriate to extrapolate to the intact organism.
Human Stud ies.
The demonstration of ISA in man is 
necessarily indirect. The effect of pindolol on 
heart rate in man has been shown to be dependant on the 
initial level of sympathetic activity. (41) For example, 
in a study examining the effect of pindolol on heart rate,
Heart rate 
A beats /m in
80
iso
60H
40H
pindolol
oxprenolol
20 H
practolol
alprenoloi
o-J
-log M
FIGURE 1.4
Positive chronotropic effect of 4 beta blocking drugs 
with partial agonist activity in the isolated right 
atrium of the cat.
(Reprinted from Kaumann and Blinks (40).)
iso = isoprenaline.
in 7,000 hypertensives, (42) the subjects who exhibited 
initial resting heart rates of over 90 beats per minute 
(bpm) responded with a significant reduction in heart 
rate when given pindolol. However, those with heart rates 
in the region of 70-90 bpm had little change in heart 
rate and those with rates less than 70 bpm responded 
with an increase in heart rate. Overall, drugs possessing 
ISA cause a smaller reduction in resting heart rate than 
beta blockers without ISA (8,10,43), however, tachycardia 
induced by exercise (8,10), or Isoprenaline, is attenuated 
to a similar extent by all beta blockers. Thus, the 
greatest influence of ISA occurs when sympathetic tone is 
low, and will therefore be appreciated only in resting 
subjects. This effectively alters the circadian rhythm of 
heart rate, such that profound reduction in heart rate 
during sleep is countered by ISA while peaks during 
exercise or emotional stress (high sympathetic tone) are 
attenuated (44) (Figure 1.5). The effect of ISA will 
predominate over the beta blocking effect at times of 
low sympathetic activity and visa versa when sympathetic 
activity is high.
Thus, although beta blockers with ISA can be shown 
indirectly to influence changes in heart rate in a unique 
way when compared to other beta blockers, the clinical 
relevance is debatable and will now be discussed.
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1.7. HAEMODYNAMIC EFFECTS OF BETA BLOCKERS -
WITH AND WITHOUT I S A .
The effect of beta blockers on cardiovascular 
haemodynamics has been investigated in a number of 
situations.
Beta blockers are known to diminish heart rate and 
to reduce the positive inotropic effects of sympathetic 
activity, this leads to a reduction in left ventricular 
contractility and consequently a fall in cardiac output. 
These effects are aggravated by an increase in left 
ventricular afterload which is caused by blockade of the 
peripheral vasodilator beta2 receptors with resultant 
vasoconstriction and indirect reflex vasoconstriction 
secondary to the reduction in left ventricular 
contractility.
Theoretically it would be expected that a beta 
blocker possessing significant ISA would offset these 
effects by providing direct positive inotropic stimulation, 
causing a smaller reduction in heart rate and by 
stimulating peripheral vasodilator B e t a 2 receptors thereby 
reducing the rise in left ventricular afterload caused by 
pure beta blockade.
In a comparison of pindolol, atenolol and 
propranolol on haemodynamics of dogs, Clark (45), 
administered each drug followed by a dose of isopren a l i n e ,
to assess the degree of beta blockade. The beta blockers 
lacking ISA produced significant reductions in cardiac 
output whereas pindolol produced small increases.
Changes in total peripheral resistance occuring in response 
to each drug were inversely proportional to the changes in 
cardiac output, since blood pressure remained constant.
These results have been confirmed in healthy human 
volunteers and in patients with ischaemic heart disease.(22)
Using intravenous administration in patients with 
ischaemic heart disease, Svendson (46) found that the 
reduction in cardiac output was attenuated by beta blockers 
with ISA. For example, cardiac output was reduced by 
26-28% by propanolol and atenolol, 12-17% by practolol 
(moderate ISA) and was not altered by pindolol. In another 
short-term intravenous study the effects of four beta 
blockers were compared in subjects with severe coronary 
artery disease - all four drugs caused a reduction in 
cardiac output, but oxprenolol and practolol (with ISA) 
produced significantly less depression than propranolol or 
metoprolol. However, in a longer term study over 7 weeks 
comparing oxprenolol and propranolol in hypertensive 
subjects, Franciosa (47) could not demonstrate any 
significant difference in haemodynamic parameters between 
both drugs. It may be that if a drug with a greater 
potency of ISA were used in long-term studies a more 
attractive haemodynamic profile would be found when 
compared with beta blockers without ISA. In this respect, 
Man in't Veld et al (48,49), investigated the effects of 
chronic oral therapy with pindolol in patients severely
disabled by orthostatic hypotension and confirmed that 
heart rate, stroke volume, cardiac output and mean arterial 
pressure were increased by pindolol.
Systemic vascular resistance has been shown to 
fall to a greater extent after treatment with oxprenolol 
or pindolol (with ISA) when compared to propranolol in 
numerous studies in patients with CAD (50,51) and 
hypertension. (52) In general, beta blockers without ISA 
cause an increase in systemic vascular resistance by direct 
blockade of vasodilator Beta 2 receptors in arteriolar 
vessels, together with an indirect reflex vasoconstriction 
mediated through Alpha 1 adrenoceptors resulting from a 
reduction in left ventricular contractility. Systemic 
vascular resistance falls when a beta blocker with ISA is 
given because vasodilation occurs due to stimulation of 
the B e t a 2 vasodilator receptors.
Therefore, beta blockers with ISA may have value in 
minimising the haemodynamic disturbance associated with 
blockade of cardiovascular sympathetic drive.
Left Ventricular Function and Beta Blockade.
In addition to the probable haemodynamic benefits 
of a beta blocker with ISA, myocardial contractility has 
also been assessed. It has been suggested that left 
ventricular contractility in animals and humans may be 
impaired to a lesser extent with beta blockers possessing 
ISA. (51,53,54) However, it would be misleading to suggest
that beta blockers with ISA cannot compromise left 
ventricular function, as it has been shown that cardiac 
contractility can fall with pindolol.
Different methods of investigating left ventricular 
performance have been used in the assessment of pindolol on 
these parameters, including thermodilution (46,55), dye 
dilution (56), measurements of systolic time intervals (57) 
echocardiographic techniques (58) and more recently 
measurement of left ventricular ejection fraction and other 
parameters of left ventricular contractility by radio­
nuclide methods. (59,60) These latter methods tend to be 
more reliable and reproducible than the previous techniques 
In general, but not consistently, these studies suggest 
that the depressant effect of pindolol on left ventricular 
performance is less than that of propranolol. However, one 
factor shared by most studies on myocardial performance is 
that only relatively short treatment periods were used.
Thus, we still do not have information regarding the 
long-term effects of pure beta blockers or those with ISA 
on left ventricular function. As most patients with 
ischaemic heart disease or hypertension are treated with 
beta blockers on a long-term basis, it is important to 
determine the effect on left ventricular performance over 
an extended period of treatment. Perhaps this may reflect 
some further advantage of ISA.
The choice of patient in whom the drug is studied 
is also important as this can alter interpretation of the 
results. For example, in patients with normal or near
normal left ventricular function, some studies have shown 
that oral administration of propranolol does not 
significantly influence resting global or segmental left 
ventricular function using radionuclide techniques. (61-63)
In a separate study of patients with moderate to marked 
left ventrcular dysfuntion, a significant reduction in left 
ventricular ejection fraction was observed in a group 
treated with a pure beta blocker. (64) This would imply 
that if ISA has any beneficial effect on left ventricular 
performance, it would be most evident in patients with 
impaired left ventricular function before commencing therapy.
Pure beta blockers cause a reduction in the heart's 
pump capability secondary to a reduction in the myocardial 
force of contraction and an excessively slow heart rate.
In the healthy heart, stroke volume is more dependant on 
sympathetic drive than contractility. In the failing 
heart, stroke volume is more dependent on contractility 
and pump function may only be adequate in the presence of 
compensating sympathetic excitation. Pure beta blockers 
will suppress this excitation and may precipitate 
myocardial insufficiency. To compound the situation, in 
addition to contractility, the increase in heart rate 
required to compensate for the reduction in stroke volume 
is also inhibited, and pure beta blockers will block 
peripheral vasodilator Beta 2 receptors causing a tendency 
to vasoconstriction and an increase in systemic vascular 
resistance. It is probable that in the failing heart, a 
beta blocker with ISA would be less likely to cause these 
effects.
1.8. CLINICAL APPLICATIONS OF BETA BLOCKERS WITH ISA.
Ischaemic Heart Disease.
Beta blockers are one of the major drug groups 
used in the medical management of angina pectoris. The 
rationale behind their use lies in their ability to reduce 
myocardial oxygen demand. The major determinants of 
myocardial oxygen demand are heart rate, systolic blood 
pressure, myocardial contractility, the duration of left 
ventricular emptying or ejection, and ventricular size.
In the normal individual oxygen demand rises during 
exercise due to an increase in heart rate, blood pressure 
and contractility. Subsequently the oxygen supply is able 
to increase as there is an increase in perfusion pressure 
in the coronary arteries. However, if there is compromised 
flow in the large coronary arteries due to atheromatous 
plaques or coronary artery spasm then perfusion pressure 
falls and oxygen supply declines, resulting in myocardial 
ischaemia.. Since a beta blocker can attenuate the heart 
rate, blood pressure and contractility response to exercise 
or emotional stress then they are capable of maintaining 
myocardial oxygen demand within the limits allowed by the 
diseased supply vessels.
Since beta blockers with ISA will only reduce 
heart rate at times of increased oxygen demand (42,43) it 
could be argued that subjects with rest or nocturnal 
angina would not be suited to these drugs and would
benefit more from a pure beta blocker. One recent report 
from Quyyumi et al (65) compared the effect of pindolol 
and atenolol in fifteen subjects with effort and nocturnal 
angina on symptoms and ambulatory S-T segment responses. 
This was a short-term study, but confirmed that heart rate, 
frequency of angina and the frequency and magnitude of 
episodes of S-T depression were reduced significantly more 
by atenolol than by pindolol. The suggestion is that a 
reduction in resting heart rate is especially important 
when treating rest angina and ISA may be a deleterious 
property in patients with severe angina. Thus, in certain 
patients with angina at rest the ISA effect may 
occasionally inhibit the achievement of bradycardia 
sufficiently slow to lessen the risk of developing 
ischaemia. However, it is unusual to use a beta blocker 
alone for rest angina, so it is difficult to place this 
suggestion into clinical perspective.
In contrast to the above study, several authors 
have failed to show any significant antianginal differences 
between various beta blockers with different pharmaco­
logical properties. When administered on a short or 
long-term basis to patients with stable, exertional angina 
pectoris (9,66-69) (distinct from severe or rest angina 
pectoris) most beta blockers are equally effective in 
reducing the frequency of anginal episodes and glyceryl 
trinitrate consumption.
For subjects with exercise induced angina,, this 
would appear to be a consequence of the ability of beta
blockers with ISA to be equally effective in blocking 
exercise induced tachycardia as discussed earlier. (43)
One would expect that exercise tolerance would be 
improved equally by pure beta blockade and beta blockers 
with ISA, and this has been confirmed in one study of 52 
patients with angina pectoris comparing pindolol and 
propranolol. (8) Single dose studies using small doses 
of pindolol (2-5 mg) in patients with angina have 
demonstrated increases of 35-45% in work capacity until 
onset of symptoms as measured by bicycle ergometry. 
(70,71) To compound this issue however, it must be 
appreciated that pure beta blockade can diminish exercise 
capacity (72) in normal individuals and although overall 
exercise tolerance is improved by pure beta blockers in 
angina pectoris this is attenuated by other influences of 
the drug. In hypertensive patients, Franciosa (73) has 
found less depression of exercise tolerance with beta 
blockers with ISA. Thus, exercise tolerance may be 
enhanced by a beta blocker with ISA - although this has 
not yet been clearly demonstrated in patients with CAD.
In summary the available evidence suggests that 
patients with effort angina will benefit equally from 
treatment with beta blockers with or without ISA in terms 
of decreasing symptoms. Because of other beneficial 
effects already discussed in this section, however, a 
beta blocker with ISA may be the drug of choice for mild 
to moderate angina pectoris. However, in patients with 
angina at rest, pure beta blockers, by lowering resting
heart rate appear to have a distinct advantage over beta 
blockers with ISA when used as monotherapy. (65) In terms 
of antianginal efficacy only, no advantage has been 
demonstrated for beta blockers with ISA.
Hypertension.
Beta blockers with ISA are effective antihyper­
tensives. The efficacy of pindolol in hypertension has 
been established in numerous placebo controlled trials 
(10), and the blood pressure lowering effect is quanti­
tatively similar to propranolol, thiazides, and 
methyldopa. (10) Systolic and diastolic blood pressure 
is reduced by approximately 15% with postural hypotension 
a very rare complication. (10) The maximal hypotensive 
effect occurs in the first week of treatment with a dose 
of 15-20 mg/day. (10) However, one of the drawbacks to 
treatment has been a greater frequency of central nervous 
system side effects compared to propranolol. This aspect 
shall be discussed in Section 1.10.
The mechanism by which beta blockers lower blood 
pressure is a matter for conjecture. One possibility is 
that cardiac output falls (74), however, as pindolol causes 
a smaller reduction in cardiac output that pure beta 
blockers, the antihypertensive effect of pindolol may 
result from a reduction in peripheral vascular resistence 
(46), as a result of stimulation of peripheral vaso­
dilating beta 2 receptors. (75)
Thus, reports indicate that beta blockers with ISA 
are effective antihypertensives. However, there are 
reports of a paradoxical rise in blood pressure in 
response to large doses of beta blockers. The first 
reports attributed this phenomenon to a beta blocker with 
ISA leading to a suggestion that all beta blockers with 
ISA had the unique action of causing a rise in blood 
pressure. However, this anomalous reaction has now been 
described with pure beta blockers also. (76)
Use of Beta Blockers with ISA as Antiarrhythmic D r u g s .
Beta blockers with ISA have antiarrhythmic
properties similar to pure beta blockers. This results
from the ability of a beta blocker to antagonise the
effects of catecholamines on cardiac automaticity. (74)
Intrinsic sympathomimetic activity does not seem to negate
this effect as pindolol has been shown to be as effective
as propranolol in the treatment of supraventricular
«
tachyarrhythmias (11,12) and useful for the treatment 
of ventricular tachyarrhythmias.(13)
1.9. EFFECT OF BETA BLOCKERS ON PLASMA LIPOPROTEINS.
Although changes in the lipoprotein profile 
induced by a beta blocker could be designated an adverse 
effect, I shall discuss this aspect separately because some 
of the effects induced by beta blockers with ISA may be 
advantageous, and a major part of this thesis deals 
exclusively with these changes.
Inevitably treatment of ischaemic heart disease or 
hypertension with beta blockers is a long-term prospect, and 
it has been appreciated for some time that such treatment 
may result in an adverse effect on the lipoprotein profile - 
thus reducing the benefit of beta blockade.
The literature concerning the effect of beta 
blockers and lipids is conflicting and no consistent 
differences have been found which suggest that ISA or 
cardioselectivity may profer an advantage. As with studies 
concerning left ventricular function and haemodynamics, 
there are very few investigations examining the effect of 
chronic therapy. Since these drugs are usually prescribed 
on a long-term basis clinical trials over a longer period 
of time are required.
In an early study, Tanaka (77) administered 
Propranolol to ten patients over an eight week period and 
found an increase in very low density lipoprotein (VLDL) 
triglyceride and reduction in low density lipopotein (LDL)
- triglyceride and high density lipoprotein (HDL) 
cholesterol. Of four other, more recent medium-term 
studies (78-81) studying the effect of propranolol on 
lipids, two (79,81) showed a significant elevation of 
serum triglyceride and none showed any change in 
cholesterol. In two of these studies (81,82), HDL 
was significantly reduced. Thus, medium term studies are 
conflicting and there are no long-term studies in the 
literature involving propranolol to provide further 
information. Only one long-term study of a pure beta 
blocker exists, in which Lehtonen, (82) using sotalol, 
found increased.levels of total triglyceride, cholesterol, 
VLDL and LDL with a reduction in HDL cholesterol.
Of several studies (83-85) involving cardio- 
selective beta blockers approximately half of the studies 
show an elevation of triglycerides. None show any change 
in cholesterol and the few investigators who have measured 
HDL and it's subfractions have shown either no change or a 
reduction. (83,85) Therefore cardioselectivity does not 
seem to alter the response of plasma lipids to beta 
blockade.
Studies involving beta blockers with ISA (86-88) 
again show conflicting results. Serum total cholesterol 
was found to rise in only one (87), and triglycerides do 
not seem to change significantly. HDL either maintains 
its pretreatment level or rises. This latter effect is in 
distinction to the fall which occurs with pure beta 
blockers. (80-82,85) Since an increase in LDL and a
reduction in HDL are associated with an increased risk 
of CAD (89,90) - beta blockers with ISA may offer an 
advantage over other beta blockers in terms of plasma 
lipoprotein metabolism in long-term therapy. However, no 
consistent effect can be seen on reviewing the literature 
(91), and further long-term studies are required to 
confirm the influence of ISA on plasma lipoproteins.
1.10. ADVERSE EFFECTS OF BETA BLOCKADE - INFLUENCE OF ISA.
Like all beta blockers, those with ISA are 
associated with a number of adverse or unwanted effects. 
These adverse effects are similar to other beta blockers 
and seem to be related to the beta blocking activity of 
the drugs. (92,93) The adverse effects are generally not 
dose related, will occur relatively early after 
administration and are invariably mild. The reported 
adverse effects experienced with pindolol are summarised 
in Table 1.3. (42,94,95) In terms of frequency, dizziness 
and dyspepsia are the most commonly reported adverse 
effects. It is noteworthy that dyspnoea or wheeze occur 
in a very small proportion. Whether compounds with ISA 
behave as pure beta blockers in terms of adverse effects, 
or confer some clinical benefit shall now be discussed.
Heart Rate and Cardiac Condu ction.
Pure beta blockers can be associated with severe 
symptomatic bradycardia. For example, both propranolol and 
atenolol slow the sinus rate, prolong sino-atrial and 
a trio-ventricular nodal conduction time and prolong the 
effective refractory period of the atrio-ventricular node. 
(96) In a study using beta blockers in mild to moderate 
hypertensives, McNeil and Lewis (43) found that a heart 
rate of less that 55 beats per minute was present in 17% 
and 31% of subjects being treated with metoprolol and 
atenolol respectively. In contrast, only 0.03% of subjects
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treated with a beta blocker with ISA (pindolol) developed 
this level of bradycardia. As with other beta blockers 
pindolol may increase the degree of atrio-ventricular block 
and can cause atrio-ventricular dissociation in patients 
with heart block, but this is to a lesser extent than with 
pure beta blockers. (97)
Despite this difference, it is not clear whether 
protection from severe bradycardia in the majority of 
patients offers any advantage and may detract from the 
benefit of beta blockade in a patient with severe or rest 
angina pectoris.
Myocardial Contractility.
Beta blockers are capable of precipitating 
congestive cardiac failure in susceptible individuals. 
Patients with a poor cardiac reserve may rely on a high 
level of sympathetic tone to maintain cardiac output - if 
this is removed by effective beta blockade then myocardial 
insufficiency may result. A beta blocker with ISA is less 
likely to remove sympathetic stimulation to the same extent 
and may protect against the development of congestive 
cardiac failure. However, pindolol does not provide 
absolute protection in this respect (98), and has been 
associated with heart failure with severe acute pulmonary 
oedema on initiation of therapy. (99) In addition, in two 
large studies of patients with hypertension treated with 
either propranolol (pure beta blocker) or oxprenolol with 
moderate ISA, the incidence of heart failure was shown to
be low and similar for both drugs. (100,101)
Thus, although a number of studies have 
demonstrated protection of myocardial contractility with 
beta blockers possessing ISA (46-49,51,-53,54,), those 
examining the symptomatic occurrence of congestive cardiac 
failure have been unable to demonstrate a clear advantage 
of beta blockers with ISA over pure beta blockers.
Withdrawal Phenomena.
Although not strictly an adverse effect, withdrawal 
of a beta blocker can result in clinical deterioration, 
and it is possible that ISA may influence such phenomenon.
In the setting of angina pectoris, if a pure beta 
blocker is withdrawn abruptly there can be a resurgence of 
symptoms and occasionally precipitation of myocardial 
infarction, cardiac arrhythmias or sudden death. (102)
This phenomenon usually occurs 1-21 days after discon­
tinuing the drug (103,104) and the cause is unknown. Heart 
rate rises for several days after withdrawal (105), and it 
has been suggested that an overshoot of catecholamines may 
be responsible. Such phenomena may not be apparent on 
withdrawal from treatment of a beta blocker with ISA 
(103,104), but it is still the general recommendation that 
withdrawal is carried out gradually.
There are few clinical situations where withdrawal 
of a beta blocker need be abrupt, suggesting that any
possible benefit of beta blockers with ISA in this context 
may not be clinically useful. In the Coronary Care 
situation folowing myocardial infarction beta blockers 
occasionally have to be withdrawn because of hypotension 
or congestive cardiac failure. Abrupt withdrawal of a pure 
beta blocker at this time may increase the possibility of 
cardiac arrhythmia or infarct extension whereas an "ISA 
blocker" may be less likely to do so, but this remains to 
be proven.
Peripheral Circulatory Effects.
The contractile state of the peripheral arteriolar 
vessels is the result of two competing influences. 
Sympathetic stimulation of B e t a 2 adrenoceptors results in 
vasodilation, whereas, stimulation of Alphax adrenoceptors 
results in vasoconstriction. Thus, if stimulation of 
Beta2 receptors is antagonised, an unopposed arteriolar 
constriction occurs, and this can result in symptoms of 
cold extremeties or aggravation of Ray n a u d ’s Phenomenon 
and intermittent claudication. These latter adverse 
effects are amongst the most frequently reported with 
pure beta blockers (106) - primarily due to diminished 
peripheral vascular blood flow mediated by vasoconstriction 
and perhaps contributed to by a reduction in cardiac output. 
One would expect that partial stimulation using a beta 
blocker with ISA of the peripheral Beta2 receptor would 
offset this adverse effect, by diminishing systemic 
arteriolar resistance and increasing organ blood flow. 
However, this hypothesis has been difficult to prove.
Likewise Betai selective (cardioselective) beta blockers 
would be expected to result in less vasoconstriction than 
a pure beta blocker.
According to various sources, the incidence of cold 
extremeties varies from 10-60% of patients on propranolol, 
21% with metoprolol, 19% with atenolol, but only 10% with 
pindolol. (76) Quantitative measurements of peripheral 
blood flow are difficult to make and so one cannot draw 
absolute conclusions from the results of such studies. 
However, oxprenolol (with moderate degree of ISA) has been 
shown to have less effect on forearm blood flow and skin 
temperature than propranolol (107), and pindolol has been 
shown to reduce the resistance in the femoral vascular bed 
of dogs (15) and to reduce the systemic vascular resistance 
of hypertensive patients. (46,92) From a symptomatic 
viewpoint Marshall et al (108) have indicated that cold 
extremeties and R a y n a u d ’s Phenomenon are less common with 
cardioselective beta blockers than those with ISA.
Thus, there may be an advantage in using beta 
blockers with ISA in subjects with peripheral vascular 
disease or Raynaud's Phenomenon to prevent a deterioration 
in symptoms.
Respiratory Effects.
Beta-adrenoceptors in the lung are predominantly 
B e t a 2 receptors, sympathetic stimulation of these receptors 
effecting bronchodilatation. By preventing stimulation of
these receptors, pure beta blockers can precipitate 
bronchoconstriction and this was confirmed with propranolol 
shortly after its introduction when administered to 
asthmatics. There is evidence suggesting that a cardio- 
selective (Betai) beta blocker or one with ISA offsets this 
disadvantage. However, it should be appreciated that even 
these drugs can precipitate bronchospasm in individual 
cases, especially asthmatics. (109,110) Most studies which 
have assessed respiratory function during beta blocker 
therapy have shown a benefit with cardioselective drugs or 
those with ISA as opposed to pure beta blockers (11,111,112) 
which invariably induce bronchospasm in susceptible 
individuals. Although some patients with bronchospastic 
disorders tolerate pindolol reasonably well (11,113,114), 
the opposite is also true and the use of all beta blockers 
in patients with chronic obstructive airways disease or 
overt asthma is not recommended. There is no evidence in 
the literature suggesting that ISA is superior to cardio- 
selectivity in this respect.
Central Nervous System.
From Table 1.3 it can be seen that central nervous 
system adverse effects are among the most common 
reported with pindolol. As pindolol is considered to have 
intermediate lipid solubility (or lipophilicity) in 
comparison with other beta blockers (115), it is capable 
of crossing the blood-brain barrier (116) and exerting CNS 
side effects as enumerated in Table 1.3, and changes from 
normal, in the electro-encephalogram. (117) In comparison
with metoprolol and atenolol, abnormally vivid dreaming and 
insomnia is reported twice as often in patients taking 
pindolol. (112) In three studies (112,118,119) CNS adverse 
effects were more severe and frequent with pindolol 
compared to other beta-blockers and occurred in 20% of 
pindolol recipients.
Thus, there is a clear disadvantage with beta 
blockers possessing ISA in terms of central nervous system 
adverse effects.
Carbohydrate Metabolism.
Impaired glucose metabolism (120), hypoglycaemia 
(121) and reduced insulin secretion (122) have all been 
reported with beta blocker therapy. It is not clear at 
present whether the possession of ISA alters these 
responses. It has been suggested that the serum insulin 
response to a glucose load is inhibited by propranolol and 
metoprolol, but not by pindolol (123), but whether ISA is 
an important determinant of carbohydrate metabolism, 
especially in diabetics, is uncertain.
Summar y .
In terms of adverse effects there are numerous 
theoretical benefits in using a beta blocker with ISA.
It would appear that myocardial performance, respiratory 
function and peripheral circulation are maintained, but it 
is still not clear whether patients with myocardial
dysfunction, conduction disorders, bronchospastic disease, 
or peripheral vascular disease derive benefit. In the 
context of cardiac failure, heart block or bronchial asthma 
there is currently a dearth of information to suggest that 
beta blockers with ISA are safer than pure beta blockers.
1.11. RECENT DEVELOPMENTS.
At present attempts are being made to exploit the 
pharmacological property of ISA in terms of a positive 
inotropic agent in the treatment of heart failure (124), 
and a new group of drugs, including prenalterol, dobutamine 
and ICI-118587 are currently being used or are under 
investigation. These compounds are structurally similar 
to beta blockers and possess 20-60% of the inotropic effect 
of isoprenaline. In high dosage, however, their beta 
blocking effect becomes more prominent and prevents further 
stimulation of the heart.
Assuming an oral preparation of these drugs can be 
formulated, they may prove useful in the long-term 
management of myocardial insufficiency.
1.12. SUMMARY.
Beta blockers with ISA offer an alternative 
treatment with possible clinical benefit, which may have 
no significant disadvantages over pure beta blockers. 
However, the distinction of clinical benefit is not clear 
cut between drugs with and without ISA. Beta blockers 
with ISA seem to confer some protection against myocardial 
insufficiency, broncho-spastic disorders, reduction in 
peripheral blood flow and conduction disturbances, and 
may possibly present a more favourable lipoprotein profile. 
The disadvantages appear to occur in i t ’s use in severe 
or rest angina, where a significant fall in resting heart 
rate is not always observed. However, to date, there is 
a dearth of information concerning the long-term use of 
beta blockers with and without ISA in chronic stable 
angina - the clinical condition along with hypertension, 
which accounts for the largest treatment group. Hard 
information is lacking in terms of difference with pure 
beta blockers on myocardial and respiratory performance, 
lipoprotein profiles and assessment of the degree and 
frequency of myocardial ischaemia.
Numerous published clinical reports may be collated 
to produce many interpretations of the clinical relevance 
of ISA in ischaemic heart disease, but further long-term 
study of the above parameters in chronic stable angina are 
required before firm conclusions can be drawn.
SECTION 2 .
P ATIENTS. COMPLIANCE AND ADVERSE EFFE C T S .
2.1. Patient Recruitment.
2.2. Drug Compliance.
2.3. Adverse Effects.
2.1. PATIENT RECRUITMENT.
The majority of investigations reported in this 
thesis were performed on subjects with chronic stable 
angina pectoris. Eighty consecutive male patients 
attending a Cardiology Clinic were invited to participate 
in these experiments on the basis of the following 
criteria:
1. Patient history of chronic stable, effort 
angina pectoris (New York Heart Association 
Class II or III), either previously untreated 
or inadequately controlled on current therapy. 
No patient suffered pain at rest.
2. A positive exercise electrocardiogram using a
modified Bruce Protocol (125), defined as ST- 
segment depression of >1 mm. for 0.08 seconds 
after the J point, developing in a previously 
normal lead and persisting for at least three 
complexes in conjunction with anginal chest 
pain. Patients who showed some ST segment 
depression before exercise were included only 
if the ST segment depression became deeper by 
by >1 mm. during exercise and if a previously 
normal lead showed ST depression.
3. Absence of clinical history or findings
suggesting chronic obstructive airways disease,
valvular or congenital heart disease,
cardiomyopathy, renal impairment, diabetes 
mellitus, unstable angina or myocardial 
infarction in the year prior to recruitment.
Patients were fully informed of the nature of the 
investigations and gave their written consent.
Using these selection criteria 40 male subjects 
were recruited and after baseline evaluation were 
randomised to treatment with either propranolol or 
pindolol. All patients were followed for 3-6 months before 
entry to the study to ensure their condition was stable.
Two weeks before entry into the study a second exercise 
electrocardiography was performed to establish stability.
These results are summarised in Table 2.1a. Apart from 
Glyceryl Trinitrate and longer acting nitrates or a beta 
blocker no other medication was consummed in this "run in" 
period. One month before entry into the study the longer 
acting nitrate or beta blocker was gradually withdrawn and 
for two weeks before entry only sublingual Glyceryl Trinitrate 
was allowed. Each patient was given written instructions 
to take either propranolol 40 mg. t.i.d. or pindolol 
2.5 mg. t.i.d. for two weeks, then to double the dose of 
each. This dose was maintained for a further 50 weeks. 
Treatment was single-blind. Propranolol and Pindolol were 
supplied by I.C.I. Pharmaceuticals and Sandoz Pharmaceuticals 
Ltd., respectively. The tablets were reduced to powder 
form and placed in opaque, two-piece hard gelatin capsules.
All analyses were performed without knowledge of the 
patient’s treatment. After 52 weeks treatment with each
drug, the first nine patients completing the protocol in 
the propranolol group and first eight in the pindolol group 
were entered into a study using a double-blind crossover 
technique, to investigate the effect of these beta blockers 
on heart rate, arrhythmias and myocardial ischaemia. The 
physical and clinical characteristics of the two treatment 
groups is shown in full in Table 2.1b and c, and the study 
design represented in Figure 2.1. The randomisation resulted 
in even matching in terms of age, body mass, resting heart 
rate and blood pressure, severity and duration of symptoms 
and results of exercise electrocardiography. In Section 5,
13 subjects with mild to moderate hypertension were 
recruited in order to study the effect of sotalol hydro­
chloride on plasma lipoproteins and in Section 4 a group 
of 16 normal volunteers were recruited in order to perform 
an evaluation of radionuclide ventriculography in terms of 
reproducibility and in the detection of coronary artery 
disease. Thirty-four additional patients with chronic 
stable angina were recruited to investigate the reproduc­
ibility of radionuclide ventriculography and the usefullness 
of the cold pressor test (CPT) and sustained isometric 
handgrip (SIHG) exercise (Section 4).
Full details of the patient cohort used in each 
investigation is given in the respective section.
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Table 2.1b GROUP AND INDIVIDUAL, PHYSICAL AND CLINICAL QiARACIERISITCS OF PATIENTS
TREATED WI1H FROPRAfOJX.
n Age
(yrs.)
Previous
MI.
Height
(m)
Weight
(Kg)
Quetelet Index 
(Kg/cm2 xlO?)
Smoking 
(no./day)
Resting 
HR EP
1 57 1.676 76.2 2.71 _ 51 115/84
2 53 - 1.791 79.4 2.47 10-15 78 135/78
3 57 YES 1.702 67.1 2.32 - 73 184/103
4 51 YES 1.778 72.2 2.28 Ex-anoker 67 120/76
5 53 YES 1.803 75.3 2.32 - 79 111/77
6 54 YES 1.829 79.8 2.39 10-15 70 146/81
7 47 - 1.727 69.8 2.34 Ex-snoker 62 96/53
8 59 - 1.727 65.3 2.19 20 86 119/67
9 41 YES 1.676 74.8 2.61 Ex-smoker 62 109/79
10 64 - 1.791 80.7 2.52 Ex-smoker 61 171/89
11 45 - 1.803 110.7 3.40 4 63 109/84
12 52 - 1.727 75.3 2.52 - 62 149/39
13 46 - 1.626 58.5 2.21 20 80 121/86
14 58 - 1.803 72.6 2.23 - 87 159/85
15 55 - 1.791 81.6 2.55 - 71 207/103
16 59 YES 1.600 69.4 2.71 5 62 107/74
17 50 - 1.676 69.8 2.49 20 67 118/65
18 54 - 1.714 69.4 2.36 20-30 70 116/79
19 44 - 1.727 88.0 2.95 Ex-smoker 75 139/94
20 60 - 1.702 72.6 2.51 - 71 134/79
21 49 - 1.778 68.0 2.51 - 88 138/84
Mean or 52.7 ± 6 or 1.73 ± 75.1 ± 2.49 ± S 38% 70.7± 133±28.8
Total 5.9 28.5% 0.063 10.42 0.288 Ex-S 24% 10.28 . 79±15.0
ABBREVIATIONS: ME = Myocardial Infarction; BP = Resting Blood Pressure (mriEg.);
HR = Heart Rate (bpm.); S = Current Smokers; Ex-S = Ex-smokers.
Table 2Jc G M P  AND INDIVIIXJAL, fflYSICAL AND CLINICAL CHARACTERISTICS OF PATIENTS
TREATED WITH PINDODX.
n Age
(yrs.)
Previous
MI.
Height
On)
Weight
(Kg)
Quetelet Index 
(Kg/cm2xl03)
Smoking 
(no./day)
Resting 
HR BP
22 48 _ 1.753 70.3 2.29 Ex-anoker 68 148/58
23 49 - 1.727 67.1 2.25 7-8 59 121/76
24 45 - 1.880 69.8 1.98 Ex-smoker 61 118/81
25 68 - 1.829 73.5 2.20 - 76 125/64
26 58 - 1.727 74.4 2.49 - 70 145/85
27 67 - 1.727 69.8 2.34 Ex-anoker 67 136/79
28 39 YES 1.842 72,6 2.14 5-10 70 100/76
29 64 - 1.753 80.7 2.63 10 66 120/70
30 62 YES 1.600 59.9 2.34 Ex-anoker 73 139/73
31 38 YES 1.778 92.1 2.91 10 75 135/91
32 48 YES 1.676 73.0 2.60 Ex-smoker 59 118/83
33 56 YES 1.867 89.8 2.58 Ex-anoker 63 131/77
34 64 - 1.740 72.6 2.40 Ex-smoker 70 134/68
35 62 - 1.676 62.1 2.21 - 56 137/31
36 44 - 1.778 84.8 2.68 Ex-smoker 86 124/66
37 60 - 1.702 76.2 2.63 2 76 176/93
38 41 - 1.714 61.2 2.08 5 68 101/60
39 55 - 1.778 88.9 2.81 - 48 108/69
40 60 - 1.702 89.6 3.09 20 73 120/78
Mean or 54.1 ± 6 or 1.74 ± 75.2 ± 2.'45 ± S 37% 67.6± 128±17.7
Total 9.76 31.5% 0.070 9.96 0.297 Ex-S 42% 8.64 72±13.9
ABBREVIATIONS: As For Table 2.1a.
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2.2. DRUG COMPLIANCE.
"Keep watch also on the fault of patients which 
often make them lie about the taking of things 
prescribed."
Hippocrates.
The problem of adherance or compliance with 
prescribed medication has long been recognised as a 
potential reason for lack of therapeutic effect. Non- 
compliance with short-term regimens has been as high as 
92% (126), although this was recorded in children. Thus, 
non-compliance may influence the interpretation of the 
results of clnical investigations (127), and it is 
appropriate to consider this aspect in any study dependant 
on patient compliance with prescribed treatment. Few, 
if any, studies which have examined the role of beta 
blockers in the treatment of hypertension or angina 
pectoris, have given consideration to compliance. In 
addition to failure to take prescribed medication, non- 
compliance may include the failure of patients to attend 
clinics or for investigations. The phenomenon of patients 
missing appointments or dropping out of studies, has been 
extensively studied. Caldwell et al (128) reported a 74% 
withdrawal rate in a 5 year period of chronic hypertensive 
patients attending an outpatient clinic while Stumler et 
al (129) found that 19.8% of a patient cohort was lost to 
follow up within 12 months of commencement of anti­
hypertensive treatment. In terms of ingestion of 
prescribed medication, McKenney et al (130) observed that
only 16-25% of a group of hypertensives took 90-110% of 
their medication. Sackett (131) reported that only 48-62% 
of a study group are complaint with at least 80% of their 
medication while Marshall and Barritt (132) found that 72% 
of hypertensives were compliant with once a day medication, 
but only 64% on a twice daily regime.
Methods of assessing Compli ance.
Several methods of assessing compliance have been 
devised. One method is the patient interview, asking 
he/she to estimate the number or percentage of tablets 
taken or missed out. This method has been shown to be 
relatively unreliable (133), but may provide some useful 
information, as about half of noncompliant patients will 
admit that they are ommitting at least some of their 
medication. (134,135)
Pill counts can be performed by asking the patient 
to return any unused tablets at each clinic visit.
Thus calculating the number of pills consummed. A 
compliance value can then be determined for each patient 
from the following formula:
Compliance (%) = No. of prescribed tabs, taken by patient x 100
No. of tablets prescribed 1
However, the results of pill counts must be 
interpreted with caution. It has been noted that some 
patients will dispose of medication that they have not
taken to give the impression that they have complied 
with treatment (136), and one study showed a 36% 
discrepancy between pill counts and physiological 
measurements used to determine consumption of antacids 
by subjects with peptic ulceration. (137)
Analysis of body fluids is commonly considered to 
be the most reliable method for assessing complaince. (138) 
However, such a random analysis provides an "all or none" 
result which may lead to an underestimation of non- 
compliance .
During the course of the investigations reported 
in this theses, compliance was assessed by patient inter­
view, pill count and plasma beta blocker levels determined 
by a fluorimetric method described elsewhere. (139)
Patients were asked if at least 90% of prescribed tablets 
had been consummed since the previous visit and if any 
had been ommitted. Drugs were packaged in such a way that 
there was an excess for each period between assessment 
visits. Pill count was thus performed at the 26 and 52 
week visits following commencement of treatment. In 
addition 10 mis. of blood was taken from the sample 
required for other purposes (Section 5), for beta blocker 
estimation at each visit. Thus, patients were unaware 
that their compliance was being checked in this way.
R es u l t s .
Only one patient defaulted from some attendances 
after the 12 weeks visit. All patients reported that at 
least 90% of tablets had been consummed at the prescribed 
treatment times. Only 7 patients admitted occasional 
ommission of single doses usually because of employment 
restrictions. Two patients were found, from the pill 
count, (both taking pindolol) to habitually take more than 
the prescribed dose of drugs. Excluding these subjects, 
the remaining 38 individuals had a mean compliance of 
91 ± 8% and 87 ± 5% at 26 and 52 weeks respectively. There 
was no significant difference between compliance estimated 
by pill count at these time, between those taking 
propranolol and pindolol.
The results of beta blocker assay at each interval 
of treatment are shown in Table 2.2. There was no 
significant variation in the levels of beta blocker in 
either group although the levels increased after 2 weeks 
therapy, which coincides with the doubling in dose of each 
beta blocker. The lower levels of beta blocker found in 
those taking pindolol reflect the lower oral dose required 
for therapeutic benefit compared to propranolol.
C o m m e n t .
There is no ideal way of assessing drug compliance, 
but the accepted techniques used in these patients 
indicated acceptable adherance to prescribed treatment.
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The mean value of compliance in this group of patients 
assessed by pill count, (91% at 26 weeks) is higher than 
levels previously reported. (130-132) The reasons for 
this high level may be explained by the circumstances in 
which these studies were performed. Throughout the 
investigation, the patients attended a separate clinic, 
with no limitation on time available for consultation.
At the appropriate stages of investigation a thorough 
explanation of the disease process and individual tests 
was given. In addition the patient was seen by the same 
physician at each visit, thus allowing a close physician- 
patient relationship to be formed. As the patients were 
also participating in a research study, it is probable 
that they were a highly motivated group - in comparison 
to their counterparts attending a busy Cardiac Clinic.
Factors shown to be consistently influential in 
improved compliance are patient-practitioner interaction 
and patient satisfaction with the clinic visit and the 
practitioner. (140,141) Examination by a regular physician 
was shown by Alpert (140), to result in better compliance. 
Impersonality and brevity of the encounter have been shown 
to negatively affect patient compliance. (142) Compliant 
behaviour can also be obtained by improving the p a t i e n t ’s 
perception of his illness and the benefits of therapy.
(143) Providing the patient with a written explanation 
of his illness and prescription, as in this study, has 
been found to improve compliance. (144)
Thus, these investigations were conducted in an 
environment which encourages satisfactory compliance with 
drug therapy. The plasma beta blocker levels show 
satisfactory mean levels, although there were large inter­
individual variations. This is a well recognised 
phenomenon during treatment with beta blockers and does 
not necessarily indicate a similar variation in pharmaco- 
logical effect. (145,146) Such estimations only serve to 
support the clinical impression, patient response and pill 
count which suggest adequate compliance.
2.3. ADVERSE EFFECTS.
Adverse effects of beta blockers may include 
detrimental effects on left ventricular function, 
respiratory function and the plasma lipoprotein profile. 
These influences are described in detail later in this 
thesis. The purpose of this sub-section is to document 
adverse effects which were described by patients taking 
pindolol or propranolol during the investigations.
Several factors influence accurate detection and 
categorisation of adverse effects. Depending on the 
definition of a particular adverse effect the frequency 
may vary between series of patients. The method of 
detection can also lead to discrepancies in reported 
frequency.
The use of a physician completed questionairre may 
reflect more serious adverse effects while patient 
completed questionairres may lead to reporting of trivial 
as well as serious episodes. Using the latter it is 
possible that suggestion of an adverse effect will 
precipitate its occurance in some individuals. Another 
method of assessing adverse effects is to record spontan­
eously reported complaints from the patient and include 
direct questioning by the physician as to the presence of 
any unwanted symptoms or effect which the patient believes 
to be attributed to the drug. According to R a w l i n ’s et al 
(147), adverse effects of beta blockers can be classified 
as follows:
Predictable
Bi adverse effects : Hypotension
Bradycardia 
Cardiac Failure
Exaggerations of 
” the normally
expected response
B 2 adverse effects : Bronchospasm. 
Vasoconstriction.
Metabolic function upset, 
eg. carbohydrate homeostasis
Unpredictable (Short-term)
Fatigue, sexual dysfunction, gastrointestinal
symptoms
During the course of the investigations contained 
in this thesis, patients were encouraged to volunteer any 
adverse effects at each assessment visit (2,6,12,26 and 52 
weeks after commencing therapy) and were directly questioned 
regarding the presence of any "side effects” , without 
specific adverse effects being mentioned.
Results.
Sixteen patients taking propranolol and 17 taking 
pindolol reported at least one adverse effect during one 
y e a r ’s follow up. The frequency of these adverse effects 
is shown in Table 2.3 and the frequency in the first three
months and in the last 9 months shown in Figure 2.1. The 
most commonly occurring complaint was of fatigue which 
occurred in 43% of those on propranolol and 32% of those 
on pindolol. This complaint seemed to decrease after the 
first three months of treatment as did limb or muscle pain 
which occurred in 32% of those on pindolol, but in only 10% 
taking propranolol in the first three months of treatment, 
but was not reported by any patient thereafter. Complaints 
of cold extremeties were four times commoner in those 
taking propranolol and did not diminish in frequency with 
duration of treatment.
Central nervous system side effects were more 
common in those taking pindolol, four subjects (21%) 
describing vivid dreams or nightmares and two subjects 
describing hallucinations. One of these subjects described 
seeing a large block of ice at the foot of his bed on 
several occasions, associated with a feeling of cold. 
Another believed he was seeing small animals moving around 
his house. Three subjects complained of increasing anxiety 
and irritability, one undergoing what his family described 
as a "personality change", becoming very short tempered, 
intolerant and aggressive. In addition three subjects on 
pindolol complained of insomnia.
Comment.
Most subjects in each group complained of at least 
one adverse effect, but no patient felt his symptoms severe 
enough to warrant discontinuation of medication. Because
TABLE 2.3 FREQUENCY OF ADVERSE EFFECTS DURING ONE YEARS TREATMENT 
WITH PINDOLOL AND PROPRANOLOL. PERCENTAGES IN BRACKETS.
TREATMENT GROUP
Side Effect Pindolol (n=19) Propranolol (n=21)
Oedema 1 5) 1 (5)
Anxiety/Irritability 3 16) 1 (5)
Blurred Vision 1 5) 1 (5)
Cold Periphery 1 5) 4 (19)
Dyspnoea 1 5) 1 (5)
F atigue/Lethar gy 6 32) 9 (43)
Frequency/Nocturia 1 5) 1 (5)
Gastrointestinal 5 26) 5 (24)
Headaches - -) 2 (10)
Insomnia 3 16) - (-)
Lighthheadedness/Dizziness 1 5) 2 (10)
Limb/Muscle Pain 6 32) 2 (10)
Paraesthesiae 1 5) 2 (10)
Pruritus - -) 1 (5)
Rhinorrhoea - -) 3 (14)
Vivid Dreams/Hallucinations 4 21) - (-)
Weight Gain 2 11) - (-)
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FIGURE 2.2
Frequency of adverse effects during treatment with 
propranolol and pindolol. A. during the first three 
months of therapy and B. during the last 9 months of 
therapy.
of the small numbers, firm conclusions cannot be drawn 
from this evaluation regarding the difference between 
propranolol and pindolol in terms of adverse effects. 
However, some striking features are evident from the data. 
Bizarre dreams, visual hallucinations, nervousness and 
insomnia were more common with pindolol, and this has been 
the experience of others (148), although propranolol is 
also known to cause these complaints. (149) White (150) 
reported a case similar to those outlined above concerning 
a patient who developed visual hallucinations lasting 15-20 
minutes after only two days therapy with propranolol. 
Gershon (151) suggested that the psychosis may be caused 
by the blockade of post-synaptic beta adrenergic receptors, 
with inhibition of noradrenaline release from nerve endings 
or antagonism of serotonin in the CNS also playing a role. 
It is not clear why pindolol should be associated with a 
higher frequency of CNS adverse effects, although it is 
known to have the highest CSF/plasma concentration ratio 
of the beta blockers studied by Patel and Turner (152) 
suggesting that greater concentrations may be present 
within the brain.
The higher frequency of complaints of cold 
extremeties in those taking propranolol may be related 
to blockade of peripheral B 2 receptors, allowing 
predominant alpha stimulation and thus resulting in vaso­
constriction. The role of alpha mediated vasoconstriction 
in the face of a falling cardiac output is uncertain.
Complaints of cold extremeties, with or without 
R a y n a u d ’s phenomenon is a well recognised side effect of 
several beta blockers (108,153)', but is also common among 
patients taking other anti-hypertensives, and also before 
treatment is commenced. (154) In a study of 758 hyper­
tensives Feleke et al (154), found that 44% complained of 
cold extremeties and of this number 40% were taking beta 
blockers and 18% diuretics. No significant difference was 
found in the prevalence of symptoms among patients taking 
propranolol, pindolol or cardio-selective beta blockers. 
Some workers have measured limb blood flow in response to 
beta blockers. Ohlsson and Lindell (155) found that in 9 
patients already on beta blockers, changed to pindolol, 
limb blood flow increased and Vandenburg (156) found that 
although both oxprenolol (weak ISA) and propranolol 
reduced forearm blood flow, this was significantly greater 
after a single oral dose of propranolol. It is presumed 
that ISA protects against unopposed alpha adrenergic vaso­
constriction by maintaining vasodilatation by providing 
some stimulation of the peripheral B 2 vasodilator 
receptors.
It is noteworthy that no subject complained of 
sexual dysfunction during the study as this has been found 
to be a relatively common complaint of beta blockade. (157) 
This may be explained by the natural reluctance and 
embarrassment in divulging such information to the 
investigator. The most frequent adverse effect of both 
drugs was fatigue or lassitude. This was reported as early, 
as 1965 following single oral and intravenous doses of
propranolol. (158) Stone (159), claims that 30% of patients 
on beta blockers complain of leg weakenss and inability 
to move faster on hills or stairs. The reason for this 
fatigue is not clear and may in part be related to a 
placebo effect.
One uncommon adverse effect reported in those 
taking propranolol in this study is rhinorrhoea. This 
has previously been reported in two subjects taking 
propranolol and may be an effect more common with 
propranolol than other beta blockers. (160)
Concl usions.
In summary there is no standard method of' 
collecting and reporting side effects. The methods used 
in this study found fatigue/lassitude to be the commonest 
complaint in both groups with patients taking pindolol 
experiencing more central nervous system adverse effects 
and fewer complaints of cold extremeties. No adverse 
effect was thought serious enough by either the patient 
nor the author to warrant discontinuation of the drug.
SECTION 3
THE EFFECT OF CHRONIC BETA BLOCKADE ON LEFT 
VENTRICULAR FUNCTION; POSSIBLE INFLUENCE OF 
I.S.A. IN CHRONIC STABLE ANGINA PECTORIS.
This study was carried out in collaboration 
with Mr. M. Cooke, Principal Physicist, 
Department of Clinical Physics, West Graham 
Street, Glasgow.
3.1. INTRODUCTION.
From the results of short-term, intravenous 
experiments, it is known that pure beta blockers are 
prone to reduce cardiac output to a greater extent than 
those with ISA. Svendson (46) found that a reduction in 
cardiac output experienced with propranolol and atenolol 
was reduced by administering practolol (weak ISA) and more 
so by pindolol (potent ISA). Taylor et al (51) confirmed 
that beta blockers with ISA produced less depression of 
left ventricular function than other beta blockers when 
given intravenously to subjects with ischaemic heart 
disease. These studies compliment several earlier 
investigations observing a consistent negative inotropic 
effect of pure beta blockers given intravenously. (161- 
163) Conversely there is evidence that beta blockers with 
ISA given acutely may attenuate this effect and preserve 
myocardial function, while affecting adequate beta 
blockade. (46) In terms of oral administration, the 
effect of propranolol on left ventricular performance is 
less consistent. One study found that propranolol reduced 
the echocardiography derived ejection fraction and 
posterior wall motion while others have failed to observe 
significant changes. (164-166)
The results of acute intervention studies may not 
reflect the effects of long-term oral treatment on left 
ventricular performance. In this respect several authors 
have reported the effects of continued oral treatment. 
Tarazi and Dustan (167) showed that during chronic adminis­
tration with propranolol, heart rate and cardiac output 
remained depressed. Guazzi et al (168), however, have 
reported an increase in cardiac output in some hypertensive 
patients being treated with propranolol for months or 
years. Man i n ft Veld et al (48,49) investigated the 
effects of chronic oral therapy with pindolol in patients 
severely disabled by orthostatic hypotension and confirmed 
that heart rate, stroke volume, cardiac output and mean 
arterial pressure were increased by pindolol suggesting a 
potential benefit of beta blockers possessing ISA.
However, extrapolation to the patient with angina pectoris 
may not be appropriate. Of the chronic studies,
Frishman et al (58), examined the effect of pindolol and 
propranolol on echoc'ardiographic left ventricular perfor­
mance and found an increased left ventricular ejection 
fraction (EF) after pindolol and reduced EF after 
propranolol compared to control values. However, part of 
the reason for this finding may relate to the high oral 
dosage of pindolol used which may not have resulted in an 
equipotent beta blocking effect when compared to the 
propranolol dose used. In a recent controlled cross-over 
study between oral propranolol and pindolol in equipotent 
doses over 4-6 weeks Manyari et al (60) failed to find any 
significant change in EF with both drugs in 23 patients 
with chronic effort angina pectoris who had normal or near 
normal left ventricular function before treatment.
The cummulative effect of oral propranolol or 
pindolol in the long-term on left ventricular function 
has not been reported, despite the use of these drugs in
patients with ischaemic heat disease, hypertension and 
cardiomyopathy for extended periods.
The purpose of this investigation was to establish 
the effect of pure beta blockade on left ventricular 
performance at intervals over the course of one year and 
to compare this wih a beta blocker possessing ISA. In 
addition, the study protocol allowed for the determination 
of the effect of long-term therapy with beta blockers on 
the haemodynamic responses to cold stimulation and 
isometric exercise, and the possible effect of ISA.
Previous studies of this sort have used thermo­
dilution (46), dye dilution (56), echocardiographic measure­
ments (58), measurements of systolic time intervals (57), 
and recently measurement of left ventricular performance by 
radionuclide ventriculography (RNV). (60)
The latter method was chosen for the purposes of 
this thesis and this section relates to the findings of 
the experiments using RNV.
Following i t ’s description by Zaret et al (169) in 
1970, RNV has become accepted as an accurate and reproduc­
ible measure of left ventricular performance. It provides 
a safe, non-invasive, repeatable method for determining 
indices of myocardial performance. There is now indisput­
able evidence that this technique provides an estimate of 
left ventricular EF which correlates very well with that 
derived by contrast cineangiography (170-173) (r = 0.76-
0.94). In addition it provides a means of measuring 
ventricular performance during exercise and other inter­
ventions.
Serial measurements of left ventricular function 
by calculation of the EF and other indices provides an 
objective means of assessing the effect of drugs on 
myocardial performance. Gated RNV is a scintiphotographic 
technique that records the distribution of a blood pool 
tracer in the heart throughout the cardiac cycle. The 
images recorded are used to calculate left ventricular EF 
and other indices of left ventricular performance. As it 
is noninvasive and presents a negligible radiation risk to 
the patient, it is particularly suitable for repeated 
investigation. The usefulness of the technique has in the 
past been limited by reproducibility of left ventricular 
EF measurements. (174) However, a high degree of auto­
mation is now available when analysing the images, thus 
circumventing the problems previously encountered and 
improving reproducibility. This aspect is explored in 
detail in Section 4. It is important to study the effects 
of beta blocker therapy on left ventricular function, not 
only at rest, but during daily environmental stress of 
which cold and isometric exercise are two, both recognised 
to precipitate angina in certain individuals. The choice 
of these interventions is discussed in greater detail in 
the following section of this thesis. Briefly, the cold 
pressor test has been shown to induce changes in the 
haemodynamic profile including an acute increase in blood 
pressure, probably secondary to a neurogenic increase in
peripheral vascular resistance (175), and an increase in 
heart rate. (176,177) These effects increase myocardial 
oxygen demand and can induce changes in left ventricular 
performance. As this intervention is easy to apply without 
the risk of motion artefact induced by dynamic exercise, 
it was chosen at the commencement of this investigation.
It is stressed, that although this technique may have 
limitations as an aid in the detection of CAD, it was not 
used for this purpose in this study. SIHG testing was 
applied for similar reasons. It is a safe and simple 
test which yields predictable elevations of heart rate 
and blood pressure (178), but does not induce the degree 
of ischaemic stress manifested by angina or ST changes 
comparible to bicycle ergometry. (179) This intervention 
may unmask latent abnormal ventricular performance in 
patients with CAD, and the effect of beta blockade on this 
change with exercise may be of importance.
3.2. PATIENTS AND METHODS
Patient Group.
Patients were selected as described previously (p 70) 
Forty male subjects seen consecutively at a Cardiology Clinic 
with ischaemic heart disease manifesting as chronic stable 
angina (New York Heart Association class II or III), were 
recruited to the study if they were untreated or inadequately 
controlled on previous therapy. The subjects had a mean age 
of 53.4 years (SD + 7.9) and a range of 38-68 years. No 
patient was admitted to the study if there was any evidence 
of, or previous history of diabetes mellitus, renal failure, 
chronic obstructive airways disease or asthma, valvular 
or congenital heart . disease , unstable angina, clinical 
or x-ray evidence of cardiac failure or cardiac conduction 
abnormalities. All subjects were in sinus rhythm and none 
had suffered a myocardial infarction in the previous year. 
Apart from glyceryl trinitrate and the trial medication, 
no other drug therapy was permitted durng the course of 
the study. Informed written consent was obtained from all 
patients and the study protocol was approved by the local 
Ethics Committee. Their physical characteristics are 
summarised in Table 3.1.
Study Protocol.
A treadmill exercise test using a modified 
Bruce Protocol (125) was first performed. Horizontal or 
downsloping ST segment depression of at least 1 mm.,
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0.08 secs, in duration after the J point for at least 
three consecutive cardiac cycles, in a lead with a normal 
resting recording occurring in conjunction with exercise 
induced chest pain, supported a diagnosis of CAD.
If patients were taking medication this was 
gradually tailed off over two weeks and after a further 
two weeks, patients were randomly allocated to treatment 
with either pindolol 2.5 mg. t.i.d. or propranolol 40 mg. 
t.i.d. for two weeks, increasing thereafter to 5 mg. t.i.d. 
and 80 mg. t.i.d. respectively at which they were maintained 
for the duration of the study, (p. 71). These doses 
(16:1 ratio) have previously been shown to exert a similar 
beta blocking effect (180) and are the dosage regimens 
most often used in clinical practice.
■ti
V
Left ventricular performance was assessed before 
the commencement of beta blockade and then at intervals of 
2,6,12,26 and 52 weeks afterwards.
Assessment of Left Ventricular Performance.
Left ventricular performance was assessed using 
RNV. This is carried out by using a scintilation camera 
with'a collimated detector to record the distribution of 
a radioactive tracer within the heart. The aquisition 
of data is synchronized to the R wave of the ECG using a 
gating device, and stored for analysis in a computer 
interfaced to the gamma camera. Figures 3.1 and 3.2 
outline the basic principles behind this technique.
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FIGURE 3.2
The method by which the computer generates 
multiple gated images. The cardiac cycle is 
divided into a preselected number of frames 
of equal duration (n = 16 in this study). 
Scintigraphic data from successive beats are 
placed into separate parts of the computer 
memory, depending on the temporal relation of 
the scintigraphic data to the R wave marker 
(R). For each frame (1....N), scintigraphic 
data from successive beats are accumulated.
Twenty to 30 minutes following an intravenous 
injection of 15 mg. stannous pyrophosphoate into a right 
antecubital vein, an intravenous injection of 740 MBq 
(20 mCi) 99m Tc was administered, thus effecting in vivo 
labelling of the red blood cells as described by Pavel 
et al (181) and Stokely et al. (182) This method has been 
found to result in a mean red blood cell labelling of 
> 95% during the first hour after injection of the radio­
isotope and has been found to produce cardiac images of 
high quality which are not substantially different to those 
obtained with in vitro red cell labelling. (183) This 
method of labelling was chosen because of i t ’s ease of 
application.
Radionuclide ventriculography was performed within 
120-180 minutes after the last dose of beta blocker and 
at the same time of day (1400-1600 hours). Imaging was 
performed in the left anterior oblique projection which 
best separated right and left ventricles (usually 35-45°) 
and with a 10° caudel tilt. The same angle was used at 
each study interval. A Technicare Sigma 410 large field 
camera (year of manufacture: 1978) was used with a 
general, all purpose, low energy (140 KeV) parallel hole 
collimator. This system was calibrated daily, before 
each set of investigations, using a 99m Tc flood field, 
and uniformity correction performed by microprocessor 
based camera electronics. An ECG signal from the patient 
obtained on an Elcomatic EM810 monitor was used to trigger 
the computer to record images synchronised with the R wave.
An ADAC (CGR) 7310 computer with a 40 M Byte Winchester 
disc and a double 1 M Byte floppy disc drive was used to 
store images in histogram mode in 16 sequential frames in 
a 64 x 64 data matrix with the zoom set at x 3. Data 
collection was halted automatically after 6 minutes for 
resting studies and 5 minutes for stress studies. The 
aquisition protocol accepted all cardiac cycles within 
+ 20% of the central frequency, thus excluding ectopic 
beats. During resting studies a fixed framing rate was 
set by the computer at the start. The computer then 
calculated an average beat to beat interval and set the 
centre frequency for the study. During stress studies a 
variable framing rate option was used to track increasing 
heart rate. This operates in a similar fashion to the fixed 
rate but a beat outside the "window” causes the' computer to 
set itself on a new centre frequency and so increasing 
heart rate does not halt imaging. Before analysis of the 
data computer electronics "normalises" the heart rate, and 
thus the LV volume curve is independent of heart rate.
The composite 16 frame dynamic study was then 
stored on disc for later analysis at the end of the study.
Studies were performed after 5-10 minutes supine rest 
and during sustained isometric handgrip (SIHG) and a cold 
pressor test (CPT). SIHG was performed by asking the patient 
to squeeze the bulb of a hand dynamometer (Martin Vigorimeter) 
to the maximum extent, 30% of this load was maintained for 5 
minutes, during which time heart rate and blood pressure were 
recorded every minute in the left arm using a Hitachi HME-20
pulse and blood pressure monitor. The performance of this 
monitor has been evaluated for the purpose of this thesis 
(184) and is described in detail in the following section. 
During SIHG care was taken not to allow the patient to perform 
a Valsalva manouvre. After SIHG when pulse and blood pressure 
had fallen to basal values (usually 10 minutes) imaging was 
repeated during cold pressor stimulation. The cold pressor 
tests were applied by immersing the right hand in a mixture 
of crushed ice and water to the level of the styloid process 
for 5 minutes. Throughout the test mixing of ice and water 
was maintained to ensure an adequate cold stimulus. Blood 
pressure and heart rate were recorded as previously described. 
In both stresses, imaging was commenced 30 seconds after the 
start of the stress test.
Image analysis was performed using the Stanford 
Automatic LV Analysis program, which constructs an 
activity time curve from which indices of left ventricular 
performance can be calculated (Figure 3.3.). The method 
is described in detail in the literature, (185,186) but 
briefly, the edge detection algorithm is based on a one­
dimensional LaPalcian filter applied to the end-diastolic 
image vertically, horizontally, and along both diagonals.
A search is made for the first edge which completely 
encloses the left ventricle, and the left ventricle is 
located by calculation of the x-y co-ordinates of the 
centre of gravity of an amplitude image constructed by the 
system.
FIGURE 3.3.
Left ventricular activity time curve and first derivative with 
report parameters.
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Abbreviations;
FET; Fast ejection time. The point on the curve when maximal ventricular 
emptying occurs in relation to the total curve (%).
-dVs/dt; Maximum rate of negative change of ventricular volume with 
time (ie. ventricular emptying).
FEL; The duration of fast ventricular ejection in terms of percentage 
of the total curve.
ST; Total duration of systole as a percentage of total curve.
SL; Percentage of curve occupied by interval between peak systolic and 
diastolic volume change.
FFT; Fast filling time - point on the curve at which fastest filling 
of the ventricle occurs after closure of the aortic valve. (% of total curve) 
+dVd/dt: Maximum rate of positive change pf ventricular volume with 
time. (ie. ventricular filling).
FFL; Fast filling length - duration of period of fast ventricular filling 
after closure of the aortic valve (% of total curve).
The program transforms the data to frequency 
domain, and retains the zero, first, second, and third 
harmonics, as well as the diastolic image. The program 
locates the left ventricle on the left part of the stroke 
volume image, and identifies the edges of the ventricle 
on the diastolic image. A left ventricular area of 
interest (AOI) is created and subsequently used for inter- 
polative background subtraction. The AOI is also used 
to create a 100-point volume curve using the frequency 
components. From this curve the system calculates 
ejection fraction, including dv/dt, (maximum rate of 
filling or emptying). The times when maximum filling and 
emptying occur and the length of filling and emptying. All 
of these latter parameters are expressed in terms of 
percentage of the total curve. Although EF, dVs/dt and 
dVd/dt are of recognised value and are frequently used, 
the other parameters are of some value when demonstrating 
a change in both systolic and diastolic function. 
Unfortunately at present, there is little uniformity between 
centres in their choice of report parameters, EF excepted.
Global ejection fraction is calculated from the 
following equation:
EF(%) = End diastolic counts - end systolic counts x 100
End Diastolic Counts 1
Statistical Analysis.
Each parameter of haemodynamic response was analysed
by two-way analysis of variance to compare the mean 
response at the six stages. If a significant difference 
was indicated by the F Value obtained, post-hoc comparisons 
of weeks 2,6,12,26 and 52 with basal values were performed 
using a Student’s paired t-test and a Wilcoxon signed rank 
test for paired observations or a Student's unpaired t-test 
and a Mann-Whitney test for unpaired observations. In all 
cases, the most conservative estimate of significance is 
reported. Heart rate and blood pressure changes were 
compared using S t u d e n t ’s paired t-test and the Wilcoxon 
signed rank test. Unless otherwise stated, results are 
expressed as mean 4^ SD.
3.3. RESULTS
Of the forty patients recruited, one subject 
failed to complete the study, defaulting from further 
follow-up at the 12 week stage. Two other subjects 
(one from the propranolol group and one from the pindolol 
group) were excluded from analysis as their radionuclide 
ventriculograms were unsatisfactory. Of the remaining 
37 subjects, randomisation of treatment resulted in an 
even distribution of patients to propranolol (n = 19) 
or pindolol (n = 18).
Angina Pectoris.
All but one subject (propranolol) had a subjective 
improvement of at least one division on the New York Heart 
Association classification, such that all patients were 
NYHA class I or II while taking the peak beta blocking 
dose. The remaining subject continued to suffer 3-4 daily 
episodes of short-lived angina on effort, and ultimately 
underwent coronary artery bypass graft after completion of 
the study. The mean frequency of anginal attacks per 
week fell from 5 ± 5.3 to 1 ± 2.4 at one year for those 
taking pindolol and 7 ± 6.0 to 3 ± 6.5 at one year in 
those taking propranolol (Table 3.2). There was no 
significant difference between the two drugs in terms of 
their ability to suppress angina pectoris.
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Heart Rate and Blood Pressure.
Resting heart rate was significantly reduced by 
propranolol after six weeks treatment, when compared to 
basal values (p < 0.01), falling from a mean of 70 ± 10.4 
bpm before treatment to 59 ± 7.7 bpm at 52 weeks 
(Table 3.3). Likewise, both systolic (p < 0.01) and 
diastolic (p < 0.05) blood pressure fell significantly 
(Table 3.3). There was no significant change in resting 
heart rate at any time during treatment with pindolol 
(Table 3.4), although systolic and diastolic blood pressure 
fell throughout the study, this only reached significance 
at six weeks (p < 0.05).
Radionuclide Ventriculography.
Cold Pressor and Sustained Isometric handgrip T e s t s .
In general, both these interventions were well 
tolerated, although several patients complained of hand 
pain during the CPT. Seven patients experienced 
difficulty or complications with the tests. One patient 
(propranolol) experienced a prolonged episode of angina 
pectoris immediately after cold pressor testing at the 
52 week stage. This was accompanied by 2-3 mm. ST 
segment depression and hypotension. He was admitted to 
the Coronary Care Unit for observation and made an 
uneventful recovery with no ECG or enzyme evidence of a 
myocardial infarction. The CPT was presummed to have 
precipitated a severe episode of angina, possibly by
TABLE 3.3 MEAN HEART RATE AND BLOCD PRESSURE RESPONSES TO SUSTAINED ISCMEIRIC HANDGRIP
AT INTERVALS THROUGHOUT 1 YEARS TREATMENT WTIH PROPRANODX.
Week of 
Treatment
TIME FROM START CF ISCMEIRIC HANDGRIP TEST (minutes)
BASAL 1 2 3 4 5
0 H.R. 70 ± 10.4 77 ± 11.4 81 ± 10.9 83 ± 12.1 86 ± 16.0 88 ± 17.1
S.B.P. 134 ± 28.0 155 ± 32.4 165 ± 31.4 173 ± 29.3 169 ± 25.9 184 ± 30.7
D.B.P. 79 ± 14.7 93 ± 18.1 96 ± 17.9 97 ± 17.6 
+
103 ± 12.1 
+
98 ±17.9
2 H.R. 74 ± 21.9 67 ± 6.3 61 ± 7.8 64 ± 6.5 68 ±8.3 68 ± 8.6
S.B.P. 112 ± 13.0 143 ± 15.2 148 ± 22.2 147 ± 23.4 164 ± 32 167 ± 20.7
D.B.P. 72 ± 9.0 88 ± 8.4 90 ± 12.0 94 ± 12.7 98 ± 15.9 100 ± 15.6
6 H.R. 58 ± 6.7 63 ± 7.2 66 ± 7.6 66 ± 8.5 66 ± 9.2 67 ± 8.6
S.B.P. 115 ± 17.3 131 ± 23.3 144 ± 28.3 147 ± 27.3 159 ± 30.8 161 ± 33.7
D.B.P. 69 ± 13.3 81 ± 12.6 85 ± 14.8 88 ± 13.7 89 ± 14.5 92 ± 12.3
12 H.R. 57 ± 6.7 61 ± 9.3 63 ± 9.4 63 ± 10.6 64 ± 10.3 66 ± 9.5
S.B.P. 114 ± 15.8 131 ± 21.7 139 ± 21.0 145 ± 22.8 156 ± 23.1 160 ± 27.0
D.B.P. 70 ± 9.6 79 ± 10.6 81 ± 11.4 86 ± 13.7 86 ± 12.6 90 ± 14.1
26 H.R. 57 ± 6.7 59 ± 7.0 61 ± 6.7 61 ± 7.0 62 ± 6.6 67 ± 9.1
S.B.P. 116 ± 18.9 127 ± 20.7 137 ± 22.4 149 ± 25.7 152 ± 27.9 152 ± 20.3
D.B.P 64 ± 12.8 73 ± 13.6 79 ± 15.7 82 ± 18.2 85 ± 19.7 82 ± 18.3
52 H.R. 59 ± 7.7 64 ± 10.8 63 ± 9.4 63 ± 10.9 68 12.6 71 ± 12.3
S.B.P. 118 ± 26.4 132 ± 28.0 138 ± 29.1 152 ± 30.0 159 24.3 166 ± 25.1
D.B.P. 67 ± 11.4 75 ± 14.6 80 ± 14.1 85 ± 15.4 89 17.2 98 ± 12.6
ABBREVIATICNS: H.R. = Heart Rate - expressed as b.p.m.
S.B.P. = Systolic Blood Pressure (mnHg). 
D.B.P. = Diastolic Blood Pressure (nnttg).
Results expressed as mean ± S.D.
TABLE .3.4 MEAN HEART RATE AND BLOOD PRESSURE RESPONSES TO SUSTAINED ISCMEIRIC HANDGRIP
AT INTERVALS THROUGHOUT 1 YEARS TREATMENT WITH PINDOLOL.
Week of TIME FRCM START OF ISCMEIRIC HANDGRIP TEST (minutes)
Treatment BASAL 1 2 3 4 5
0 H.R. 
S.B.P. 
D.B.P.
2 H.R. 
S.B.P. 
D.B.P.
6 H.R. 
S.B.P. 
D.B.P.
12 H.R. 
S.B.P. 
D.B.P.
26 H.R. 
S.B.P. 
D.B.P.
52 H.R. 
S.B.P. 
D.B.P.
67 ± 8.6 
128 ± 17.7 
73 ± 13.9
66 ± 7.6 
117 ± 8.8
67 ± 10.8
70 ± 7.7 
115 ± 11.33 
66 ± 11.7
66 ± 7.1 
119 ± 16.4
68 ± 9.9
66 ± 5.6 
121 ± 20.0
65 ± 14.0
66 ± 5.7 
121 ± 14.3
66 ± 14.9
77 ± 11.6 
151 ± 25.1 
84 ± 15.2
74 ± 11.3 
139 ± 15.2 
86 ± 13.3
72 ± 8.5 
130 ± 15.6
77 ± 13.1
73 ± 8.4 
136 ± 15.2
80 ± 9.4
72 ± 6.8 
130 ± 17.1 
72 ± 17.3
72 ± 7.3 
132 ± 15.7
74 ± 17.7
79 ± 11.9 
158 ± 27.3 
86 ± 18.2
78 ± 12.-2 
157 ± 28.3 
99 ± 15.0
73 ± 9.6
139 ± 18.4 
83 ± 13.6
74 ± 7.4 
143 ± 17.0 
85 ± 13.4
72 ± 6.7
140 ± 18.5 
77 ± 18.1
74 ± 8.6 
140 ± 18.5 
77 ± 18.9
83 ± 13.1 
166 ± 28.3
92 ± 19.2
78 ± 13.9 
166 ± 32.2
93 ± 22.9
75 ± 11.8 
148 ± 18.4
84 ± 16.2
75 ± 8.6 
154 ± 20.0 
89 ± 15.6
73 ± 7.8 
150 ± 19.1
82 ± 21.1
74 ± 8.7 
150 ± 21.3
83 ± 21.4
84 ± 13.4 
171 ± 29.6
93 ± 18.9
79 ± 15.1 
173 ± 27.1 
96 ± 14.2
75 ± 10.0 
154 ± 21.0 
89 ± 17.0
76 ± 9.1 
163 ± 24.7
94 ± 7.4
74 ± 8.9 
162 ± 25.0 
81 ± 19.2
76 ± 8.9 
157 ± 21.2 
88 ± 23.7
84 ± 13.2 
175 ± 28.4 
98 ± 11.9
76 ± 11.6 
165 ±19.1
93 ± 11.7
74 ± 9.3 
156 ± 17.2 
88 ± 16.9
77 ± 9.4
163 ± 20.3
94 ± 17.2
75 ± 8.5 
162 ± 24.1 
87 ± 18.9
77 ± 9.9
164 ± 19.9 
90 ± 23.9
ABBREVIATIONS: As for Table 3.3.
inducing coronary vaso-constriction. Another patient 
experienced mild angina pectoris between three and five 
minutes of the SIHG test before treatment and during the 
CPT after two weeks treatment. Both of these episodes 
were accompanied by a 1-2 mm. ST segment depression, but 
were promptly relieved by sublingual glyceryl trinitrate 
after completion of the test. A further episode of angina 
at 12 weeks, after SIHG was not accompanied by any ST 
segment changes.
Three patients experienced severe hand pain during 
the CPT. One patient who suffered from rheumatoid 
arthritis experienced prolonged pain in the hand used for 
cold pressor testing up to two days later. He was there­
fore excused further investigation using this inter­
vention.
Only one subject found difficulty sustaining 30% 
of maximum voluntary handgrip for five minutes. This 
subject developed an increased frequency of ventricular 
ectopic beats (VEBs) (1:6) during the test. Another 
subject developed a similar frequency of VEBs during 
SIHG, but did not find any difficulty maintaining his 
grip.
Haemodynamic Responses.
Prior to treatment both SIHG and CPT caused 
highly significant increases in heart rate and blood 
pressure in both groups (Figures 3.4-3.7). Sustained
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FIGURE 3.4
Comparative responses of mean heart rate and systolic blood 
pressure, before and after six months treatment with 
propranolol to isometric handgrip test. Results are expressed 
as mean ± SE.
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FIGURE 3.5
Comparative responses of mean heart rate and systolic 
blood pressure, before and after six weeks treatment 
with pindolol to isometric handgrip test. Results 
are expressed as mean ± SE.
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FIGURE 3.6
Comparative responses of mean heart rate and systolic 
blood pressure, before and after six months treatment 
with propranolol to cold pressor testing. Results are 
expressed as mean ± SE.
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FIGURE 3.7
Comparative responses of mean heart rate and systolic 
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isometric handgrip caused a sequential rise in systolic 
blood pressure and heart rate in both groups (Figures 3.4 
and 3.5) while the CPT resulted in a more variable, but 
significant, increase in these indices with some decay 
noted in the increments of heart rate and systolic blood 
pressure between 3 and 5 minutes (Figures 3.6 and 3.7).
The mean response to each of these interventions at each 
study interval is shown in Table 3.3 (SIHG responses 
during treatment with propranolol), Table 3.4 (SIHG 
responses during treatment with pindolol), Table 3.5 
(CPT responses during treatment with propranolol), and 
Table 3.6 (CPT responses during treatment with pindolol).
Both drugs attenuated the rise in heart rate and 
systolic blood pressure, the maximal attenuation of 
response occurred after 26 weeks treatment with propranolol 
for both CPT and SIHG, but after six weeks treatment with 
pindolol. Systolic blood pressure and heart rate rises 
were attenuated to a similar extent with both drugs 
(Figures 3.4 - 3.7).
Left Ventricular F unction.
There was no significant difference between the 
pre-treatment resting indices of left ventricular function 
in the two groups (Table 3.7). Resting EF was 49 ± 10.7% 
in those assigned to propranolol and 52 - 16.3% in those 
to pindolol (p = NS). During SIHG, this fell 
significantly by a mean of 4 ± 4.2% in those in the
TABLE 3.5 MEAN HEART RATE AND BLOCD PRESSURE RESPONSES TO CUD PRESSOR TEST AT INTERVALS
THROUGHGUT 1 YEARS TREATMENT WTIH FROFRANCUX
Week of TTME FROM MTERSICN CF HAND IN ICE (minutes)
Treatment BASAL 1 2 3 4 5
0 H.R. 
S.B.P. 
D.B.P.
2 H.R. 
S.B.P. 
D.B.P.
6 H.R. 
S.B.P. 
D.B.P.
12 H.R. 
S.B.P. 
D.B.P.
26 H.R. 
S.B.P. 
D.B.P.
52 H.R. 
S.B.P. 
D.B.P.
68 ± 10.7 
136 ± 28.1 
78 ± 11.8
55 ± 6.1 
123 ± 20.4
73 ± 8.2
56 ± 5.6
117 ± 19.3 
71 ± 10.7
56 ± 8.0
118 ± 13.1 
73 ± 8.1
57 ± 7.2 
120 ± 20.1
70 ± 12.7
58 ± 9.4
119 ± 22.0 
67 ± 13.0
73 ± 13.7 
165 ± 39.8 
96 ± 17.5
59 ± 6.2 
159 ± 39.1 
93 ± 13.3
59 ± 8.2
149 ± 34.3 
89 ± 16.3
58 ± 8.6 
151 ± 23.6 
87 ± 10.6
58 ± 6.3 
143 ± 29.7 
85 ± 16.0
66 ± 17.4
150 ± 30.1 
84 ± 18.9
74 ± 12.9 
164 ± 37.2 
92 ± 14.4
59 ± 6.0 
140 ± 21.7 
92 ± 13.7
61 ± 9.5 
153 ± 36.0
87 ± 13.5
58 ± 9.4 
150 ± 19.8
88 ± 11.9
57 ± 6.2 
152 ± 31.9 
84 ± 13.5
64 ± 14.3 
161 ± 31.7 
83 ± 18.4
84 ± 15.5 
151 ± 29.0 
89 ± 11.4
60 ± 7.5 
154 ± 32.7 
94 ± 17.3
64 ± 8.4 
143 ± 26.2
85 ± 12.3
59 ± 9.0 
151 ±22.7 
87 ± 7.0
61 ± 9.6 
159 ± 30.2 
84 ± 22.6
74 ± 11.2 
160 ± 36.8 
95 ± 14.2
59 ± 6.7 
154 ± 40.3 
93 ± 15.8
62 ± 9.3 
152 ± 35.2 
87 ± 15.8
58 ± 8.6 
148 ± 22.6 
84 ± 10.6
62 ± 15.2 
154 ± 32.6 
86 ± 22.5
76 ± 12.0 
163 ± 41.5
92 ± 10.7
59 ± 10.1 
160 ± 37.5
93 ± 14.0
61 ± 9.3
150 ± 33.8 
85 ± 13.6
58 ± 7.9
151 ± 22.8 
84 ± 9.0
59 ± 13.0 
145 ± 22.6 
80 ± 13.7
60 ± 13.5
152 ± 17.3 
88 ± 16.3
58 ± 7.0 57 ± 7.1
151 ± 30.0 152 ± 33.9 
83 ± 14.0 82 ± 14.9
ABBREVIATIONS: As for Table 3.3.
TABLE 3.6 MEAN HEART RATE AND BLOCD PRESSURE RESPONSES 10 GOLD PRESSOR TEST AT INTERVALS
THROUGHOUT 1 YEARS TREATMENT WTIH PINDOLOL.
Week of TIME FROM HMERSICN OF HANDS IN ICE (minutes)
Treatment BASAL 1 2  3 4 5
0 H.R. 
S.B.P.
D.B.P
2 H.R. 
S.B.P. 
D.B.P.
6 H.R. 
S.B.P. 
D.B.P.
12 H.R. 
S.B.P. 
D.B.P.
26 H.R. 
S.B.P. 
D.B.P.
52 H.R. 
S.B.P. 
D.B.P.
67 ± 6.8 
132 ± 18.6 
76 ± 12.6
64 ± 9.2 
118 ± 9.2
71 ± 7.2
67 ± 7.6 
118 ± 11.6
68 ± 10.5
65 ± 6.3 
125 ± 13.4
72 ± 6.8
65 ± 7.8 
121 ± 17.9 
64 ± 14.4
66 ± 6.3
125 ± 16.5
65 ± 10.5
75 ± 9.7 
162 ± 26.5 
93 ± 16.4
68 ± 12.4 
153 ± 12.3
91 ± 13.5
69 ± 7.0 
148 ± 17.5 
84 ± 17.2
70 ± 9.9 
155 ± 22.2 
.91 ± 14.5
68 ± 8.3 
147 ± 18.0 
80 ± 19.2
70 ± 5.9 
147 ± 20.7 
83 ± 15.7
74 ± 10.1 
168 ± 29.3 
91 ± 16.5
69 ± 9.9
156 ± 19.0 
95 ± 15.9
68 ± 7.6 
145 ± 15.1 
81 ± 16.2
67 ± 8.7 
159 ± 21.6 
87 ± 15.1
69 ± 9.6
157 ± 23.2 
79 ± 18.5
72 ± 11.2 
154 ± 22.3 
81 ± 18.2
73 ± 9.1 
164 ± 25.4 
91 1 17.8
70 ± 14.2 
154 ± 19.1 
90 ± 15.2
68 ± 7.7 
144 ± 17.1 
82 ± 15.4
67 ± 8.7 
154 ± 22.6 
85 ± 13.4
66 ± 6.6
154 ± 21.3 
75 ± 17.8
70 ± 6.8
155 ± 26.5 
80 ± 21.9
75 ± 8.6
156 ± 26.4 
88 ± 14.4
69 ± 10.7 
152 ± 10.6 
91 ± 14.1
68 ± 8.7 
148 ± 18.7 
80 ± 16.2
66 ± 8.6
157 ± 17.8 
84 ± 15.2
67 ± 7.3 
154 ± 20.9 
75 ± 17.3
70 ± 8.4 
159 ± 26.9
79 ± 16.5
73 ± 8.7 
161 - 23.7 
89 ± 14.5
71 ± 13.0 
154 ± 18.2
89 ± 14.3
68 ± 8.5
148 ± 20.1 
82 ± 14.9
69 ± 10.9
153 ± 15.5
90 ± 19.7
67 ± 6.4
149 ± 20.1
76 ± 12.6
68 ± 8.8
154 ± 21.6
77 ± 17.9
ABBREVIATIONS; As for Table 3.3.
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propranolol group (Figure 3.8) and by 5 - 8.8% in the 
pindolol group (Figure 3.9) (p = NS between the two groups). 
During CPT, there was a highly significant fall in EF in 
both groups, but the difference between the groups was 
not statistically significant,, falling by 5 - 5.3% in the 
propranolol group (Figure 3.10) and 8 ± 8.5% in the pindolol 
group (Figure 3.11).
There was no significant change in the resting EF 
in those taking pindolol throughout the study. However, 
the resting EF in those taking propranolol was 
significantly higher six weeks (p < 0.02) and six months 
(p < 0.01) following commencement of the beta blocker. 
Individual resting EF changes during treatment with 
propranolol and pindolol are shown in Figures 3.12 and 
3.13 respectively.
Neither beta blocker significantly altered the 
response to SIHG or CPT at any stage of therapy (Table 
3.8 and Figures 3.8-3.11).
In the group taking propranolol, the maximum rate 
of ventricular emptying in systole (dVs/dt) increased both 
at rest and during SIHG and CPT in a sequential manner 
throughout treatment (Tables 3.9-3.10). Fast ejection 
length, (FEL), systolic time (ST), systolic length (SL), 
fast filling time (FFT) and fast filling length (FFL) all 
fell during treatment at each stage of therapy, at rest 
and during SIHG and CPT. Although there was no 
significant change in the maximal rate of ventricular
TA
BL
E 
3.
8 
ME
AN
 
EJ
EC
TI
ON
 
FR
AC
TI
ON
 
RE
SP
ON
SE
 
TO
 
CH
RO
NI
C 
BE
TA
 
BL
OC
KA
DE
 
WI
TH
 
PR
OP
RA
NO
LO
L 
AN
D 
PI
ND
OL
OL
CN vO O ' CN I - -
• •  • • • •
vO vO r - r -- ON
i—H rH  rH rH rH rH
H
P h +1 +1 +1 +  1 +  1 + i
O
CO n o  m m nO •
Li
cn
a)
H
P h
IG) Sh
o rH rH rH m <fr o
0 4 • •  • • • • cn
O 0 0 N  O  CO oo ON cn
O rH rH  rH  r—1 rH rH rH CD
-P tn u
O f—i +1 + i ii + i +1 + i +1 P h
COo O  G r - •vt uo - a
« NT l O N /N f NT "Cf rH
;z ; o
M CJ
cl,..
II
CO 0 0  VO ON CN rH H
• • • • • . P h
NO NO VO oo ON o
rH i—f rH iH rH rH
p *
+1 + i + i +1 +1 +  1 • »
CL
CN O  CN 0 0 CN OO •H
m no m m U0 uo Pi
00
X )
G
cd
o
•H
U
Li
CD
e
CO CN o
rH O  i—i m r-- « cn
. # • . • o KH
ON r-~ O ' oo rH
H X3
P h +  1 + i + i + i + i + i CD
O G
' t f m uo nO NO •rH
NT N f Cd
■p
cn
P h 3
GO CN CN CN NO COo CN < f  r-s . . * «
0 4 . • rH rH o rH i™H IIo CO ON rH rH i—H rH rHffi o
!—1 + 1 + i II + i + i +1 + i ppo CO M
—1 ON <r c  r-'- r-. ON NO COo N  n h N- ■Mf Nf
< •
Ps5 Li
P h cno •K- *- CD
0 4 l^ > O  CN o .jj. O 0 4
P h • . • • CO •o O  CN CN • o IIrH rH rH rH ON rH
Pi 0 4
+i +1 +1 +1 +1 + 1
O ' rH CO co m CO • *m  m m uo UO CO
2r O
l—1
Eh
<
• M
o >
W
T—1 04
0 4 CO CP
CD cn CN nO CN PP
<1) CO CN MO rH CN U0 <
CQ
o
o
•
o
V
a.
■K-
t—H
o
o
V
cl
in
o
o
V
CL
TA
BL
E 
3.
9 
RE
SU
LT
S 
OF
 
RA
DI
ON
UC
LI
DE
 
VE
NT
RI
CU
LO
GR
AP
HY
 
IN 
PR
OP
RA
NO
LO
L 
GR
OU
P:
 
RE
ST
•K-
*
CO *- •iS- * oo
00 C- St m CO CN O NO
0 o st O rH • - 00 uo ON
0 • . « . o • • • •
5 CN O co CO i—H ON o CO ON
CN +1 +1 +i +1 +i +1 +1 +1 +1
UO
o 00 nO 00 NO NO I-'- rH CN
« • • • • • • . •
1"- St o st o CO rH CO
rH I CO CO st U0 CO in
-K- *
•£ *- *
■£ * * O *
rH 00 NO 00 st 00 f" st o
nO sf St CO • st st ON CO. • . ♦ O * • • •
CN o CO CO i-H ON o CO ON
\o +1 +1 +1 +1 +i +1 +1 +1 +1
CN
CN 00 rH ON r"» ON rH uo. • « . • • « . •
r-» o st ON NO CO rH U0
rH 1 CO CO co m CO U0
•K- •K- K
* -K- jj.•M. -K- CO
ON m n» CN rH CN ON NO o
rH St rH NO St NO U0 uo •
« • • . • • • CN
CN o CO CO St St o CO rH
CN +1 +i +1 +1 +1 +1 +1 +1 +1
rH
r-" 00 uo rH r- St NO NO St
. • • . . • • . .
i^» <r ON m NO CO rH co
rH i CN co CO m CO uo
•M.
ji. •5f *- ■&
* •* •K- NO
00 CO O' CN nO CN NO CN rH
o st rH St NO CN co O *
. . • • . • CN
CN o CO CO st St o CO rH
nO +1 +i +1 +1 +1 +1 +1 +1 +1
O nO rH NO 00 00 rs. CO CN
• • . . . . . . •
CO <■ rH NO O'. uo CO o CO
rH 1 co co CO in CO in
•£
■Jf *-
00 o rH O' r-'- NO CN
,—\ o NT CN NO CO uo U0 st ON
rH . • • . • • • . •
rH CN o st co m r-' o CO ON
I +1 +1 +i +i +i +i +1 +1 +1
c in Nt r*» NO CN o st CNV / « • « • . • • • •
00 ON m U0 CN st o rHCN rH 1 CN CO CO UO CO uo
O
CN St i—i CN st NO O' st rsCN in oo co »-H ON CO r^- •• • * . • • • • o
CN o <t m NO NO o NO rH
-<5 ■ 00 +1 +1 +1 +i +1 +1 +1 +1 +1<
PQ 00 st r-T CN CN CN NO r-" CO• • • • • NO . « .
r-» st o st CO CO ONtH 1 CO st st CO st
-P ■P
X) XJ
H CO rJ H -a
W > W Eh rJ Ph > Ph PhPh -a Ph 00 00 Ph X) Ph Px3
CO
•
CO
0u
3
00
•H
Ph
u
o4-1
CO
<
CO
2
oM
H<M
>W
on
PQ
PQ<
TA
BL
E 
3.
10
 
RE
SU
LT
S 
OF
 
RA
DI
ON
UC
LI
DE
 
VE
NT
RI
CU
LO
GR
AP
HY
 
IN 
PR
OP
RA
NO
LO
L 
GR
OU
P:
 
SI
HG
X x X X
X X M. X X X
cn X •X. X * X X- r x
j * r"> CN uo r - rx CO 00 rH uo
Cl) U0 rH CN CN ON U0 CO •
CL) • • • . . « • • rH
? CN O uo N f UO O 00 rH
CN +1 +1 +1 +1 + i +1 +1 +1 +  i
uO
rH CO o CO NO I-" CO. • • . . • • • •
r x NO rH «H CO rH NO
rH i co S f NO CO
x X X X- X- X
X X X X if. X X
X •X- X X- X X r x
CN rH 0 0 uO 0 0 1—1 rH rH
uo UO ON r-"- oo uo < r .
. • • . • • . • rH
i-H O ■vf CO CO O CO rH
nO +1 +1 +1 + i +1 + i +1 +1 +1
CN
nO U0 CN 00 NO CN CN
. m « . • • • • .
vO uo O CN ON CO ON ON
rH 1 CO < r x t U0 CN H t
■M. J5. X X
X- X X if. X X
x X X- X- X X 00
in rx o rx NO CN uo o rH
rH m o rH rx U0 U0 CN .
# • . . . . . # o
CN o < r CO CO o NO rH
CN +1 + i +1 + i +1 +1 +1 +1 +1
rH
oo CN NO N f co NO NO o CN. • . . • • • • •
rx. N f in o rH ON CO o r"x
rH 1 CO s t x l- uo CO < r
X- X X-
X X .54. X-
X- ■K. X X X- X CO
o n '< r rH CO CO nO ON UO CN
co NO rH N f CN CO n T ON .
. • ' • . . • • • rH
cn o 0 0 r x UO rx o x j- rH
vO + i +1 +1 -:-i +1 + i +1 +1 +  1
CN rH o 00 CN 1"- uo CN• • . • • • • • •
ON CO CN CO CN CO ON rx
T—1 i co "vt xT NO CN <r
■54.
■S'. if. JJ. it.
J5. X ■SJ. X if
CO rx ON ■xl- H C" xT CO
CO ON <}• Vi- ON CO co NT
rH . • • • • . • . •
rH -vf o <r <r uo CO o CN rx
ii +1 + i +i + i +1 +1 +1 +1 + i
c ON rH o rx ON ON rH I^ x• . • • • « • • •
oo NO CN i—f ON CO 0 0 CO
CN rH 1 CO <r uo CN x tf-
in
co vO NO CO co ON oo uo
o I""- UO ON uo • NO r-» CN• . • • . O • « «
fa rx o rx U0 CO rH o r-~ ON
•<3
CO +1 +1 + i +1 +1 + i +1 +i +1
<3
PQ rH o 00 O ' H t NO NO• . . • • • • • •
rH CO CO r- rH CN CO o uo
CN 1 N f uo |x •xf
4-) fa
T3
H cn fa H fafa > fa EH fa fa > fa fa
fa -o fa C/2 CO fa T3 fa w
CO
CO
<DU
33
00
•H
tii
U
Oifa
cn
<
CO
2
OM
H<M
>
W
Pi
PQ
PQ
<
TA
BL
E 
3.
11
 
RE
SU
LT
S 
OF
 
RA
DI
ON
UC
LI
DE
 
VE
NT
RI
CU
LO
GR
AP
HY
 
IN 
PR
OP
RA
NO
LO
L 
GR
OU
P:
 
CO
LD
 
PR
ES
SO
R 
TE
S
T
■3E *
CO •* * ■3f * CO
<r CN Nf >d NO O CN NO CN
d) CN p- CN CO p- O NO 00 •
(D • • • • . • • . o
? CN o nO m O Nf rH
CN +1 +1 +1 +i +i +i +1 +1 +i
in ON CN oo 00 NO
• • • • • • • • •
nO m o NT o co ON m
>H 1 CO ■vt <r NO CN 'd
■3(- * ■H.
*- * * •K- ■X-
ON CN CN r-> O CN CN H NO
O' nO in NO p- NO m o NO♦ « • • • • • • •
nO o 00 NT NO o
no +1 +1 +1 +i +1 +1 +i +1 +i
CN
O CN NO CO rH 00 I''- rH• • • • . • . •
ON NO o i-H o CO ON NOiH 1 co -d NO CN -d
* -X-
■3E-K. •35- -35-
00 o CO m co CO 00 CN O
CO NO ON -d m NT in m. « • . • • . . •
CN o CO ~d CO o CN 00
CN +1 +1 +1 +t +t +1 +1 +1 +1
rH
CO p- 00 oo m r^> CN rH
. • • . • . • • •
CO oo o 00 CO o in
•h 1 CO CO -d in co
¥r
-3:- j;. ■35--J!. * ¥r * *
oo co 00 ON in CO CO
CN <r nO o O 00 *d r"- rH
. • • • • • • • .
nO o "d m ON 00 o p» ON
vO +1 +i +1 +i +1 +1 +i +i +1
nO CO ON rH CN 00 P"- o CO. • • • • • • • •
ON -d CO o rH o co rH in
i—( 1 CO -d NO co
-x- •J!.
m 00 r—1 CO o m 00 CO o
t—i -d ~d P*- CO m o. • • • . • • • •
t—i O co 00 oo o CN I"'-
i +i +1 +i +1 +1 +i +1 +1 +1
c O' rH o m NO m rH NO NO« • « • • • • • .
o m CN ON o oo CO
CN CN 1 CO CO NO CN 'd
oo CN
nO rH Nf ON CO NO o
i—l nO NO • • m' P- rH
. • . • H i—H • • .
fa nO o i""- NO i-H rH o ON ON
<
CO +1 +1 +i +1 +1 + 1 +i + 1 +1
<
PQ ON o CO m m Nf in P" 00
• m • • • # • • •
ON <T ON m rH rH CO NO CO
rH i CO NT m CO <d
fa fa
X) "d
E-• CO fa H fa
fa > fa Eh fa fa > fa fafa x> fa CO CO fa X) fa fa
CO
CO
Q)
U3OO
•H
fa
5-i
O
*4-1
CO
<
CO
2:oI—I
H<M
>
fafa
PQ
PQ<
B
as
al
 
6 
w
ee
ks
 
12 
w
ee
ks
 
26
 
w
ee
ks
 
52
 
w
ee
ks
 
F
I
G
U
R
E
o
•H
c P X
o 4H 00 u
•H <U G • CO
4-) S •rH ■— i <u
<J O P o c
CU 03 P rH o <X
•i- ) •rH X o •H o
<u G X
O 03 CO o X
i-H X i— 1 P p o
03 03 O* X o
p 03 > O a) MH
X a) in P p
•rH 03 CU 04 <u
> G x rH r;
•H o G X CO P
X CH •H 4H P
G 03 x X
•H <13 X £ •H CO
S-i 03 >
X x •H X
G G a. G nr) CU
03 O •H CL) G X
•H P £ ■H CO
CU X 00 X u
p U nr) 0) G •H
O 03 G <u CO X
P P 03 p CU G
O X x X  s •H
% uouoejj uo!joaf3
O'
CO
w
CSc5 
O  
O  
I—I
c d JO
o 4-1 00 u
•H CD d CO
4-1 s •H CD
a o d d
a) C/3 3 • o <4-1
•<■0•H ~o i—i •rl o
a) o 4-1
O CO i—i a 4-1
■—i 4J 1—1 o 3 O
co CO XI X) o
3 C/3 > CD <4-4
X) CD u •H 5-i
•H C/3 <13 cu CD
> d 4-1 i—1-d
•H O d i: CO 4-1
■a cu •H 4-1 3 •
c C/3 •H d 4-1 4-1
•H a) 4-1 £ •H CO O
d CO > i—1
X5 4-1 •H XJ CU
d d CU d XI CD
CO o •H CD d 4-> d
■H d S •rH CO CD
CU +J OO 4-1 a 4-1
3 O X) CO d •H 4-1
O CO d CD CO X) CO
d d CO d <D d a
O <4-4 -d -d S •H CO
%  U O HO BJJ U O U 0 9 ( 3
G c -G
o 0 0 O
•H rH 5-4 0
4-> T3 0 CU 0
O i—1 > o G
0 O u 5-i O HH
•r~) o 0 Cu•H O
0) 4-1 4-4
o G -G u 4-J
i—1 4-1 •H 4-) G o
0 •H "G o
0 0 4J 0 HH
T3 0 0 5-i
•H 0 4J 0
> c 00 G i—1uG
•H o G 0 0 4->
T3 CU •H E G •
C 0 4J 4-J 4-4 -5J
o •H 0 0 0 •H 0 o
t—! 5-i 0 0 > 1—1
• T3 4-) 5-4 •rH -G Cu
CO G G 4-J TO 0
0 O 5-4 G 4-J 5-i
w •H O 00•H 0 0
p=: CU -P 0 G u 4-)
C3 0 O 0 •H G ■H 4-)
O o 0 0 5-i 0 T3 0
M 5-i 5-4 5-i G 0 G O
O  HH cux> S ■H 0
CO
.*<53
0
$
CM
0
0
0
$
(0
CM
0
5
CM
0
0
0
<0
0
0
0
OQ
'h
V
{
~T~sIOCD 8 8 O oCO IoCM
% uoijoejj uojjoofg
p<
0.
00
1 
p<
0.
00
1 
p<
 
0.
00
1 
p 
< 
0.
00
1 
p 
<0
.0
01
-
5
±
5.3
 
— 
8 
±
6.1
 
—
8
±
6.7
 
-
9
±
6.3
 
-8
 
+ 
6.
3
co
w
PH
Z3
QJ
M
Plj
S-i
0
4-J
4-J
c o 0
o 0 1—1 O
•H rH O 0
4-JX3 0 T3
O rH > G G -G
0 o 5-i •H O O
•r“!u 0 Oh•H 0
0 4-J 4-J 0
o G -G O
i—14->•H 4-J G 4H
0 •H -o o
0 0 4-J £ 0
X5 0 0 o 4->
•H 0 4-J O
> G 00 G i— l o
•H O G 0 0 *4H
XJ Oh•H e G
G 0 4-J 4-JX) 4-J
•H 0 0 0 •H 0
5-i 0 0 >
XJ 4-J P •H XJ
G G 4-JX) 0
0 O S-t G 4-J
•H O 00•H 0
CU 4-J 0 G U •
G O 0 •H G •H 4-1
O 0 0 U 0 X) o
S-t S-t 5-t G 0 G rH
o <4H O h X3 S •H O h
V) 
X
o
O
S
CMin
0)
o
9
$
<£>
CM
WX.
V
9
S
CM
CO
JC
0)
9
*
<0
0
(0
0
m
£ +
v
o
0>
o
CO
~to o
(O 8 O
~r
o
CO
~ro
CM
Vi
\
Vi
Vi
\
<S>
<$►
% uonoejj uoiioefg
00
G 0 -G i-H
•H 0 4-1 0
4-> 0 •H 1—1 0
0 G 2 0 0
0 O a -a
S-i Oh 4-J •H
0 G 4-1 JC •
i—1 0 0 0 4-> 4->
0 Pi £ •H •H G
G 4-J 4-> 0
X G 0 0 a
•H O 0 4-> 0 •H
> •H 5-4 CO -G *4-4
•H 4-1 4-1 0 •H
X3 a £ G
G 0 0 • 00
CN •H S-i 5-i i—1 0 •H
rH <4-1 0 o G 0
• X 0 t—1 O
CO G G o 0 4-1
0 O G •H • o
w •H 0 0 5-i 0
Oh 4-1 G 5-i 0 0
P=> G a O Oh Oh G ll
O O 0 O £ i—1
M 5-i •r~) O 5-i O 0 CO
pH o 0 4-1 Oh O > ;s
oco
COz
o
o
V
a
coz
CM
O
o
v
a
o o
co
i
o
m
i
o oco oCM
I
o
r«L
Hs*.
\
% uojjoejj uouoafg
O 0
4-> U
00 G
G CO 0
•H 0 Ci
4-> CO 0
CO G x: U-4
0 o 4-> <4-1
u cu •H •H •
CO T3 0
1— 1 0 G
CO Ci 4-1 4-1 i— 1
G G G 0
T3 G 0 0 >
•H o S O
> •H 4-1 •H rH
•H 4-1 0 CM 0
T3 O 0 •H CO
G 0 Cl G 0
CO •H Ci 4-1 00 JD
r-H CM •H
• T3 CO • CO 6
CO G G Ci i-H O
cd O 0 O o M
w •H 0 rH CM
Pi CU 4-1 o
Z D G U 'G l
O o 0 0 G
M m •i—) G •H CO
Ch O 0 o CU
<; +
% uoijoej; uo|)oef3
filling in diastole (dVd/dt) at rest, this increased 
significantly during SIHG and CPT. These results are shown 
in Tables 3.8-311.
In those taking pindolol there was no significant 
change in dVs/dt at rest or during CPT although this 
increased during SIHG at each stage of investigation.
The maximal rate of diastolic filling (dVd/dt) fell at 
rest throughout the study, but did not change signifi­
cantly during SIHG or CPT. (Refer to Tables 3.12-3.14 
for details). At rest (Table 3.12), there were small 
reductions in FEL, ST, SL, and FFT up until 26 weeks after 
the start of therapy, but small rises occurred in SL and 
FFT at 52 weeks, in contrast to the sustained fall in 
these indices experienced during treatment with propranolol. 
Fast filling length (FFL) increased at all staged through­
out treatment. During SIHG all of these parameters fell 
(Table 3.13) although this was not as marked as occurred 
during treatment with propranolol (Table 3.10). During 
CPT, however, small increases were observed in FEL, ST,
SL, FFT and FFL (Table 3.14), which is in contrast to 
the findings during CPT in the propranolol group (Table 
3.11).
In order to demonstrate any differential effect of 
these beta blockers on those with normal or near normal left 
ventricular EF or those with moderately subnormal E F ; patients
were subdivided into groups according to a basal resting 
EF of above or below 50%. This resulted in 10 patients 
with an ejection fraction below 50% in the propranolol
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group and 8 in the pindolol group and 9 with an EF > 50% 
in those taking propranolol and 10 in those taking 
pindolol (Table 3.15).
In those with subnormal EFs, the resting EF 
improved significantly throughout treatment with 
propranolol rising from a basal value of 39 - 10.5 to 
51 ± 8.5 at 26 weeks (Table 3.15). No significant change 
was noted during treatment with pindolol. In these groups, 
small increases in EF during SIHG and CPT were observed in 
the propranolol group, but small falls occurred in the 
pindolol group.
In those with a basal resting EF ^ 50%, small 
increases in resting EF occurred at rest in both the 
propranolol and pindolol groups. During SIHG, no 
significant changes occurred in EF or between the 
different treatment groups. During CPT, no change in 
response occurred in those taking propranolol, but there 
was an increase in EF in those taking pindolol, although 
there was no significant change in the fall in EF from 
rest to CPT between the groups taking propranolol and 
pindolol. These results are summarised in Table 3.15.
TABLE 3.15 EJKTICN FRACTION RESPONSE ID P M X U X  AND FROPRANOLCL BASED CN INITIAL
RESTING EF OF GREATER THAN OR LESS THAN 50%.
Propranolol Group Pindolol Group
< 50% (i*=10) < 50% (n=8)
R SIHG CPT R SIHG CPI
BASAL 39.3 ± 
10.51
38.8 ± 
6.04
38.3 ± 
9.13
36.8 ± 
9.26
31.9 ± 
9.01
30.9 ± 
9.40
6 46.8 ±* 
11.56
39.7 ± 
9.69
40.4 ± 
8.11
36.0 ± 
10.40
31,2 ± 
11.83
31.2 ± 
12.97
12 49.6
12.91
42.3 ± 
8.06
41 ± 
7.57
35.6 ± 
9.24
28.6 ± 
11.61
29.4 ± 
10.74
26 51.3
8.51
43.3 ± 
10.98
43.5 ± 
8.64
36.0 ± 
10.29
30.0 ± 
11.79
29.6 ± 
11.39
52 49.9 ±* 
11.61
42 .2 ± 
7.37
42.1 ± 
11.55
36.1 ± 
13.17
30.9 ± 
10.97
31.4 ± 
13.22
> 50% (n=9) > 50% (n=10)
R SIHG CPT R SIHG CPI
BASAL 57.6 ± 
6.94
53.1 ± 
6.03
49.9 ± 
3.62
63.5 ± 
9.12
60.8 ± 
12.37
53 ± 
13.70
6 60.3 ± 
8.60
56.3 ± 
5.34
50.7 ± 
7.16
64.1 ± 
6.66
60.1 ± 
11.04
57 ± 
11.98
12 57.7 ± 
9.99
51.7 ± 
10.14
49.1 ± 
7.93
66.1 ± 
9.08
57.5 ± 
11.66
57.5 ± 
8.97
26 60.2 ± 
8.12
55.4 ± 
10.42
49.0 ± 
5.48
64.4 ± 
11.08
57.4 ± 
10.11
58.3 ± 
9.18
52 56.9 ± 
6.55
52.4 ± 
11.29
49.4 ± 
7.30
66.2 ± 
10.50
60.4 ± 
13.66
60.9 ±* 
12.77
ABBREVIATIONS: < = Less than.
> = Greater than or equal to.
R = Rest.
SIHG = Sustained Isometric Handgrip. 
CPT = Cold Pressor Test.
Results are expressed as mean ± S.D.
* p < 0.05; ** p < 0.001.
Discus sion.
In keeping with other studies, the present study 
demonstrated that both propranolol and pindolol have 
similar antianginal efficacy. (9,60,66) Few studies have 
assessed the influence of ISA on left ventricular function, 
in patients with ischaemic heart disease. (50,60,187) 
Frishman et al (58) using M-mode echocardiography found 
that pindolol increased the E F , but propranolol caused a 
decrease. That study can be faulted on the grounds of 
the technique used for assessing LV performance which has 
accepted limitations (188,189), and also because the doses 
of propranolol (up to 40 mg. q.i.d.) and pindolol (up to 
10 mg. q.i.d.) may not have exerted equivalent beta 
blocking activity. Two studies have assessed the influence 
of ISA on LV function using RNV. (60,187) Using equipotent 
doses of propranolol and pindolol Manyari et al (60) in a 
short-term study failed to find any difference between the 
drugs in 23 patients with CAD and normal or near normal 
resting EF. Kaul et al (187) using acebutalol and 
propranolol also over a short period of treatment (5 days) 
found that both drugs improved exercise E F , but exerted 
approximately similar effects.
In the present study, pindolol was used as the 
prototype of a beta blocker with ISA, as it is recognised 
as having the most potent ISA of commercially available 
beta blockers. The doses of propranolol and pindolol 
were at levels that previously have been accepted to 
produce effective and equipotent beta blockade and are the
most commonly used in clinical practice. The patients 
allocated to each treatment group were similar in terms 
of severity of angina pectoris, age, resting heart rate, 
blood pressure and left ventricular EF. All the radio­
nuclide studies were analysed blindly using a semiautomatic 
analysis protocol at the end of the study, thus removing 
any observer error or bias from the results. In addition 
all patients recruited to the study were either previously 
untreated or had their medication, (always a nitrate or 
beta-blocker), gradually withdrawn over a two week period, 
a further two week period off all medication except 
sublingual glyceryl trinitrate before baseline evaluation. 
Thus, rebound phenomenon were unlikely to have occurred.
Multiple gated equilibrium nuclear angiography, 
used in this study, is a non-invasive technique which 
has been shown to reliably assess left ventricular 
function (190,191), and provides a useful method for 
evaluating the effect of pharmacological interventions. 
(60-62)
Heart Rate and Blood Press u r e .
Resting heart rate was significantly reduced, 
throughout the study by propranolol, but not by pindolol, 
as one may expect. Both drugs, however, lowered systolic 
and diastolic blood presure, but this was less marked in 
the pindolol group. During cold pressor stimulation and 
SIHG, both groups showed highly significant increases in 
heart rate and blood pressue. This effect was inhibited
by both beta blockers, with propranolol causing a 
significantly greater attenuation of heart rate during 
both interventions.
Cold Pressor Test and Sustained Isometric Handg r i p .
Both these interventions were well tolerated.
Cold pressor stimulation precipitated angina pectoris in 
only two subjects, in one case this was severe enough to- 
warrant admission to the Coronary Care Unit. This 
undesired effect may be due to the induction of coronary 
vasoconstriction mediated by alpha adrenergic receptors. 
(192,193) One case of transient complete coronary 
occlusion has been reported with this technique in a male 
with variant angina (194), and in one case acute myocardial 
infarction occurred (195), indicating that individuals with 
CAD and a tendency to vasoconstriction may be at increased 
risk when exposed to cold.
Both beta blockers attenuated the rise in blood 
pressure experienced with CPT to a similar extent.
Houben et al in a short-term study using normal volunteers 
(196), found that propranolol and metoprolol did not 
inhibit the rise in blood pressure with CPT. It is 
possible that established beta blockade is necessary for 
such attenuation to occur. It might be expected that a 
pure beta blocker will cause an augmentation of the CPT 
induced increase in blood pressure, as a result of 
unopposed alpha agonistic activity causing vasocon­
striction. However, other mechanisms must be operative
to result in the attenuation observed in this study.
Sustained isometric handgrip was found to be well 
tolerated and easy to perform and maintain. Only two 
patients developed an increased frequency of VEBs. Like 
CPT an attenuation of HR and BP response occurred 
following both beta blockers, but this was most marked 
with propranolol.
For the purposes of this thesis, both inter­
ventions have been assessed with regard to heart rate, 
blood pressure and EF responses in normals and subjects 
with CAD. Their usefulness for detection of CAD and their 
reproducibility have also been evaluated, and the findings 
are discussed in the following section.
Radionuclide Ventriculography.
In our laboratory the spontaneous variability of 
EF measurements is 5.0%, which is comparable to other 
centres (171,197), and the use of an automatic analysis 
protocol minimises observer error. Pindolol had no 
effect on resting EF or that recorded during SIHG, 
although there were small increases in response to CPT 
at each study interval. Propranolol, on the other hand, 
caused significant increases in resting EF at 6 and 26 
weeks, and a small increase in EF during SIHG, but no 
significant change during CPT, perhaps due to the increased 
LV afterload secondary to unopposed alpha adrenergic 
vasoconstriction.
Global EF is the most useful single parameter of 
ventricular function. But, it depends on variables other 
than intrinsic myocardial contractility and may be 
influenced by changes in HR, preload or afterload. Thus, 
if propranolol decreases HR and BP, the negative effects 
on LV performance may be masked. Other indices of LV 
performance such as the maximum rate of LV emptying 
(dVs/dt) and filling (dVd/dt) have been proposed as a 
sensitive index to pharmacological changes in inotropic 
s t a t e . (198,199)
Propranolol increased dVs/dt both at rest and 
during CPT and SIHG throughout the study while pindolol 
only increased dVs/dt during SIHG. Diastolic function, 
expressed in terms of dVd/dt did not change at rest in 
those taking propranolol, but improved during both CPT 
and SIHG, whereas in those taking pindolol, there was a 
fall in dVd/dt at rest throughout the study, and no change 
during CPT or SIHG. Other indices of systolic function 
(FEL, SL) and diastolic function (FFT, FFL) all 
improved throughout the study in those taking propranolol. 
The effect on these variables in those taking pindolol was 
less consistent with small rises in SL and FFT observed 
after 52 weeks and FFL increasing at all stages throughout 
therapy. The response during SIHG was more favourable, 
but not as marked as those noted during propranolol and 
the changes noted during CPT were also less favourable. 
Thus, both global EF responses and other indices of LV 
systolic and diastolic performance appear to be enhanced
during treatment with propranolol, but either unchanged or 
worsened during treatment with pindolol. By subdividing 
the patients into those with normal or near normal EFs and 
those with subnormal EFs, it was possible to assess any 
benefit of ISA in those with subnormal LV performance in 
whom any beneficial effect would be more important. (58,200) 
Propranolol was shown to increase resting EF by a highly 
significant margin at rest, while no benefit was shown 
with pindolol and small increases in EF occurred during 
SIHG and CPT in the propranolol group, but small reductions 
occurred with pindolol. Thus, even in those with subnormal 
LV function, propranolol had significant and consistent 
advantages at rest, and during CPT and SIHG, over pindolol. 
However, these results do not disprove the potential value 
of ISA in patients with severely compromised LV function 
as this group of patients was not studied.
The changes in ejection fraction found with both 
drugs (with the exception of those on propranolol at 26 
weeks), were within the spontaneous variability of EF found 
in our department. However, the author feels that this may 
be partially offset by the fact that this was a controlled 
study, two-way analysis of variance was used to establish 
significance and the variability of the technique was 
calculated using the results from normal volunteers who 
are known to have greater variability of LV performance.
In those with subnormal basal EF (<50%), however, 
the rise in EF observed in the propranolol group at rest
was well in excess of that which could be explained 
by spontaneous variability.
Previous Stud i e s .
Previous studies reporting the effects of 
intravenous and oral beta blockers on LV function have 
not shown uniform results. The effect of long-term oral 
beta blockade, or the influence of ISA has not been 
reported.
Intravenous Administration.
Svendson et al (46), examined the acute effects 
of equipotent doses of propranolol, atenolol, practolol 
and pindolol on cardiac output, heart rate and blood 
pressure at rest only. Propranolol reduced cardiac 
output by 26-28% and heart rate 15-17%. Practolol 
(weak ISA) caused cardiac output to fall by 12-17% and 
heart rate by 7-10%, but with pindolol (potent ISA) no 
change occurred in cardiac output or heart rate.
Taylor et al (201) investigated the acute haemodynamic 
effects of propranolol in twelve patients with CAD, and 
found depressed LV function. Similarly from the same 
centre Silke et al (202,203) investigated the haemo- 
dynamid effects of propranolol and pindolol in a 
randomised study of patients with CAD at rest and during 
exercise and found that propranolol caused a reduction 
in cardiac output and reduction in heart rate while
pindolol did not affect these parameters at rest.
During exercise the fall in cardiac output observed 
in the propranolol group was attenuated by pindolol.
In addition to cardiac output, studies of the effect 
of intravenous propranolol on the maximum rate of change 
in ventricular systolic pressure (dP/dt) have shown 
significant reductions. (204,205)
Thus, acute, intravenous studies consistently 
demonstrate an impairment of LV performance after 
the administration of pure beta blockers with some 
protection against this being proferred by those with 
ISA. The effects of oral administration may differ, 
however.
Oral Administration.
Frishman et al (58),- using M-mode echocardiography 
found that resting EF was increased after administration 
of pindolol, but fell with propranolol. This study had 
several shortcomings already discussed (page 123). Tarazi 
and Dustan (167) showed that chronic oral administration 
of propranolol resulted in depressed HR and cardiac output. 
However, Guazzi et al (168) reported an improved cardiac 
output in some patients who had been treated with 
propranolol for months or years.
Of particular relevance to the present study 
are a number of investigations which have reported this 
effect of beta blockers on RNV derived LV function.
The first of these was carried out by Marshall 
et al. (61) This was performed in 22 subjects with CAD 
who were given a mean of 165 + 13 mg. propranolol per 
day. First pass RNV was used to determine resting EF and 
LV ejection rate. No exercise evaluations were performed. 
Although the group were described as having chronic stable 
angina pectoris, two patients had angina at rest (NYHA 
Class IV), four subjects had a history of congestive 
cardiac failure and were taking digoxin or diuretics 
and an additional seven were receiving anti-arrhythmic 
drugs. No change in EF or ejection rate was found, but 
these results must be interpreted with caution as this 
was an uncontrolled study, the dosage of beta blocker was 
not standardised and several participants were taking 
concomitant medication. In addition it is not clear 
how long after base line evaluation, the second RNV 
evaluation was performed.
Another study assessing the effect of propranolol 
on LV function (62), using multiple gated radionuclide 
angiography in 10 subjects with CAD taking 120-400 mg. 
of propranolol per day, this time assessed the effect of 
long-term treatment on rest and exercise LV function.
They found that propranolol caused a significant fall in 
EF at rest, but EF improved in every patient by a mean of 
22% during exercise (p < 0.001). However, this study was 
also uncontrolled, utilised a wide range of dosage regimens 
and was complicated by the fact that five participants 
were also taking long-acting nitrates. Again, using first 
pass RNV, Port et al (206) examined the effect of two days 
treatment with propranolol in 12 normal young men, finding 
EF and cardiac output reduced at rest and during exercise 
after propranolol. Using long-term treatment Manyari 
et al (60) in a controlled cross-over study involving 
equipotent standard doses of propranolol and pindolol, 
failed to demonstrate any benefit of ISA on LV function. 
This study involved 23 patients with an age range similar 
to that in the present study, with normal or near normal 
pretreatment LV function. Although resting EF was 
unchanged by both drugs 4-6 weeks after treatment, there 
were small improvements during exercise, but no difference 
between the drugs could be discerned. More recently,
Kaul et al (187), assessed the difference between five days 
administration of acebutalol (moderate ISA) and propranolol 
on LV function using gated radionuclide ventriculography. 
Acebutalol caused an exercise induced increase in E F , 
whereas this was not marked with propranolol. However, 
they do conclude that propranolol and acebu tolol are 
equivalent in influence on LV function. Another recent 
study, (207) examined the effects of two weeks treatment 
with timolol and propranolol on first pass RNV. The 
results with both drugs were combined and showed that the 
EF was unchanged at rest, but increased significantly
during exercise.
Thus, the findings of intravenous and oral studies 
differ considerably with the exception of Manyari et al 
(60), who assessed LV function 4-6 weeks after commencement 
of beta blockade, no study has adequatly evaluated the 
chronic effects of beta blockade on LV performance. Until 
the present study, the cummulative effect of chronic 
administration of propranolol was not known and the 
influence of ISA was in doubt. I have demonstrated 
an advantage of propranolol over pindolol on LV 
performance in patients with chronic stable angina. It 
is doubtful whether ISA has any beneficial effect, on 
LV function, even with pre-treatment impairment, over 
pure beta blockade in chronic administration although 
acute studies suggest a possible benefit. The results 
of the present study do not disprove the potential 
value of ISA in those with severe LV dysfunction, 
as this group was not a subject of this investigation.
Beta Blockade and LV function: Possible Mechanisms.
In acute studies it has been postulated that beta 
blockers with ISA will result in less depression of heart 
rate and left ventricular contractility compared with a 
pure beta blocker, by a number of mechanisms:
1. Direct stimulation of B i receptors.
2. By stimulation of pre-synaptic B 2 receptors 
by which the further release of noradrenaline 
from the terminal sympathetic neurone is 
enhanced.
3. By stimulation of non-inervated B 2 adreno­
ceptors in peripheral arteriolar resistance 
vessels, thereby countering the full blockade 
of these receptors and indirectly opposing 
reflex alphai adrenoceptor vasoconstriction 
as a consequence of diminished LV pumping 
fun ction.
4. By enhancing renin released and subsequent 
activation of angiotensin which directly 
augments the sympathetic outflow from the 
vasomotor centre of the central nervous system.
These mechanisms may be the major reasons for the 
apparent benefits of ISA observed in acute, intravenous 
administration of pindolol, but do not explain the lack
of influence found by Manyari (60), or the advantage of a 
pure beta blocker in this study.
All beta blockers reduce myocardial oxygen demand 
by reducing HR and BP at rest and during exercise.
Thereby, the blood flow to ischaemic areas is increased 
as the fall in heart rate, causes an increase in diastolic 
filling time and improved perfusion of the coronary 
vasculature. This latter factor may be responsible for 
the benefits for pure beta blockade found in this study. 
Heart rate, both at rest and during CPT and SIHG was 
reduced to a greater extent with propranolol while changes 
in systolic BP were similar. This implies a reduction in 
the double product, which is an accepted determinant of 
myocardial oxygen consumption. (208,209) However, pure 
beta blockers may also be expected to cause peripheral 
vasoconstriction by blockade of vasodilator B 2 receptors 
in the peripheral circulation, thereby increasing systemic 
vascular resistance which may further impair the ischaemic 
left ventricle. In addition, propranolol has been reported 
to induce an increase in coronary artery tone. (210-212) 
These latter effects may cause impairment on LV 
performance.
It is likely that the resultant effect of a beta 
blocker, whether with or without ISA, on LV performance 
will be a balance between the above effects. In the 
patients involved in this study it is probable that the 
reduction in double product and hence myocardial oxygen
consumption was the dominant influence, making the effect 
of ISA less disernible.
3.5. CONCLUSIONS.
Previous studies of pure beta blockade on left 
ventricular performance have not shown uniform results. 
Many, report intravenous administration and have usually 
found a negative inotropic effect in terms of cardiac 
output, stroke volume, dP/dt and ejection rate. Some 
studies failed to find any impairment in LV performance 
Of the studies examining the effect of oral administration, 
most have been acute and have usually found no change 
in parameters of LV function. The significance of ISA in 
this respect has until now been in some doubt, with several 
acute intravenous studies involving pindolol suggesting 
a benefit over pure beta blockers, but longer studies 
involving oral administration finding no difference between 
pure beta blockers and those with ISA. This study examined 
the long-term effect of propranolol and pindolol in 
patients with chronic angina pectoris and failed to 
demonstrate any advantage of ISA in LV function - showing 
instead an improvement in LV function indices during 
treatment with propranolol, both at rest and during SIHG 
and CPT.
The differences between this study and others may 
relate to the different dosage regimes and pretreatment 
characteristics. In the present study the groups were 
evenly matched in terms of age, resting heart rate, BP,
EF and severity of angina pectoris. The dosage regimes of 
pindolol and propranolol were those most commonly used in 
clinical practise and are accepted to result in equivalent
beta blocking effect. In addition, the patients were 
treated exclusively with a beta blocker and sublingual 
trinitrate, no other medication being allowed.
It is concluded that ISA is an unhelpful property 
in terms of LV function during chronic therapy for stable 
angina pectoris.
SECTION 4 . 
VALIDATION OF METHODOLOGY
4.1. Repeatability of Radionuclide ventriculography 
and the effect of Cold Pressor Stress and 
Sustained Isometric Handgrip Exercise on heart 
rate, blood pressure and left ventricular 
function in patients with coronary artery 
disease and a control group.
4.2. Assessment of Hitachi HME-20 Pulse and Blood 
Pressure Monitor.
4.1. INTRODUCTION
During assessment of myocardial peformance using 
various techniques it has become apparent that stressing 
the heart may uncover latent abnormalities. This is 
especially true in patients with chronic stable angina who 
may have normal ventricular function at rest, but when 
stressed, may develop abnormalities, as the myocardial 
oxygen supply - demand equilibrium has been upset.
Several interventions have been contrived to stress the 
heart during radionuclide ventriculography (RNV). These 
have included the administration of drugs such as 
angiotensin (213,214) and phenylephrine (215), to increase 
left ventricular afterload, and the provocation of 
myocardial ischaemia by atrial pacing. (216,217) Both the 
cold pressor test (CPT) (176,218) and sustained isometric 
handgrip exercise (SIHG) (219,220) have become popular as 
safe, simple interventions of particular use during RNV. 
These methods have been employed in preferance to dynamic 
exercise because movement artefact is reduced, and because 
both tests can be applied to virtually every patient, 
unlike dynamic exercise which demands a high degree of 
patient co-operation and may be more likely to precipitate 
symptoms in patients with ischaemic heart disease, when 
compared to CPT and SIHG, and may result in cancellation 
of the study. Even when the patient is immobilised in a 
large polystyrene bead bag with subsequent vacuum pumping, 
there has been a reported loss of approximately 15% of 
studies. (221) The performance of serial imaging at each 
stage of exercise is time consuming and the equipment used
can be cumbersome. Often gamma camera systems are 
housed in small spaces which are unable to accommodate 
additional equipment for dynamic exercise and great demands 
are placed on camera time. It is for these reasons that 
both CPT and SIHG are used in our department. Both of 
these tests are relatively fast and easy to perform with 
the minimum of additional equipment. In our experience 
very few studies have to be abandoned because of the onset 
of symptoms in patients with CAD or intolerance to the 
test. In the studies contained in this thesis RNV was 
used serially to examine left ventricular performance in 
subjects with CAD and it was therefore important to use 
interventions which were unlikely to precipitate symptoms 
and unnecessarily prolong aquisition time. Although it is 
appreciated that dynamic exercise is a more physiological 
intervention, these other factors prompted the use of CPT 
and SIHG. Since I was not concerned with the detection of 
CAD in these patients and since they were effectively 
acting as their own controls the choice of intervention 
did not seem inappropriate.
There follows a description of the effects of both 
CPT and SIHG when used with RNV and their usefulness in the 
detection of CAD in our department.
Cold Pressor T e s t .
Exposure to cold precipitates angina in those with 
CAD in both the natural and laboratory environment. (175, 
222,223) Because of this, the cardiovascular responses to
cold stimuli have been of interest. The CPT was originally 
described by Hines and Brown in 1932 (224) and the 
haemodynamic responses described by Green in 1965. (175)
The CPT is now used in conjunction with RNV and has been 
shown to induce left ventricular dysfunction in a 
proportion of patients with CAD. (176,225) The CPT is an 
accessible, less cumbersome and time consuming procedure 
than dynamic exercise and the haemodynamic changes elicited 
are usually brief, (175,226,227) while those with exercise 
may last 30 minutes. (228)
Several reports have challenged the usefulness of 
CPT in the detection of CAD, in comparison to the 
sensitivity and specificity of dynamic exercise (176,229), 
but no study has yet examined the reproducibility of the 
test in the context of comparative left ventricular 
function studies to determine relative change over a period 
of time. As imaging and processing protocols vary 
considerably between centres, and as the performance of 
the CPT may also differ, I undertook these studies to 
determine the effects of the CPT in patients with CAD and 
a normal control group in our laboratory on heart rate, 
blood pressure and left ventricular performance. An 
assessment was also made of its reproducibility.
Isometric Handgrip Tes t .
Isometric exercise is defined as a form of 
exercise where the contracting muscles develop force 
without shortening. Sustained isometric handgrip stress
has previously been used as an alternative to dynamic 
exercise in several studies. (219,230-232) It too is an 
easily applied intervention which has been shown to induce 
predictable increases in heart rate and blood pressure 
which return to basal levels within seconds of release 
(127,233) and to induce left ventricular dysfunction in 
diseased states. (234) The test has pronounced chrono­
tropic, inotropic and pressor effects, which do not 
produce the degree of ischaemic stress manifested by 
angina pectoris or ST segment depression experienced 
with dynamic exercise. (179)
Several investigators have found a modest increase 
in heart rate and blood pressure during isometric handgrip 
when compared to dynamic exercise, with a 15-40% increase 
in systemic blood pressure, heart rate and cardiac output 
being reported. (235,236) Such changes increase myocardial 
oxygen demand, and if this supply is compromised by 
coronary atherosclerosis, then abnormalities of left 
ventricular function may occur.
The test itself, requires patient co-operation and 
motivation, but blood pressure recording and radionuclide 
imaging can be performed easily without risk of distorted 
results..
Although the test is a potentially useful inter­
vention for the non-invasive detection of CAD (230,231,237) 
there are conflicting reports on the sensitivity of the 
test in this respect. (178,230) In a similar way to the
CPT, SIHG testing has predominantly been evaluated with 
respect to the detection of CAD. I am not aware of any 
report which has assessed reproducibility of the technique 
and i t ’s potential for serial evaluation of left 
ventricular function during exercise.
Patients and Meth o d s .
Four groups of patients were investigated.
1. Sixteen asymptomatic male volunteers were recruited
from hospital staff and associates. All were in 
sinus rhythm and were normotensive and life-long 
non-smokers. Each subject had a normal rest and 
maximal graded exercise electrocardiogram using
a modified Bruce protocol as previously described. 
(125) Chest x-ray was normal including the 
cardiothoracic ratio, and no subject was taking 
any medication at the time of the study. No 
subject had evidence of valvular or congenital 
heart disease, respiratory disease or peripheral 
vascular disease and they were presumed to have 
normal hearts. Their physical characteristics are 
shown in Table 4.1.
2. Twenty male patients with a diagnosis of CAD and
stable angina pectoris (New York Heart Asssociation 
Grade II or III), confirmed by a positive exercise 
electrocardiogram as previously described (page 70) 
and either confirmatory evidence of CAD at coronary 
arteriography (n = 8) or a documented history of 
myocardial infarction (n = 12). Evidence of 
significant CAD at coronary arteriography was taken 
as at least one stenosis of a major coronary artery 
of ^ 70% of the luminal diameter and a myocardial 
infarction was diagnosed on the basis of a
prolonged episode of central chest pain, with 
characteristic ECG and cardiac enzyme changes, 
occurring at least one year prior to the study.
These subjects had a mean age of 53 - 6.7 years and 
had a wide range of resting ejection fractions, 
(range of 18-63). Their other physical 
characteristics are shown in Table 4.1. None had 
a history or evidence of respiratory disease, 
valvular or congenital heart disease, unstable 
angina, cardiac arrhythmias or conduction 
abnormality or of cardiac failure. Apart from 
glyceryl trinitrate no other medication had been 
taken in the two weeks prior to the study.
Twenty male subjects with chronic stable angina 
as defined above and confirmed by an exercise 
electrocardiogram who had no previous history of 
myocardial infarction and had a normal or near normal 
resting EF (range of 50- 79%).’ These subjects 
had a mean age of 54 - 8.1 years (mean - S D ) , and 
had received no medication apart from oral Glyceryl 
Trinitrate in the two weeks prior to the study. 
Exclusion criteria were as described above in 
Group 2. Six patients in this group were common 
to Group 2.
To assess variability of resting ejection fraction 
and its response to CPT and SIHG, a group of 20 
subjects were drawn from groups 1 and 2 above, with 
chronic stable angina. These subjects underwent
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RNV with CPT and SIHG on three occasions 3 and 6 
months apart. All these subjects were taking 
Propranolol 80 mg. t.i.d. and GTN for chest pain 
and this treatment was unchanged for the duration 
of the study.
Study Protocol.
Radionuclide ventriculography was performed at the 
same time of day in each subject as previously described 
in Section 3.
The normal control group underwent imaging at rest 
on two separate occasions to assess the reproducibility of 
the technique. In all subjects, resting aquisition time 
was 5 minutes. Thereafter both an isometric handgrip test 
followed by a CPT were performed on the right hand. The 
time between these studies was at least 10 minutes, blood 
pressure and heart rate having returned to basal levels 
before the CPT was commenced. After the basal study at 
rest, SIHG was performed using a hand dynamometer (Martin 
Vigorimeter). Initially, the patients maximum voluntary 
contraction was determined and he was asked to maintain 
30% of this value for a period of 5 mins 30 secs., allowing 
a lag period of 30 seconds before imaging commenced.
Imaging was performed for 5 minutes in each case. In 
previous studies, the duration of the CPT and time of 
commencement of imaging varied - some starting 15-30 
seconds after immersion of the hand in iced water with a 
2-3 minute aquisition time (218,225,229), while Wainwright
et al delayed the start of imaging for 1 minute and 
acquired for 5 minutes. (176) In our hands, haemodynamic 
changes are evident 15-30 seconds after immersion of the 
hand in ice, with maximal changes occurring between 1 and 
3 minutes and being maintained for 5 minutes, (unpublished 
observations) Because of these observations and as we were 
using a general purpose collimeter we felt it appropriate 
to commence imaging after 30 seconds and to acquire for 5 
minutes. In addition, as this protocol was almost 
identical to that of Wainwright et al (176), this permitted 
comparison with that study. The CPT was administered by 
immersing the right hand in a mixture of crushed ice and 
water to the level of the styloid process. Throughout the 
test, mixing of water and ice round the hand was performed 
to ensure maintenance of the cold stimulus. Heart rate 
and blood pressure were monitored every minute before, 
during and after both interventions by a Hitachi HME-20 
pulse and blood pressure monitor.
Statistical Analysis.
Discrete variables were analysed using S t u d e n t ’s 
paired t test and a Wilcoxon signed rank test for paired 
observations. Unpaired observations were analysed using 
a S tudent’s unpaired t test and a Mann Whitney test.
(The most conservative estimates of significance are 
reported).
The variability of sequential EF measurements and 
the reproducibility of interventions, was estimated by
calculating the coefficient of variance. Values of <10% 
were accepted to indicate low variance and satisfactory 
reproducibility. Values of 10-20% indicated moderate 
reproducibility and values > 20%, unacceptable reproduc­
ibility. The 95% confidence interval about a resting E F ; 
used to define a subsequent significant change during 
CPT or SIHG in the individual subject was determined by 
calculation of the pooled variance as described by 
Caldwell et al. (238) Sensitivity and specificity were 
calculated as previously described (239), and expressed 
in percent units.
Res uIts.
Both the CPT and SIHG were tolerated well by all 
subjects. In each case the tests were completed without 
the development of chest pain or ECG evidence of ischaemia. 
Several individuals complained of pain in the immersed 
hand during the CPT which was most marked in the first 
1-2 minutes after immersion and in the first few minutes 
after withdrawal. Groups 1, 2 and 3 were similar in terms 
of age and resting heart rate, although both resting 
systolic and diastolic blood pressure was higher in those 
with CAD. Their physical characteristics are summarised 
in Table 4.1.
Heart Rate and Blood Pressure.
Both heart rate and systolic blood pressure rose 
in response to SIHG (Table 4.2) and CPT (Table 4.3) at each 
minute during these interventions. There was a mean 
increase of 27% in group 2 ’s heart rate in response to 
SIHG at the 5 minute stage, but only a 15% increase in 
group l fs response (normals). Similarly a mean increase 
of 39% in systolic blood pressure occurred in group 2, 
but only a 27% increase occurred in group 1, although 
diastolic blood pressure increased in each group to a 
comparable degree.
During the CPT those with CAD (Group 2) increased 
heart rate by 13% and systolic blood pressure by 24% and 
in the controls (Group 1) these parameters increased by
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10 and 31% respectively with similar changes occurring in 
diastolic blood pressure in both groups. (Table 4.3)
In both tests the haemodynamic response was evident 
during the first minute and was maintained for the 5 minute
period of imaging. Maximum group and individual responses
of heart rate to SIHG are shown in Figure 4.1. Heart rate 
increased by a mean of 21 ± 14.2 bpm. (p < 0.001) in the
CAD group (Group 2), and by 14 ± 13.4 bpm (p < 0.01) in
the normal subjects (Group 1) - but the difference between 
groups was not statistically significant. Systolic blood 
pressure increased by a mean 51 ± 18.1 mmHg. in CAD 
subjects (p < 0.001) and 38 ± 21.7 mmHg. in controls 
(p < 0.01), but this difference in response was not 
statistically significant. (Figure 4.2)
During the CPT, maximal heart rate increased by 
14 - 11.8 bpm in CAD subjects (group 2), but by only 
8 - 6.7 in controls (group 1), this difference not reaching 
statistical significance. (Figure 4.3)
Systolic blood pressure increased by a mean of 
39 ± 18.6 mmHg. (p < 0.001) in CAD subjects and by 44 ± 23.0 
(p < 0.001) in controls, the difference in response not 
being significant. (Figure 4.4)
During SIHG heart rate increased in all subjects 
with CAD, but fell in one normal subject while systolic 
blood pressure rose in all subjects. During CPT heart 
rate fell in only one subject with CAD, but fell in two
\CAD subjects (n = 20) Controls (n = 16)
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FIGURE 4.1
Scatter plot of maximal heart rate response to
sustained isometric handgrip in subjects with CAD(Group 2)
and a control group.
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FIGURE 4.2
Scatter plot of maximal systolic blood pressure 
response to sustained isometric handgrip in 
subjects with CAD (Group 2) and a control g r o u p .
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FIGURE 4.3
Scatter plot of maximal heart rate response to 
cold pressor test in subjects with CAD (group 2) 
control group.
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FIGURE 4.4
Scatter plot of maximal systolic blood pressure 
response to cold pressor test in subjects with 
CAD (group 2) and a control group.
controls (Figure 4.3). Systolic blood pressure rose in 
a l l s u b j e c t s .
SIHG caused greater heart rate and blood pressure 
responses compared to cold pressor test, but these 
differences were not statistically significant. Maximal 
haemodynamic responses tended to occur from minutes 3-5 
during SIHG and in minutes 1-3 during CPT. There was no 
difference in the timing of these maximal responses between 
CAD subjects and normals.
Variability of EF Determinations.
The variability of EF measurements was determined 
using the results of the 16 norma1 control subjects 
(Group 1), each of whom underwent two sequential resting 
studies. The difference of 1.25% between the means was 
not statistically significant (Table 4.4). From the 
individual mean of the two resting values and knowledge of 
the pooled variance, the 95% confidence limits for a 
significant change of a subsequent EF measurement is 
given by the equation:
x ± 2.12 / V ' U / n  + 1
- where x is the observed measurement, the value of 2.12 
represents the t-value, taken from the distribution of t, 
where the number of observations is 16 at the 5% 
significance level; S is the pooled variance, and n is 
the number of resting observations per patient. Thus, for
the 16 subjects, S2 = 19.6 per cent units, n = 2 and the 
95% confidence interval for a given patient may be estimated 
as "x ± 11.49 EF percent units. This implies that the 
individual change of EF to any intervention must be 12% 
(absolute value) or more to be considered significant at 
the 5% level. Variations of less than 12% can be 
attributed to physiological and statistical fluctuations.
At rest this would imply that a value would have to be 12% 
below the normal mean value to be regarded as an abnormal 
EF response.
The coefficient of variance between these two 
resting studies was 5.1% indicating satisfactory 
reproducibility. (Table 4.4) The results of sequential 
resting RNV studies in the normal subjects are summarised 
in Table 4.5. No statistically significant differences 
were observed for each parameter between the two resting 
studies. Linear regression analysis of EF response 
revealed a correlation coefficient of 0.85 between the two 
resting studies.
The patients recruited into group 4 underwent three 
separate studies 3 and 6 months apart. The responses to 
SIHG and CPT are shown in Tables 4.6 and 4.7 respectively. 
The coefficient of variance was 10% for SIHG indicating 
acceptable reproducibility, and that for the CPT was 9% 
indicating satisfactory reproducibility.
TABLE 4.4 COEFFICIENT OF VARIANCE FOR EJECTION FRACTION
RESPONSE IN TWO SEPARATE STUDIES , IN NORMAL
CONTROLS (GROUP 1).
PATIENT
NO.
Ri r 2 SD
1 73 72 0. 707
2 67 77 4.110
3 57 58 0.707
4 57 55 1.414
5 58 59 0.707
6 47 43 2.828
7 60 47 9. 190
8 81 82 0. 707
9 65 61 2.828
10 57 56 0.707
11 58 69 7. 778
12 55 53 1.41
13 62 58 2.828
14 71 74 2. 121
15 58 52 4.24
16 58 48 7.07
Column Mean 
± S.D.
61.5 ± 8.20 60.25 ± 11.42
3.0854 ± 
2.739
Overall Mean 60.87 ± 9.807
Coefficient of Variance
Mean SD
Overall Mean
100 _ nA<7 
x — r—  = 5.06%
ABBREVIATIONS; Ri = First Resting Study.
R 2 = Second Resting Study. 
SD = Standard Deviation.
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TABLE 4.6 COEFFICIENT OF VARIANCE FOR EJECTION FRACTION RESPONSE TO
ISOMETRIC HANDGRIP ON THREE SEPARATE OCCASIONS.
Patient No. Si s2 s 3 SD
1 37 46 44 4.72
2 48 53 54 3.21
3 43 58 46 7.93
4 48 44 44 2.3
5 55 57 53 2
6 36 42 45 4.58
7 45 55 46 5.5
8 26 29 21 4.04
9 40 27 38 7.0
10 50 51 47 2.08
11 43 50 52 4.73
12 51 52 39 7.23
13 52 62 73 10.5
14 71 62 78 8.02 -
15 69 70 64 3.21
16 66 65 63 1.53
17 67 54 66 4.85
18 53 54 49 2.65
19 43 63 52 10.02
20 34 32 41 4.73
Colunn 
Msan - SD.
48.8 + 12.22 51.3 ± 11.79 50.7 ± 13.14 5.C4
Overall Msan ± SD 50.3
Mean SD 100 
Overall Mean 1
Coefficient of Variance = 10.02%
ABBREVIATIONS: Si - 3 = Studies 1-3.
SD = Standard Deviation
TABLE 4.7 COEFFICIENT OF VARIANCE FOR EJECTION FRACTION RESPONSE TO
COLD PRESSOR TEST ON THREE SEPARATE OCCASIONS.
Patient No. Si S2 s3 SD
1 34 39 41 3.60
2 52 50 55 2.52
3 48 50 59 5.86
4 44 49 38 5.51
5 50 56 54 3.06
6 39 44 41 2.52
7 43 42 39 2.08
8 29 29 15 8.08
9 32 34 40 4.16
10 39 37 38 1.0
11 45 52 45 4.04
12 56 53 57 2.08
13 49 45 46 2.08
14 49 55 64 7.54
15 65 67 60 3.61
16 52 55 64 6.22
17 61 58 69 6.46
18 61 53 49 6.38
19 46 58 56 6.42
20 39 34 37 2.52
Colunn Mean ± SD. 46.6 ± 9.74 48.0 ± 9.77 48.3 ± 12.80 4.287
Overall Mean. 47.67
Mean SD 100 
Overall Mean 1
Coefficient of Variance = 8.99
ABBREVIATIONS; S 1 - 3  = Studies 1-3.
SD = Standard Deviation.
Radionuclide Ventriculography.
The results of RNV in groups 1, 2 and 3 in response 
to SIHG and CPT are summarised in Tables 4.8, 4.9, and 4.10 
respectively. In all three groups LVEF fell in response 
to SIHG and CPT. In normals this was only significant for 
CPT however. Both CPT and SIHG tended to reduce dVs/dt 
and increase FEL, ST, SL, FFT in all groups. FFL was not
significantly changed in groups 1 and 3, but was increased
significantly by SIHG in group 2.
The group and individual changes in LVEF in both
groups 1 and 3 to both interventions are shown in figures 
4.5 and 4.6. SIHG caused a mean reduction of 5 ± 8.3% in 
subjects with CAD and 4 ± 6.5% in controls. This 
difference was not statistically significant. The CPT 
caused a mean reduction of 10 - 8% in subjects with CAD 
compared to 7 ± 5.6% in controls. This difference was 
not statistically significant. Two subjects in each group 
increased LVEF in response to SIHG; and one subject in 
each group increased LVEF during the CPT.
The resting LVEF in groups 1 and 3 were similar, 
although that in group 2 was significantly lower (p < 0.01). 
Two subjects in group 3 showed a significant fall in EF 
( ^ 12%) in response to SIHG, compared to no normal subjects. 
In response to CPT, six subjects in group 3 showed a 
significant reduction in EF, while only two subjects in 
group 1 had falls of this magnitude. LVEF increased 
significantly (+14%) in only one subject who had CAD.
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FIGURE 4.5
Individual and group ejection fraction response 
to sustained isometric handgrip in subjects with 
CAD and normal or near normal ejection fraction 
(Group 3) and controls (Group 1).
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FIGURE 4.6
Individual and group ejection fraction responses 
to cold pressor test in subjects with CAD and 
normal or near normal ejection fractions (Group 3) 
and controls (Group 1).
Discussion.
The CPT and SIHG have been used in previous 
studies to unmask latent abnormalities of left 
ventricular function and aid in the diagnosis of CAD. 
(176,218,225,229,231,240-243) The reproducibility of the 
responses to these interventions has not been adequately 
assessed. It is possible that these interventions are 
useful for comparative studies because of their ease of 
application and ability to stress the myocardium without 
inducing angina pectoris or ST-segment changes indicative 
of ischaemia in comparison to dynamic exercises which 
causes these phenomenon in a high proportion of subjects 
undergoing RNV. (176) Thus, the variability of response 
between studies is of importance.
Cbld Pressor T e s t .
Heart Rate and Blood Pressure.
The present study showed that in patients with CAD 
and normal controls, heart rate increased by a mean of 13% 
and 10% respectively and systolic pressure increased by 
24 and 31% respectively, both being statistically 
significant. There was no significant difference between 
the two groups however. Previous studies (Table 4.11) 
have shown increases in heart rate ranging from +4 bpm 
(240) to +11 bpm (218,229) in normals and +1 (243) to 
+10 (229) in patients with CAD. Systolic blood pressure 
rises in this study were higher in both normal controls
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and subjects with CAD than previous studies. The 
explanation for this is not obvious. Only one of our 
subjects (aged 54 years, with CAD) was considered to have 
hypertension (resting blood pressure 184/103 mmHg.) Most 
studies have observed similar changes in blood pressure 
and heart rate between normal controls and patients with 
CAD (Table 4.11), but in this study no significant 
difference in response was found (Figures 4.1-4.4).
Neither Rootwelt et al (240) or Raizner et al (244) 
observed significant heart rate response, in normals 
compared to other studies. (176,218,225,229,243) The 
variability of heart rate and systolic blood pressure 
response in these studies may be related to the application 
of the CPT. In the present study, the hand was immersed 
in iced water (0-2°c) up to the level of the styloid 
process and continuous mixing of the ice/water mixture was 
carried out to maintain a constant, adequate cold stimulus. 
In addition, a fresh ice/water mixture was prepared for 
each patient. If these latter manoevres are not carried 
out it is possible that an inadequate cold stimulus is 
applied, and this may explain the early decay in 
haemodynamic response experienced by Dymond et al (177), 
but not by others. (176,229) The maximal haemodynamic 
response to CPT has been found to occur at 60-90 seconds 
after initiation, and rapidly returns to basal values after 
withdrawal. (175,176,226,227) In this study the haemo­
dynamic responses were evident throughout the 5 minutes of 
imaging although some decay was noted after three minutes.
The haemodynamic changes are mediated by a 
predominant alpha adrenergic stimulus (245), and increase 
in systemic and pulmonary vascular resistance. (175,246) 
These haemodynamic changes result in an increase in 
myocardial oxygen consumption. Such changes may be 
enough to precipitate ischaemia in those with pre-existing 
CAD. Other mechanisms may be active - and these will be 
discussed in the following paragraphs.
Radionuclide Ventriculography.
The CPT induced significant falls in LVEF in both 
normals and subjects with CAD, the difference between the 
two groups not being statistically significant. Two 
previous studies (229,243) have observed falls in the EF 
with CPT, while others have noted no change or a small 
increase. (176,218,225,240) In contrast, all studies are 
consistent in reporting falls in EF in patients with CAD 
ranging from a mean of -3 to -13% (Table 4.11). The other 
parameters derived from RNV with the exception of SL and 
FFL did not enhance the ability of CPT to distinguish 
patients with and without CAD. In normal controls 
(Group 1) SL increased, but this was not significant, 
although the increases occurring in Group 2 and 3 were 
significantly greater. FFL showed a mean reduction in 
normals; while it was prolonged by CPT in Group 2 (range 
of E F ’s), but not Group 3 (normal or near normal E F ’s). 
None of these changes reached statistical significance 
h owever.
Thus the response to CPT in normals is inconsistent. 
This may be explained by differences in study protocol, 
some studies imaging for two minutes (225) and others for
five minutes (176), the latter study delaying imaging for
one minute. Dymond et al (177) using sequential first-pass 
radionuclide ventriculography during CPT, found that EF 
fell significantly in both controls and subjects with CAD 
after one minute, but this fall was maintained at 2.5 and 4 
minutes only in those with CAD. In both groups the maximum 
reduction in EF occurred after one minute, despite the
maximum rise in BP being noted after 2.5 minutes. They
postulate that changes in afterload induced by CPT are not 
the exclusive reason for changes in LV Function. They 
conclude that LV function changes rapidly during a period 
of cold stimulation and if the prime purpose is to detect 
CAD, then it would be prudent to delay onset of imaging 
for one minute as normal subjects will be less likely to 
show a fall in EF after this. In the present study which 
was completed before the publication of D y m o n d ’s Group 
(177), I commenced imaging after 30 seconds, as this had 
also been the practice of others who have assessed the 
CPT under similar circumstances. (218,225,229,243)
Mechanism of Cold Pressor Effects.
Cold pressor stimulation produces a modest rise 
in heart rate and marked rise in blood pressure, thus 
increasing the double product and hence myocardial oxygen 
consumption. This may compromise the supply in diseased 
coronary arteries leading to ischaemia and thereafter
a fall in EF. The increase in heart rate is partially 
caused by an increase in circulating plasma catecholamines. 
(247) The blood pressure elevation is independent of such 
adrenal activity, and it is likely that this is caused 
by activation of alpha adrenergic receptors (245), with 
an increase in systemic vascular resistance and LV after­
load. However, as Dymond et al (177) pointed out, maximal 
increases in blood pressure do not coincide with the 
maximal temporal changes of LV function suggesting a 
further mechanism behind the fall in EF experienced in 
normals and subjects with CAD. Mudge et al (192), have 
studied coronary vascular resistance in response to CPT 
during cardiac catheterisation and found a 27% increase 
in patients with CAD after 50 seconds of CPT, but no 
changes in normals. This work has been confirmed by 
Feldman et al (248) who found decreases in coronary 
arterial diameter and increases in coronary resistance. 
Further evidence of coronary arterial spasm has been 
forthcoming from a study examining Thallium 201 myocardial 
perfusion imaging during CPT. Rodger et al (249), observed 
abnormalities of myocardial perfusion in both patients with 
CAD and normals. Goldhaber et al (250), have found that 
nifedipine prevents the fall in EF experienced in patients 
with CAD, thus further supporting the possibility that 
coronary spasm is involved in the changes in LV function.
As LV end diastolic pressure and thus LV preload 
and end diastolic volume, has been noted to increase by 
60% in response to CPT (251), this will increase wall 
tension and may result in compression of intramural
coronary arteries and resistance to coronary flow which 
may further exacerbate the fall in coronary blood flow in 
addition to vasospasm. Thus, the mechanical burden of 
increased LV afterload and preload, increased coronary 
vascular resistance and double product compromise the 
LV. The resulting EF is probably a balance between these 
factors and the increased contractility mediated by the 
increase in endogenous circulating catecholamines which 
occurs with CPT.
Sustained Isometric Handgrip E x e r c i s e ,
Heart Rate and Blood Pressure.
Heart rate and blood pressure rises were higher 
than during CPT, increasing by a mean of 21 bpm in 
patients with CAD and 14 bpm in normal controls. Blood 
pressure increased by 51 and 38 mmHg. respectively. These 
changes are consistent with previous reports of increases 
ranging from 15-40% in heart rate and blood pressure. 
(235,236) Bodenheimer (219), using a similar protocol to 
ourselves observed blood pressure increases of 32 mmHg. 
in normals and 33-44 mmHg. in patients with CAD. In the 
present study, the marked rise in heart rate and blood 
pressure was maintained for the five minute imaging period 
and tended to be a sequential rise with little decay in 
the response, unlike CPT. This was also the experience of 
Lind et al (252), who found increasing blood pressure as 
fatigue developed. The blood pressure elevation in normal 
hearts is due primarily to an increase in cardiac output.
(253) In LV impairment the blood pressure rise can be 
higher due to an increase in systemic vascular resistance 
mediated by alpha adrenergic receptors due to a fall in 
cardiac output. (253)
Radionuclide Ventriculography.
Although SIHG caused a fall in EF in normals, this 
did not reach statistical significance unlike the response 
to CPT. The falls in EF experienced in groups 2 and 3 were 
significant, however. Bodenheimer (231) found an increase 
in EF in normals by a mean of 3% and a reduction of 4% in 
subjects with CAD (p < 0.005), yielding 86% sensitivity and 
87% specificity for the detection of CAD. The present 
study had a sensitivity of 80% and specificity of 84,2% in
patients with a wide range of E F ’s (Group 2), but
sensitivity fell to 25% if only subjects with normal or 
near normal resting EF were examined (Group 3). Other 
studies have observed that mean EF does not change in 
normal subjects (232), but individual normals may have 
falls of 5% or more. (232,254)
Mechanism of Haemodynamic effects of S I H G .
It is hypothesised that in normal hearts, heart
rate and blood pressure rise, producing a rise in cardiac
output in the presence of unchanging systemic vascular 
resistance. (178,252,255) This effectively increases 
afterload, but LV end diastolic and systolic volumes do 
not change and EF remains unaffected.(49,51) In the
failing or ischaemic left ventricle, the rise in heart 
rate and blood pressure occurs as in normals, but the 
increase in blood pressure is mainly due to an increase 
in systemic vascular re-sistence because of an unchanged or 
reduced cardiac output (178,230), and end systolic volume 
increases and ejection fraction falls.
However, handgrip induced vasoconstriction may 
also be important, as with CPT. (237,258) The afferent 
limb of this reflex appears to originate in skeletal muscle 
stretch receptors travelling centrally to the sympathetic 
vasomotor center. (259,261) The efferent limb travels in 
sympathetic nervous system fibres to impinge directly on 
the coronary arteries (262,263), and by increasing 
circulating catecholamines (254) which occurs during SIHG, 
leading to vasoconstriction.
Variability of EF Responses.
As a fully automatic method of analysing R N V ’s 
was used intra- and inter- observer variation was not 
relevant.
In order to demonstrate the reproducibility of the 
technique, two sequential resting studies were carried out 
in the normal controls. This yielded a coefficient of 
variance of 5%, and a correlation coefficient of 85%. No 
significant difference was observed in any parameter of LV 
function between studies. In addition the results were used 
to calculate the absolute change from normal that would be
regarded as significant. This spontaneous variability in 
EF of 12% or more to exclude nonrandom physiological 
change is more than that found in some laboratories (176, 
232,240), but comparable to others. (171)
This variability is probably higher than a group 
with CAD would exhibit, as this has been shown to be 
greater in subjects with a normal EF. (171) In patients 
with normal LV performance, there is greater ventricular 
reserve and hence a greater probability of responding to a 
variety of stimuli with augmentation of cardiac pump 
function. In those with subnormal basal ventricular 
performance, the ventricle may already be working at close 
to maximal effort and will therefore have less tendency 
to manifest comparable spontaneous fluctuations in E F .
In the present study large individual interstudy 
differences, up to 13%, were noted although the mean 
difference was, -1.2 ± 6.16 between the first and second 
study. Large individual changes (up to 21%) with a mean 
change of +4.6 ± 4.70 has been observed by Wackers et al 
in a similar study population. (171)
The response to both CPT and SIHG was found to 
have acceptable reproducability, with a coefficient of 
variance of 9 and 10% respectively and no significant 
differences in the mean response on three separate 
occasions. This indicates that these interventions are 
suitable for studies involving temporal comparisons of 
LV performance in an individual in which myocardial stress
is thought desirable. In this respect both interventions 
are suitable alternatives to dynamic exercise.
Detection of Coronary Artery Disease.
Wainwright et al (176) claimed a sensitivity of 
79% and specificity of 100% for CPT in detecting CAD.
(Table 4.11) In that study a change of 8% in EF was 
regarded as abnormal, although there does not seem to be 
any clear reason for this limit from their data. All 
normal subjects increased EF in response to CPT by a mean 
of 2%. These results are surprising, as ventricular 
peformance, even in normals, is not enhanced when 
increasing LV afterload (215,264), by increasing systemic 
vascular resistance. According to Starling (265) the EF 
of the subsequent contraction falls, thereby increasing end 
diastolic volume. The increase in fibre length would then 
cause a more forceful contraction of the following beat - 
this continuing until a new equilibrium has been achieved, 
where stroke volume is maintained at the expense of 
increased end diastolic fibre length.
In the present study, only one normal subject 
increased EF during CPT with two subjects having 
significant ( ^ 12%) falls in E F . Although the mean EF 
fall was greater in patients with CAD (Figure 4.6). This 
yielded a sensitivity of 50% for patients with CAD and 
normal or near normal E F ’s ( ^ 50% : mean of 60%), but 
a specificity of only 37.5%, indicating that, in our 
laboratory using this protocol, CPT is an inadequate 
intervention for the detection of CAD. It is possible that 
the abnormal responses obtained in these normal controls 
may be due to subclinical cardiomyopathy, intervention
induced coronary artery spasm in the absence of symptoms 
or ECG changes, asymptomatic CAD or a normal variation.
But, this group were asymptomatic, life-long nonsmokers with 
no other major CAD risk factors. Each had a normal chest 
x-ray, resting and treadmill exercise ECG and were 
presumed to have normal hearts. The study is open to 
criticism as coronary arteriography was not performed in 
order to exclude CAD. In our institution the main 
indication for coronary arteriography is the preoperative 
assessment of patients with angina pectoris and invasive 
investigation of our control group was not felt to be 
ethically justifiable.
Several studies have assessed the value of CPT in 
detecting CAD. In studies comparing it with dynamic 
exercise Manyari et al (225), and others (218,240,243) have 
found it to be an inferior discriminator although possibly 
useful in subjects who are unable to perform dynamic 
exercise.
In the present study CPT was found to have a 
different discriminatory effect if used in subjects with 
lower ejection fractions (Group 2), where the sensitivity 
of RNV at rest in detecting CAD was 55% and this increased 
to 75% with CPT, but in subjects with normal or near normal 
resting EF's, the sensitivity was only 50%. It seems 
inappropriate to compare a group of normals with a group 
with a low mean EF. Thus the results of those with normal 
E F ’s at rest ( > 50% : Group 3), may be more relevant.
Despite greater increases in heart rate and blood 
pressure compared to CPT, SIHG was only successful in 
detecting five subjects in group 3 (EF > 50%), giving a 
sensitivity of 25%, although specificity was more 
acceptable. Several studies (179,266,267) comparing SIHG and 
dynamic exercise have shown that it is of limited value in 
the detection of CAD. In contrast, Bodenheimer et al 
(219,231), using RNV found a sensitivity of 86% and 
specificity of 87% - however, these findings are of limited 
value as most of their subjects had abnormalities at rest, 
in a similar way to the results of group 2 (low mean E F ) , 
in the present study.
Conclusions.
This study has demonstrated satisfactory 
reproducibiliy of resting RNV in a control group and of 
CPT and SIHG in a group with CAD. Significant heart rate 
and blood pressure responses were observed in both normals 
and those with CAD, although elevations were higher with 
SIHG.
Both CPT and SIHG are useful when serial comparisons 
of myocardial performance are to be made. A specific area 
of application would be the serial assessment of drugs on 
the myocardium as described in the preceding section of 
this thesis. The detection of CAD is less reliable 
although a review of the literature suggests they may be 
alternatives to dynamic exercise, when this is not possible. 
In our laboratory inadequate sensitivity and specificity
was achieved in patients with CAD who had normal or near 
normal resting EF. When studying subjects with CAD, 
adequate exercise may not be possible because of the 
precipitation of angina pectoris - this did not occur with 
CPT or SIHG. One major advantage of CPT and SIHG is their 
ease of application without risk of patient movement or 
excessive use of camera-time. These factors are of obvious 
importance when serial evaluations are necessary.
SECTION 4.2. ASSESSMENT OF THE HITACHI HME-20
PULSE AND BLOOD PRESSURE MONITOR
Introduction.
All the heart rate and blood pressure recordings 
reported in this thesis were made using a Hitachi HME-20 
pulse and blood pressure monitor. This instrument has 
therefore been evaluated for the purpose of this thesis.
In recent years, increasing reliance has been 
placed on automated or semi-automated devices to measure 
blood-pressure (BP) indirectly. (268) These measurements 
are believed to be free of observer error, and thus 
provide a more reliable estimate of BP when compared to 
the traditional mercury column sphygmomanometer. Reports 
on the conventional sphygmomanometer show that as many as 
half of those used in hospital are inaccurate (269) and 
that hospitals usually have no policy for maintaining 
sphygmomanometers. For these reasons a number of new 
techniques for measurement of BP have been developed, 
(270,271) In addition, by providing a device permitting 
self-recording of blood-pressure, BP can be measured by 
the patient at home, thereby minimizing error induced by 
the anxiety of a hospital visit. Thes'e BP recordings may 
be more representative. (272,273) Serial measurement of 
BP in this way also allows for the assessment of new 
antihypertensive or vasoactive agents outside a hospital.
Despite their widespread use, however, the 
performance characteristics of such devices are often 
poorly documented. It is important, if these machines are 
to be used in screening programmes or in population studies, 
to determine the accuracy and variability of the recordings 
obtained. A number of automatic instruments have been 
developed. Some have depended on the application of 
ultrasound reflectance for the detection of arterial blood 
flow. Others depend on detection of Korotkoff sounds.
Some of these devices have the facility of automatic 
control over inflation and deflation. (274,275)
The Hitachi HME-20 blood-pressure and pulse monitor 
is one of the more recently introduced devices based on 
Korotkoff sound detection. This a low-cost device which 
has been used for research purposes, in intensive-care 
units and in rural general practice. I am not aware of 
any critical assessment of the device in the medical 
literature.
Material and Methods.
The Hitachi HME-20 pulse and blood-pressure monitor 
is a fully automatic unit which can operate from mains or 
battery. An electronic microphone, shielded from 
extraneous noise in the pressure cuff, is employed to 
detect Korotkoff sounds. Phase V of the Korotkoff 
sounds is taken as the diastolic end-point. Automatic 
inflation and deflation is performed and results are 
displayed on a fluorescent digital display. The
measuring range is from 0-300 mmHg. and 30-200 bpm. In 
operation, the cuff is positioned so that the microphone 
overlies the maximal pulsation of the brachial artery.
If an inadequate signal is detected, the instrument fails 
to produce a result and indicates an error on the display 
screen, thus minimizing possible error when used by an 
unskilled individual.
Supine blood-pressure was recorded from the left 
arm and the results compared with simultaneously recorded 
intra-arterial measurements. The procedure was performed 
towards the end of left heart catheterisation for coronary 
arteriography in eight subjects: all of whom consented to 
the study. In each case the catheter tip was positioned 
in the arch of the aorta to approximate to the innominate 
artery. Thereafter, 10 successive simultaneous measure­
ments of blood-pressure were recorded. Catheter patency 
was maintained between readings by continuous flushing 
with a normal saline and heparin mixture. Intra-arterial 
pressure was charted continuously and calculated as a mean 
of 15 complexes immediately prior to cuff inflation and 
heart-rate was calculated from a simultaneous electro­
cardiogram using the mean of five R-R intervals preceding 
cuff inflation.
Intra-arterial BP was measured using a Bentley 
Trantec Physiological Pressure Transducer (Model 800) and 
a Siemens electromanometer with a Mingograph 81 six- 
channel recorder, calibration being carried out prior to 
each procedure with a mercury manometer. Direct
calibration of the system was carried out before each 
recording against a mercury column, 100 mmHg. being 
equivalent to a 5 cm deflection on the recording paper.
One hundred and fifty cm long manometer connecting lines 
were used, manufactured by Portex. Zero reference level 
was taken as mid-thorax in the supine position. Although 
this technique has been accepted by others to provide an 
adequate standard (271), the author appreciates that such 
a system may have a tendency to over-estimate true 
arterial systolic blood-pressure. The blood-pressure cuff 
was applied to the left arm, and American Heart Association 
recommendations for cuff size were fulfilled. (276)
Intra-arterial pressures were read by the author, unaware 
of the cuff readings.
Statistical Analysis.
Comparisons between direct and indirect readings 
were made using Student's paired t-test (two tailed) and 
Armitage's test for trend. (277) Correlation coefficients 
and regression lines were calculated, together with a 
between-method frequency histogram for the difference in 
record ings.
Results.
In general, the device underestimated systolic 
blood-pressure, but reproduced an accurate assessment of 
diastolic pressure. There was a highly significant 
(p < 0.001) correlation with direct readings for both
systolic and diastolic recordings (Figure 4.7) and also 
for heart-rate (Figure 4.8). Systolic pressure was 
underestimated by a mean of -12 mmHg. (p < 0.001). Gross 
underestimation of systolic pressure tended to occur with 
a systolic pressure over 180 mmHg., where in two patients 
the device underestimated by more than 30 mmHg. on a 
number of occasions. Table 4.12 shows that no significant 
difference could be demonstrated between the mean values 
for diastolic BP, or the mean heart-rate between the 
two methods. The mean and standard deviation of each 
parameter and results of paired t-tests is also shown 
in the table. For each comparison, a histogram of 
between-method difference has been constructed (Figures 
4.9 and 4.10), only 31% of systolic recordings fell within 
± 10 mmHg. of the intra-arterial readings, although 62% of 
the readings are within 10 mmHg. of the line of iden.tity 
in the region of 100-150 mmHg. 80% of diastolic recordings 
also fell in this range. 63.9% of heart-rate measurements 
fell within 5 beats per minute of those calculated from 
the electrocardiogram. Variability of measurements was 
not significantly different for systolic blood-pressure 
when comparing IA against the Hitachi monitor (p > 0.1). 
However, there was a significant difference in variability 
for diastolic pressure (0.02 > p > 0.01).
Heart-rate measurement variability did not differ 
significantly (p > 0.1) when compared to the ECG 
recordings. The scatter diagrams for systolic and 
diastolic blood-pressure indicate a trend away from the 
line of identity. To determine if this trend is signifi-
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FIGURE 4.7
Scatter plot of intra-arterial blood-pressure versus 
cuff-recorded pressures. Line shown is line of 
identity. (* p < 0.001).
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FIGURE 4.8
Scatter plot of heart-rate obtained from 
electrocardiogram and simultaneously recorded 
by Hitachi HME-20.
(* p < 0.001; b.p.m. = beats per minute;
ECG = Electrocardiogram).
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HEART RATE
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FIGURE 4.10
Frequency histogram of between-method difference 
for heart-rate. 63.9% of monitor readings 
within 5 beats per minute (b.p.m.) of electro­
car diographically recorded rate, 86.8% of 
readings within 10 b.p.m.
cant for a given range of blood-pressures a Chi-squared 
value was calculated for successive ranges of blood 
pressures (viz. for systolic BP: <100, 100-109, 110-119, 
>120 mmHg). Thus X 2 can be split into a component due to 
linear regression (ie. trend) and a component due to 
departures from linear regression. The procedure is as 
detailed by Armitage. (277) The results for systolic 
blood-pressure are shown in Table 4.13, which shows a 
highly significant trend which results in erroneous 
measurement as the blood-pressure increases. Similar 
results (overall X 0.001) are apparent for diastolic 
blood-pressure. When heart rate is subjected to this 
analysis, no significant trend was demonstrated, and thus 
it can be accepted that the relationship between ECG and 
Hitachi HME-20 recorded heart-rate follows the line of 
identity.
I assessed the value of this device in a number
of situations. It was of particular use for home and 
ambulant BP recording. The machine is light (2.6 kg with 
batteries) and portable, and requires little maintenance. 
Patient operation is simple and the cuff is designed so 
that it is easy to apply. In addition, very little time 
is required for patient education, unlike the conventional 
sphygmomanometer. (278) Unfortunately, the device is not 
suitable for recording blood-pressure during patient 
movement, for example exercise electrocardiography, as 
even slight additional noise created by movement is 
detected by the microphone and results in erroneous 
measurement.
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Discussion.
In general, the Hitachi HME-20 pulse and BP monitor 
provides a satisfactory estimate of diastolic pressure and 
heart-rate. There is a tendency to underestimate systolic 
pressure, however, and this is most marked when intra- 
arterial pressure is more than 150 mmHg. (Figure 4.8): 
recordings in this range account for the skewed distribution 
of differences in Figure 4.9(a), which indicates that only 
31% of measurements were within ±10 mmHg of IA recordings. 
There is an acceptable standard of measurement, however, 
between 100 and 150 mmHg. Highly significant correlation 
coefficients for heart-rate and both systolic and diastolic 
BP indicate that, when changes in a parameter are of prime 
importance (for example when evaluating anti-hypertensive 
medication), the device will reproduce an accurate record 
of these changes. Because of the additional noise created 
by exercise, which is detected by the cuff microphone, I 
did not find the instrument valuable as a means of 
assessing BP during exercise.
Systolic pressure was underestimated by a mean of 
-12 mmHg. This is comparable with the standard sphygmoman­
ometer, which has been shown to underestimate systolic 
pressure by -10 mmHg. (271), and also the random zero 
sphygmomanometer which records clinic blood-pressures 
significantly lower than simultaneous IA pressures (mean 
-13/-1 mmHg.) (278) In a previous study evaluating BP 
recorders (269), all seven devices assessed gave signifi-
cantly different values compared to IA recordings for 
systolic BP and in five cases significantly underestimated 
diastolic BP. None of these alternative recorders are 
capable of measuring heart-rate. Labarathe et al (270), 
evaluated seven instruments, but used indirect means only.
I considered that an intra-arterial standard was necessary 
for evaluation of this more recent device. Many 
workers have found a wide range of differences when 
comparing IA and indirect cuff BP measurements. (279,280) 
Indirect BP is subject to considerable variability (281), 
and to minimize the effect of this variability, serial 
simultaneous measurements were taken in this study.
Thus, the Hitachi HME-20 compared favourably 
with currently available devices, and may be superior when 
measuring diastolic pressure. Its main shortcoming is 
underestimation of systolic BP, and this failing is shared 
by other devices of this sort. (271) While occasional large 
individual differences in systolic pressure did occur 
( > 150 m m H g ) , the meaned recordings from eight patients 
compared favourably, suggesting that a satisfactory 
estimate of blood-pressure patterns can be obtained with 
this instrument. Although the intra-arterial measurement 
may itself overestimate systolic blood-pressure, I do not 
feel that this could account for the gross differences in 
systolic pressure outlined above. However, I demonstrated 
a trend away from the line of identity for both systolic 
and diastolic blood-pressure. In addition, the technical 
reliability of the device over extended periods of 
operation has been found to be excellent, both during
hospital and domestic use. The number of innovations in 
techniques and devices for measuring blood-pressure is 
surprisingly small (270,271,282-284) and the reports are 
often lacking in detail. This position possibly reflects 
the gap between medical and engineering interests. I have 
evaluated a monitor, which, because of its low price and 
ease of operation, may prove attractive to both the 
clinician and patient and can be relied upon to provide 
a comparable performance to many more expensive devices.
Conclusions.
Highly significant (p < 0.001) correlations were 
found between intra-arterial systolic and diastolic 
pressures and pressures recorded by the Hitachi monitor. 
Similarly, the electrocardiographically computed heart- 
rate, and that given by the Hitachi monitor were signifi­
cantly correlated (p < 0.001). Systolic blood-pressure 
was underestimated by a mean of -12 mmHg. and tended to 
become more erroneous when intra-arterial pressure was 
> 150 mmHg. These results are comparable to more expensive 
pulse and blood-pressure monitors. I conclude that the 
instrument can reproduce a satisfactory estimate of 
heart-rate and blood-pressure and may be of particular use 
when a change of blood-pressure is of prime importance, 
rather than an absolute measurement.
SECTION 5.
THE INFLUENCE OF INTRINSIC SYMPATHOMIMETIC 
ACTIVITY ON THE LIPOPROTEIN PROFILE DURING 
CHRONIC BETA-ADRENOCEPTOR BLOCKADE.
This study was carried out in collaboration 
with the Department of Pathological 
Biochemistry, The Royal Infirmary, Glasgow.
5.1. INTRODUCTION.
Together with methyldopa, prazosin, phenytoin and 
oral contraceptives (285), beta-adrenoceptor blockers have 
been shown to have an adverse effect on serum lipids. It 
is postulated that any agent which adversely affects 
lipoproteins, may exacerbate coronary atherosclerosis and 
thus diminish the benefit of treatment. The possibility 
that the benefits of treating hypertension with beta 
blockers may be negated by the increase in risk associated 
with changes in serum lipoproteins has been suggested by
both Shaw (286) and Helgeland. (287)
It is hoped that by reducing blood pressure with 
beta blockers the medium and long-term risk of CAD is
reduced. Although the Veterans Administration Co-operative 
Group (288) provided clear evidence of an effect on cerebro 
vascular disease morbidity and mortality, no reduction 
in cardiac events was demonstrated. This failure to show 
a reduction in CAD mortality has been reported in several 
large studies investigating hypertensive individuals. 
(289-291) These negative results have raised the 
possibility that metabolic adverse effects may be negating 
the benefits of blood pressure reduction. The effect of 
at least eight commercially available beta blockers have 
been investigated with respect to plasma lipids and the 
literature concerning their effect on lipids is conflicting 
No apparent consistent differences result from the presence 
of ISA or cardioselectivity. As few studies have lasted 
more than six months, and since these drugs are usually
prescribed on a long-term basis, it is important to 
investigate these drugs over a longer period of time.
In addition since some earlier studies suggested that drugs 
with ISA might have less harmful effects' on plasma lipids 
than pure beta blockers (286,292,293), it is appropriate to 
examine the influence of ISA in chronic treatment with 
beta blockers.
The following, is a brief summary of lipoprotein 
composition and their association with CAD.
Lipoprotein Composition.
Plasma lipoproteins are macromolecular aggregates 
consisting of an apoprotein shell with a lipid core, the 
predominant lipids in plasma being triglycerides, phospho­
lipids and cholesterol esters, all of which are esters of 
long-chain fatty acids. The chief function of plasma lipo­
protein is to transport lipids from sites of absorption 
or synthesis to sites of utilisation.
Triglycerides are mixed fatty acid esters of 
glycerol and are chiefly synthesized in the liver from 
circulating nonesterified fatty acids and glycerol 
phosphate. Cholesterol is a sterol which is an essential 
component of cell membranes. Virtually all the newly 
synthesized cholesterol in plasma originates from the liver 
and distal small intestine, while dietary cholesterol is 
predominantly absorbed from the proximal small intestine.
Lipoproteins can be classified according to their 
flotation rate (Svendberg Flotation Units: Sf) on 
analytical ultracentrifugation; hydrated density; 
electrophoretic mobility or immunochemical behaviour.
I have used the former for the purposes of this thesis.
The chief characteristics of the lipoproteins are shown in 
Table 5.1.
Chylomicrons are the largest of the lipoproteins 
and are the form in which dietary triglyceride is 
transported after its absorption from the small intestine. 
Triglyceride, together with small amounts of cholesterol 
ester, is enclosed within a spherical shell of phospho­
lipid, free cholesterol and apoprotein.
Very low density lipoprotein (VLDL) is also 
relatively triglyceride rich, the particles resembling 
small chylomicrons, but containing proportionately more 
cholesterol, phospholipid and protein. They are 
synthesized mainly in the liver and act as the main 
carrier of endogenous triglyceride. VLDL synthesis is 
enhanced by an increased flux of nonesterified fatty acids 
to the liver by factors which stimulate hepatic fatty 
acid synthesis, such as a high carbohydrate intake.
Most of the cholesterol in plasma is transported 
in the form of low density lipoprotein (LDL). Each LDL 
particle contains the same amount of apo B as VLDL but 
has much less triglyceride, no apo C and a higher ratio 
of sphingomyelin to lecithin. LDL consists of one
TABLE 5.1 CHIEF CHARACTERISTICS OF PLASMA LIPOPROTF.TNS.
Density 
g/ m l . % of
Lipids 
total lipid
TG TC PL
Chyloraicrous 0.95 88 3 9
VLDL. 1.006 56 17 19
LDL. 1.091-1.063 7 59 28
HDL 2. 1.063-1.125 6 43 42
HDL 3. 1.125-1.21 38 41 55
ABBREVIATIONS: TG = Triglyceride.
TC = Total Cholesterol.
PL = Phospholipid.
VLDL = Very Low Density Lipoprotein.
LDL = Low Density Lipoprotein.
HDL = High Density Lipoprotein.
quantitatively major component ( L D L 2 ) and two minor 
components (LDL 1 ,L D L 3).11 is probable that LDL is normally 
derived exclusively from VLDL - this conversion generating 
an intermediate density lipoprotein (IDL).
High density lipoprotein (HDL) although 
precipitating as a single component, separates further on 
ultracentrifugation into minor and major subfractions 
HDL 2 and HDL 3, which have different properties and 
functions. Newly synthesized HDL contains mainly protein, 
phospholipid and free cholesterol.
Apolipoproteins.
Apoproteins are proteins which form the capsule or 
shell around the lipoproteins. Depending on molecular 
variations the apoproteins are subdivided, the major 
subdivisions being apoprotein A, B, C, and E.
The lipid composition of lipoproteins can vary 
greatly and it has been suggested that measurement of the 
apoprotein concentration provides a better index of the 
number of particles than does determination of their 
cholesterol or triglyceride content.
Apoproteins have three main functions:
1. They help solubilise cholesterol and 
triglycerides by interacting with 
phospholipids.
2. They regulate the reaction of lipids with 
enzymes such as lecithin cholesterol acyl 
transferase (LCAT) or lipoprotein lipase.
3. They bind to cell surface receptors and thus 
determine the sites of uptake.
The predominant apoprotein constituents of the 
major lipoprotein subfractions are shown in Table 5.2.
It has been suggested that measurement of the apoproteins 
may be a more powerful indicator of atherosclerotic risk, 
compared to determination of the amount of cholesterol 
these particles carry. (294,295). At present, however, 
it is accepted that analysis of apo A-I and Apo B provides 
additional information to that obtained by measuring serum 
lipids, but has not replaced the latter as criteria of CAD 
risk.
Association of Lipoprotein Changes with Coronary Heart D i s e a s e .
After hypertension and cigarette smoking, it has 
been established that disturbances in serum lipoproteins 
are associated with an increased risk of CAD. Hyper- 
cholesterolaemia is generally considered a major risk 
factor for CAD. (296-298) Some (296), but not all 
(297,298) studies indicate that hypertriglyceridaemia may 
also be a risk factor irrespective of the cholesterol 
concentration, but it is unlikely that small increases in 
serum triglycerides contribute to vascular morbidity. In
TABLE 5.2 APOLIPOPROTEIN COMPONENTS OF THE MAJOR 
LIPOPROTEIN SUBFRACTIONS.
Lipoprotein Apolipoprotein Composition
Major Component Minor Component
Chylomicrons Apo C Apo B
Apo A Apo E
VLDL. Apo B Apo E
Apo C
LDL. Apo B Apo A
HDL 2. Apo A-I )
) Apo C , E
)
h d l 3 . Apo A-II)
Abbreviations: Apo - Apolipoprotein.
addition there is still no evidence that reducing the 
triglyceride concentration to within the normal range 
results in a reduced incidence of cardiovascular disease. 
Epidemiological data (299) suggests that a combined hyper- 
lipidaemia (increased level of cholesterol and 
triglycerides) may represent a more significant risk for 
premature CAD than hypertriglyceridaemia alone.
An elevation of LDL and reduction of HDL are 
associated with an increased risk of CAD (89,90). H D L 2 
is significantly reduced in CAD and is the lipoprotein 
subfraction which correlates best with the severity of 
CAD (300), but there is no significant change in H D L 3 . 
Whether an increase in VLDL is associated with an 
increased atherosclerotic risk, is still a subject of 
controversy. (301) As suggested above apoproteins may be 
better discriminators for atherosclerosis. (302-304) 
However, Ishikama (303) considered Apo A-I to be a less 
powerful predictor of CAD than HDL cholesterol. Avogaro 
(304) in a large series of MI survivors and controls, 
concluded that Apo A-I and Apo B were as effective 
discriminators as either cholesterol, triglycerides or HDL 
cholesterol in subjects less than 50 years and superior 
discriminators in older subjects. Whayne et al (305) have 
confirmed that Apo B concentration correlates better than 
cholesterol with angiographic evidence of CAD.
As beta-adrenoceptor blockers are capable of 
altering the lipoprotein profile it is important to 
examine the effects which ISA may have as even small
changes in the lipoproteins may result in 
increased or decreased risk of CAD.
significantly
5.2. PATIENTS AND METHODS.
Patie n t s .
Male subjects referred to a Cardiology Clinic with 
a diagnosis of chronic stable angina were considered for 
the study if they were untreated or inadequately 
controlled on their previous therapy. If the patients 
were in the latter category, therapy was tailed off over 
two weeks and the subjects were given no therapy for a 
further two weeks, before entering into the study.
Written informed consent was received from each patient 
before entry to the study and the protocol was approved 
by the Research Ethics Committee. Forty subjects were 
recruited with a mean age of 53.4 years (SD ± 7.9) and 
a range of 38-68 years. No patient was admitted to the 
study if there was any evidence of, or a previous history 
of diabetes mellitus; renal failure; chronic obstructive 
airways disease or asthma; valvular or congenital heart 
disease or unstable angina. As numerous environmental 
factors are known influence the serum lipoproteins (90,306), 
participants were instructed not to change their dietary, 
smoking, exercise habits or their alcohol consumption for 
the duration of the investigation. In addition, as 
metabolic events surrounding a myocardial infarction are 
known to cause disturbances or the lipoprotein profile 
(307), no subject was included in the study who had had a 
myocardial infarction in the previous year. Other than 
glyceryl trinitrate, no other drug therapy was permitted 
during the study.
Dietary Assessment.
Particular attention was paid to diet and each 
patient underwent dietary assessment by a qualified 
Dietician at two stages separated by six months during 
the study. Of the various methods of dietary assessment 
available the seven day diet history was the method of 
choice in this study (308). This method was chosen in 
preference to other methods which involved the weighing 
of food before meals as this technique is impractical 
for working men. Each subject was asked which foods would 
normally be eaten in the course of a week and to estimate 
quantity of food eaten at each mealtime using approximate 
household measures such as tablespoons and cups. There 
then follows a breakdown list which rechecks with the 
patients the accuracy of the diet recall. The dietary 
assessment relies on the accuracy of the pati ent’s memory 
and detailed questioning by the Dietician. It is stressed 
that the resulting food analysis is an estimate of the 
food eaten. The dietary intakes were then analysed for 
protein, energy and kilocalories, total fat, saturated fat, 
polyunsaturated fat and cholesterol, as described elsewhere. 
(309,310)
Study Protocol.
On attendance at the clinic, weight and height 
was measured and the Quetelet Index (306) (weight/height ) 
was calculated. Subjects were randomly allocated to
treatment with either Pindolol 2.5 mgs. t.d.s. or 
Propranolol 40 mgs. t.d.s. on a single-blind basis.
After two weeks treatment the dose of each drug was 
doubled and held constant for one year. During this time 
patients were seen on six occasions - 2,6,12,26, and 
52 weeks following commencement of therapy. At each visit 
heart rate and blood pressure were recorded after five 
minutes supine rest, 70 ml. of blood was withdrawn in a 
sitting position for analysis of haematocrit, serum lipo­
proteins and apolipoproteins. HDL subfractions were 
measured at 0,12,26 and 52 weeks only. All blood samples 
were taken at the same time of day (usually 09.00 hours to
11.00 hours) after an overnight fast (at least 14 hours) 
and the patient was instructed to take the last dose of 
medication at 08.00 hours on the day of each hospital 
visit and also to refrain from smoking for at least 14 
hours beforehand. Compliance with drug therapy was 
assessed and is described elsewhere in this thesis. 
(Section 2)
5.3. LIPOPROTEIN ANALYSIS.
The major lipoprotein classes may be separated 
and quantified in a number of different ways. In this 
study the technique of ultracentrifugation was used.
This involves preparative ultracentrifugation of serum 
samples followed by lipid analysis of the resultant 
fractions, and is an accepted technique which has been 
used previously in studies examining the effects of beta 
blockers on lipoprotein profiles (83,311), and is the 
accepted reference technique. Separation of lipoprotein 
classes may be effected by sequential ultracentrifugation 
(312), but a modified procedure combining single ultra­
centrifugation followed by precipitation (313) of LDL to 
separate it from HDL is now widely used and was the 
technique used in this study.
After venepuncture, blood was withdrawn into tubes 
containing potassium EDTA for measurement of plasma lipids 
and lipoproteins. Plasma total triglycerides were 
estimated by a fully enzymatic method on a Technicon 
Autoanalyzer (2nd generation) according to the fluorometric 
procedure of Kessler and Lederer. (314) Plasma total 
cholesterol was estimated by an enzymatic colorimetric 
method (315) using a modified Lieberman-Burchard reaction. 
(316) Five mis. of plasma was transferred to a 6.5 ml. 
Beckman Cellulose Nitrate Ultracentrifuge tube, which was 
then filled by layering saline of density 1.006 on top of 
the plasma. After ultracentrifugation at 105,000 g 
(39,000 rpm.) for 16 hours, at a temperature of 4°C.,
three zones can be seen in the tube, a narrow top layer 
which is opalescent, a clear middle layer and a yellow 
bottom layer. The top layer (Figure 5.1a) contains the 
VLDL which is separated from the rest (Figure 5.1b) by 
slicing the tube. Both fractions, A and B, are 
quantitatively transferred to separate volumetric flasks.
A heparin - manganous chloride reagent is added to 
Fraction B (ie. the infranatant containing LDL and HDL 
and mixed by vortexing. (317) The tube is then stoppered 
and left overnight at 4°C. The following day it is 
centrifuged for 30 minutes at 10,000 rpm. at 4°C. Thus 
precipitating LDL which is packed at the bottom of the 
tube with HDL in the supernatant. The cholesterol 
concentrations of fractions A(VLDL), B (LDL and HDL) 
and of HDL were measured. The concentration of LDL was 
obtained by subtracting the HDL cholesterol concentration 
from that in fraction B.
HDL was further subfractionated into i t ’s 
components H D L 2 and HDL3 by rate zonal ultracentrifugation. 
(318,319) The sample for analysis is prepared by increasing 
the density of a 2 ml. aliquot of plasma to 1.216 Kg./I. 
by the addition of 4 mis. of a sodium bromide solution 
of density 1.31 Kg./I. The preparation is then 
subjected to ultracentrifugation for 30 hours at 40,000 rpm. 
and at 18°C. One millilitre (containing total plasma 
lipoproteins) is harvested from the top of the tube into 
a graduated volumetric cylinder and used for analytical 
ultracentrifugation. Prior to analysis the sample is 
diluted with 1.20 Kg./I. of sodium bromide solution so
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that during centrifugation the total light absorbance 
at a wavelength of 280 n m . does not exceed 1.0. An 
aliquot of the diluted sample is then injected into the 
sample side of a double sectored cell of a Beckman AN-F 
rotor for ultra-violet scanning. This technique is fully 
au tomatic.
Apoprotein Analysis.
These analyses were carried out using an Encore 
Centrifugal Analyser (Baker Instruments). The analysis 
depends on a specific protein reaction between the 
apoprotein (antigen) and an anti-apolipoprotein antibody 
in the serum which is raised in sheep. A similar process 
is described by Austin and Mazuicki. (320) A precipitation 
reaction occurs causing formation of 3-dimensional 
complexes which cause the sample to become turbid and to 
be capable of scattering and absorbing light. Light, 
with a wavelength of 292nm. is shone into the sample and 
the complexes will absorb a proportion of this. There is 
a direct relationship between the amount of light absorbed 
and the quantity of apoprotein. Using test standard with 
a known concentration of apoprotein it is possible to 
calculate the concentration in a test sample and to 
construct a calibration curve. The reaction between 
antibody and apoprotein is carried out in the rotor of 
the Encore Centrifugal Analyser. Complexes are detected 
spectrophotometrically as the reaction proceeds. Prior 
to loading the sample onto the machine, to achieve 
rapid formation of antigen - antibody complexes it is
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necessary to accelerate complex formation by adding a 
4% polyethylene glycol and isotonic saline mixture. After 
7.5 minutes, to allow for equilibration, the solution is 
then passed through a 0.22 -m. millipore filter to remove 
any debris. After mixing this diluted sample with 250 ml. 
of 1/40 diluted antiserum, mixing then occurs on the 
analyser and the reaction proceeds.
A schematic representation of the procedure from 
this stage is shown in Figure 5.2.
Statistical Analysis.
Two-way analysis of variance was carried out 
initially. Where this indicated a significant effect due 
to treatment then parametric statistical analyses (paired 
Student’s t test) were performed. In addition to a 
Wilcoxon rank sum test to test for between group 
differences. The significance levels reported are the 
most conservative obtained. Linear regression analysis 
was applied to the change from initial values of HDL 
concentrations to identify any relation between the 
magnitude of changes after treatment and the initial value.
5.4. RESULTS.
There were no significant differences in the 
pre-treatment characteristics of the two groups of subjects 
(Table 3.1), in terms of age, body mass index, resting 
heart rate or blood pressure. Dietary assessment revealed 
a similar weekly intake of protein, kilocalories, total 
fat, saturated fat and polyunsaturated fat between the two 
groups. Dietary intake between the two assessments was 
similar (Table 5.3) with the exception of saturated fat and 
cholesterol of which more was consummed by those on 
Propranolol at the second dietary assessment (p < 0.05). 
Haematocrit, as a crude assessment of plasma volume, did 
not change significantly in either treatment group through­
out the investigation (Table 5.4). The effect of each drug 
on resting heart rate and blood pressure is shown in 
Figure 5.3. There was a significant fall in heart rate in 
those receiving propranolol after two weeks (71 - 10 to
55 - 7 bpm; p < 0.01), but not with pindolol and this 
pattern was maintained throughout. Likewise those treated 
with propranolol showed a significant reduction in resting 
systolic blood pressure (134 - 29 to 112 - 14 mmHg., 
p < 0.01), but subjects receiving pindolol did not have 
a reduction in blood pressure.
The concentrations of the major lipoproteins and 
apolipoproteins at each assessment period are shown in 
Table 5.5 (Pindolol Group) and Table 5.6 (Propranolol 
Group). No significant change in any parameter occurred 
in those treated with pindolol. However there were
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significant rises in total triglyceride ( 1 13.5%) and in 
H D L 2 at 52 weeks ( 1 18%) (Figure 5.4), despite there 
being little change in total HDL or H D L 3. This is 
reflected in a sequential rise in the H D L 2 to H D L 3 ratio 
from a basal value of 0.124 - 0.0849 to 0.155 ± 0.0657 
at 52 weeks. Although no change occurred in apoprotein 
A-II, both apoprotein A-I and apoprotein B rose throughout 
the study, but these changes failed to reach significant 
levels.
As with pindolol, propranolol produced a non­
significant rise in triglyceride ( +14.2%). No significant 
change in total cholesterol or low density lipoprotein 
occurred. Very low density lipoprotein rose progressively 
to a level 38.5% higher than the basal value at 52 weeks 
(p < 0.05). Although the level of total HDL fell by up to 
12.5% at 26 and 52 weeks (p < 0.01 and p < 0.05 
respectively), the level of HDL 2 rose significantly by 
17.5% at 52 weeks (p < 0.05). This followed a fall in 
H D L 2 at 26 weeks of 20.5% (p < 0.05). H D L 3 fell by up to 
13.2% at 26 weeks (p < 0.001). These changes resulted in 
a rise in the H D L 2 to H D L 3 ratio from 0.155 - 0.0980 to 
0.195 ± 0.0982 (p < 0.01) at 52 weeks.
Apoprotein A-I rose from 127 ± 17.0 to 135 - 21.4 
(p < 0.05) at two weeks, but after six weeks began to fall 
back to pre-treatment levels. No significant change in 
apoprotein A-II occurred, but apoprotein B rose significantly 
at two weeks (p < 0.05) and 52 weeks (p < 0.05).
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FIGURE 5.5
Mean percentage changes in serum HDL subfractions at 
2, 6, 12, 26 and 52 weeks relative to basal levels.
• p < 0.05; •• p < 0.01; «««p < 0.001.
Abbreviations: HDL - High Density Lipoprotein.
N.M.- Not measured.
In order to assess whether subjects with pre­
treatment normal or elevated values of total cholesterol, 
triglycerides, and HDL cholesterol responded differently 
to each drug the participants were divided into groups 
according to basal values of these parameters. The results 
of this analysis are shown in Table 5.7. In the pindolol 
group total cholesterol rose slightly if the initial 
value was low or normal, but fell significantly at 2, 12
and 52 weeks (p < 0.01) if the value was high initially.
A less consistent response occured with total triglyceride 
which tended to rise by a maximum of 26% in those with , 
basal values <2.,00 mmols/1., but fell again at 52 weeks. 
In those with basal values >2.00 mmols/1., the levels 
tended to fluctuate more with rises and falls observed 
throughout treatment. Total HDL cholesterol rose by up to 
11% in those with initial values <1.2 mmols/1, (p < 0.05), 
but fell by up to 11% if basal values were >1.2 mmols/l.
(p < 0.05 at 26 weeks).
In the propranolol group, those with initially 
high total cholesterol levels showed a small increase, in 
distinction to the response with pindolol, and those with 
total triglyceride <2 mmols/l. showed a significant 
increase of up to 40% at the 26 week stage (p < 0.05 
at 26 weeks), although no substantial change occurred if 
the initial value was >2 mmols/l. Total HDL cholesterol 
fell slightly in those with initially low levels, but fell 
significantly by as much as 17% at 52 weeks in those with 
basal values >1.2 mmols/l. (p < 0.05 at 2, 26 and 52 
w e e k s ) .
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Linear regression analysis was applied to the 
change in H D L 2 levels compared with the initial values. 
Significantly positive relationships were shown for the 
pindolol group at 12 weeks (p < 0.05) and 52 weeks 
(p < 0.001), indicating that those with the lowest
initial concentration showed the least change. No such 
relationship was shown for those taking Propranolol. The 
results of this analysis is shown in Table 5.8.
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5.5. DISCUSSION.
The major findings of this investigation 
included a sequential rise in VLDL cholesterol in the 
group treated with propranolol (p < 0.05 at 52 weeks).
In this group also, although total HDL fell significantly 
at 26 and 52 weeks the level of H D L 2 rose significantly 
at 52 weeks (p < 0.05), despite a significant fall in 
this parameter at 26 weeks (p < 0.05). Only one other 
investigation of this sort has examined the effect of beta 
blockers on HDL subfractions (321) and this found a 
reduction of total HDL cholesterol after 6 and 12 weeks 
(p < 0.05), and small insignificant reductions in H D L 2 ,
in those taking propranolol. It is possible that this
difference is due to the length of treatment periods 
between the present investigation and that of Murphy et al 
(321). Also, in contrast to the latter report no change 
occurred in H D L 3 in the propranolol treated group until 
26 weeks when there was a highly significant fall 
(p < 0.01) which was maintained to the 52 week stage
(p < 0.05). The gross effect of these changes in H D L 2 and
H D L 3 was a favourable and highly significant increase 
(p < 0.01) in the H D L 2 to H D L 3 ratio at 52 weeks only, 
despite there being a fall of 11% (p = NS) at 26 weeks. 
This finding alone indicates that long-term effects of 
beta blockers on serum lipoproteins may differ from short­
term effects. Since patients are usually prescribed beta 
blockers on a long-term basis, it is important that the 
long-term effects be assessed. I have been unable to 
find any long-term studies involving propranolol in the
literature. Total HDL cholesterol concentration 
correlates strongly and inversely with the risk of 
atherosclerosis, but H D L 2 has the strongest negative 
correlation with the extent of CAD in angiographic 
studies. (300) Although no epidemiological evidence has 
been forthcoming, this may be because this would be 
technically demanding to achieve and because measurement 
of these substances is a relatively recent undertaking.
This suggests that the long-term effect of propranolol 
on H D L 2 is beneficial although short-term effects may be 
harmful in terms of atherosclerotic risk. It is possible 
that this effect is negated by long-term benefit, although 
this change will require confirmation.
Like Murphy et al (321), I found a small sequential 
fall in LDL cholesterol, but this was not significant.
Other positive findings in the propranolol group 
include a rise in both apoprotein A-I and apoprotein B at 
two weeks (p < 0.05) with the latter also significantly 
elevated at 52 weeks (p < 0.05). As pronounced variation
can occur in the lipid composition of lipoproteins and 
plasma, it is possible that measurement of apoprotein 
concentration provides a better index of the number of 
particles than does determination of their cholesterol or 
triglyceride content. (322) Apo B-100 can be regarded as 
a marker for LDL and Apo A for HDL. However, in this 
study a rise in Apo B (p < 0.05 at 2 and 52 weeks) 
occurred at the time of a fall in the LDL cholesterol 
(although this was insignificant). It is possible that
the cholesterol content of these particles falls, but the 
number of particles rises. A level of Apo B may be a 
better indicator of atherosclerotic risk than a rise 
in LDL cholesterol. (294,295) No correlation was 
demonstrated between changes in Apo A-I or HDL.
Using multivariate analysis, Whayne et al (305) 
confirmed that apo B concentration correlated better with 
angiographically confirmed CAD than did serum cholesterol. 
This indicates that the rise in Apo B experienced in those 
treated with propranolol may be harmful despite the 
possible beneficial effects on total HDL cholesterol and 
H D L 2 , although the latter changes were not reflected by a 
favourable change in Apo A-I. Opinions are divided 
concerning Apo A-I as a better index of CAD than HDL or 
H D L 2 (294,303,304), therefore the changes in HDL are 
probably more reliable at present until more information 
becomes available. The rise in Apo B in this study may 
also reflect the significant rise in VLDL at 52 weeks 
(p < 0.05) in the propranolol group as VLDL also contains 
Apo B although in small quantities. It is possible that 
if LDL Apo B and VLDL Apo B could be separated, the former 
would be a better index of atherosclerotic risk (301) and 
this is currently under investigation.
A rise in total triglyceride concentration was 
confirmed with both drugs in this study. Although these 
changes were not significant, the rise of around 14.% 
at 12 weeks for propranolol is similar to that found in 
other investigations (77,321,323), and the rise of 12% at
12 weeks (p = NS) in those treated with pindolol has been 
the experience of some (286,321,324), but not all workers 
(325) who have investigated pindolol.
By relating changes in lipoprotein concentration 
to the basal values, additional information was obtained.
The most important of which is a highly significant fall 
in total cholesterol in response to pindolol treatment 
for those with initial values of >7.00 mmols/l. (p < 0.01 
at 2, 12, 52 weeks). Although the numbers in this 
subdivision are small (n = 9) and caution must be 
exercised in the interpretation of this result, there is 
a clear difference with those treated with propranolol who 
had initial values >7 mmols/l. as no consistent or 
significant changes were demonstrated at any of the 
sampling intervals. The finding of a significant change 
in cholesterol concentration in response to beta blockade 
is rare. Using propranolol two reports suggest a 
significant fall (321,326), while using sotalol (pure beta 
receptor antagonist with no ISA), Lehtonen and Viikari (82) 
found a significant increase. Of the studies which have 
examined the effects of beta blockers with ISA on plasma 
lipids, only two found a significant fall, using 
oxprenolol (86) (weak ISA) and pindolol (88) (potent ISA), 
with Ballantyne et al showing a significant increase with 
oxprenolol. (87) Few of these studies have been controlled 
however, and with the exception of Lehtonen and Viikari (82) 
have been over short treatment periods. Although the 
present investigation failed to show any difference in 
cholesterol concentration in response to propranolol or
pindolol in all the participants there would appear to be 
an advantage for those with pre-treatment elevation of 
serum cholesterol who are treated with pindolol rather 
than propranolol.
Further theoretical disadvantages of propranolol 
over pindolol may include the rise in total triglyceride 
(p < 0.05 at 26 weeks) in those with initially low or 
normal values ( < 2.0mmols/l.) This change resulted in 
a number of individuals becoming hypertriglyceridaemic 
( > 2 mmols/l.) and as this may be a CAD risk factor (327), 
even small changes may enhance the atherosclerotic risk.
In addition, total HDL rises in those taking pindolol 
if the initial value is less than 1.2 mmols/l. (p < 0.05 
at 6 weeks), although in those treated with propranolol 
no significant change occurs, and a further reduction of 
approximately 7% occurs at 26 weeks. If the initial HDL 
concentration is >1.2 mmols/l. significant reductions were 
noted for both drugs.
Thus, using this form of analysis, previously 
"hidden” advantages' of pindolol have been demonstrated, 
but the interpretation of this information must be 
tempered by the small numbers available for each sub­
division. These data prompt the further long-term 
investigation of pindolol in hyperlipidaemic individuals 
in whom a beta blocker with ISA may be more appropriate.
5.6. REVIEW OF CURRENT LITERATURE.
No fewer than 31 investigations have taken 
place examining the effects of beta blockers on plasma 
lipoproteins in the last 12 years, and the results are 
often inconsistent and have led to confusion. The 
principle findings of these investigations are detailed 
in Table 5.9. Criteria used for inclusion in this table 
included a minimum duration of treatment 4 weeks, 
a minimum of 10 patients completing the study and the 
beta blocker being given as monotherapy.
The most consistent findings include a significant 
increase in triglycerides and reduction in total HDL 
in individuals treated with non-cardioselective agents 
without ISA although several studies have failed to 
find any change in these parameters.
Cardioselectivity does not appear to affect these 
changes, although the number of studies reporting changes 
in HDL cholesterol is much smaller. The effects of non­
car dioselecti ve agents with ISA do not appear to be as 
great with only two short-term studies showing an increase 
in triglycerides. (321,328) Two studies have found 
significant increases in total HDL using pindolol which 
was not confirmed in the present investigation. (88,329)
In general it appears that the lipoprotein 
profile has less tendency to change in groups treated 
with agents possessing ISA and these agents have been
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found to show the smallest mean increase in triglycerides 
and a more favourable lipid profile in a recent review. 
(330) This would support the findings of the present study. 
(Table 5.5 and 5.6). Likewise, this review also reported 
a mean reduction in total HDL of 19 ± 7% for nonselective 
beta blockers without ISA, 5 - 7% for cardioselective 
agents without ISA, but an increase of 3 - 11% for those 
possessing ISA. This finding was not confirmed in this 
st u d y .
Beta Blocking Agents with ISA and Lipoproteins.
In a three week investigation of oxprenolol,
Sommers et al (86) reported a significant decrease in 
plasma total cholesterol with no change in plasma 
triglyceride or total HDL (VLDL and LDL concentrations 
were not measured). In contrast Ballantyne et al (87), 
found significant rises in plasma total and LDL cholesterol 
after 16 weeks of therapy. No change was found in plasma 
triglyceride, VLDL cholesterol or HDL cholesterol. It has 
been suggested by Lehtonen et al (88,324) in a 52 week 
study, that pindolol significantly lowers plasma total 
cholesterol and raises HDL cholesterol. However, the rise 
in HDL was only significant at one month and, even then, 
only at the 5% level. In addition this was an uncontrolled 
studyN with a rather heterogeneous group of patients 
(11 males and 9 females). In an earlier study England 
et al (331) examined the effect of pindolol, atenolol, 
metoprolol and propranolol in combination with chloro­
thiazide. They demonstrated a small but significant
increase in triglycerides for all beta blockers. However, 
their findings are probably less meaningful than other 
studies as the therapy was complicated by the concomitant 
administration of a diuretic, and the triglyceride changes 
cannot be directly related to beta blockers, but may 
result from an interaction of the diuretic with the beta 
blocker.
Karmokoski et al (325) studied the effect of 
pindolol on 13 patients after myocardial infarction and 
11 control subjects. Baseline samples were taken within 
two hours of admission to hospital with chest pain, despite 
the fact that the patient had not been fasting. It is 
probable that a reliable baseline was not acheived. The 
results showed a slight, but not significant increase in 
HDL cholesterol and reduction in total triglyceride. In a 
cross-over study of metoprolol versus pindolol, Pasotti 
et al (329) measured lipoproteins over a 12 week treatment 
period. The only significant change was an increase in 
the HDL cholesterol after 6 and 12 weeks treatment with 
pindolol, which was significantly different from the 
effect of metoprolol. Leren et al (292) found no change 
in total cholesterol, triglyceride or HDL in a 10 week 
study of 20 patients taking pindolol. In another 
publication from the Oslo study, Leren et al (328) studied 
the effect of pindolol, atenolol, oxprenolol and 
propranolol on serum lipids and found that pindolol was 
again neutral in its effects in comparison to other beta 
blockers - but since treatment regimes varied from 5-10 
weeks for each drug direct comparisons are not appropriate.
The most recent report concerning pindolol is that 
of Murphy et al (321) who compared propranolol and pindolol 
in a double-blind trial. Unlike the present study they 
examined exclusively normolipidaemic subjects with 
hypertension or angina and found that both drugs had 
similar effects on lipoproteins with no change in total 
cholesterol and transient increases in triglycerides.
That study was the first to measure HDL subfractions and 
although small reductions in H D L 2 were found, these were 
insignificant. Intravenous intralipid clearance studies 
were also performed, and these confirmed an enhanced rate 
of clearance during treatment with pindolol.
Two studies have examined the effect of alprenolol 
on lipoproteins. Bjontorp (332), found no change in 
plasma cholesterol or triglycerides, and this was 
confirmed by Jurgensen (333) who examined a l p r e n o l o l fs 
effect on 33 post-myocardial infarction patients over a 
52 week period.
Effects of Other Beta Blockers on Lipoproteins.
Several uncontrolled population studies have 
suggested an adverse effect of beta blockers on the 
lipoprotein profile. The Lipid Research Clinics Program 
monitored the effects of 8 medications in 10 study 
populations in the USA, and found that females taking 
propranolol had a lower mean HDL cholesterol than non 
users. (311) Similarly, the Oslo Heart Study Group
reported that propranolol reduced HDL cholesterol by 
13% and also increased triglycerides by 24%, (81) and 
a population sample of Swedish women were found to have 
higher triglyceride levels when taking beta blockers, 
compared to other women. (334) No specific conclusions 
can be drawn from these studies as a variety of beta 
blockers with different properties were involved.
Barboriak and Friedberg (335) showed an enhanced 
lipaemic response to a 60G. fat meal after a three week 
period of treatment with propranolol in eight subjects 
with initially elevated triglyceride levels. -The data 
also show a small, but not statistically significant 
increase in fasting plasma triglyceride levels after only 
two weeks exposure to the drug. This rise in plasma 
triglyceride was not confirmed by Tanaka et al (77), who 
gave propranolol for eight weeks to 10 patients who had 
suffered cerebrovascular accidents. However, despite the 
lack of a significant change in total triglycerides, there 
was a significant rise in VLDL triglyceride which was 
accompanied by falls in the LDL triglyceride and in 
HDL cholesterol concentrations. Post heparin lipolytic 
activity was significantly suppressed by propranolol and 
the authors considered that inhibition of lipoprotein 
lipase by propranolol might have played a role in the 
reciprocal changes in lipoproteins.
There have been seven more recent studies of the 
effect of propranolol therapy (see Table 5.9a). The 
duration of treatment ranged from four (335) to 26 weeks.
(79) In one study, however, the length of treatment was 
not reported. (80) In four of these studies (79,81,326, 
333) a significant increase in plasma triglyceride 
occurred, but no significant change in plasma total 
cholesterol. One study which failed to show any 
significant change in triglyceride level (337) had 
treatment regimes of propranolol ranging from 30 - 120mgs. 
per day which is not desirable when trying to demonstrate 
consistent effects of drugs on lipid concentrations. Four 
of the 11 studies analysed HDL cholesterol (78,80,81,337), 
but in only two were significant falls in HDL recorded. 
(80,81)
In contrast to the report by Tanaka et al (77), 
VLDL and LDL concentrations were unchanged in the studies 
of Leren et al (81) and Bauer et al (78).
Only one study examining the effect of propranolol 
on lipids measured apoproteins (336) and found no 
significant change in Apo A-I or Apo B, unlike the present 
study which showed a significant increase in both these 
parameters. It is possible that these differences may be 
due to the methodology involved in measuring the apo­
proteins as Gemma et al (336) relied on electroimmuno­
diffusion which is regarded as a less accurate and 
reproducable form of analysis than the method described 
her e .
Propranolol is a non-cardioselective beta- 
adrenoceptor blocking agent without ISA. One might
therefore expect other drugs with this property to cause 
similar changes in lipoproteins. Sotalol is one such 
agent which was investigated by Lehtonen and Viikari (82) 
which is the only study, with the exception of the present 
one, to have lasted more than 26 weeks. They found 
significant rises in plasma total triglyceride and 
cholesterol and accompanying increase in VLDL and LDL 
cholesterol and a fall in HDL. It is not clear why this 
study differs from others of similar design and in view 
of the fact that it demonstrated such a departure from 
other published findings, I repeated the study and the 
results follow this discussion. As might have been 
predicted on reviewing other investigations of non- 
selective beta blockers without ISA, I was unable to 
reproduce Lehtonen and Viikari’s findings.
Labetolol is also a non-cardioselective agent 
without ISA, but which possesses significant alpha 
blocking activity. In a three week study, Sommers et al 
(86) found that labetolol produced a significant fall 
in plasma total cholesterol without significantly 
altering plasma triglyceride or HDL cholesterol.
Thus, a review of the literature concerning the 
non-cardioselective beta blockers without ISA does not 
reveal a consistent effect although the most frequently 
positive finding is an elevation of plasma total 
triglyceride and fall in total HDL cholesterol.
The cardioselective agents atenolol and metoprolol 
have been extensively studied. Six reports concerning 
metoprolol and five of atenolol have been reviewed 
(Table 5.9b). Only the study of Eliasson et al (83) 
lasted for longer than six months. Two groups reported 
an increase in plasma triglyceride. Five found no 
significant change, (83-85,329,338) In none of these 
studies was a rise in plasma total cholesterol found.
England et al (85) who investigated both metoprolol and 
atenolol over 12 weeks found that they produced a fall 
in HDL cholesterol but 3/4 of the study population 
were taking concurrent diuretic therapy which makes these 
results difficult to interpret. In addition only a ten 
day washout period was allowed between metoprolol and 
atenolol which is probably not sufficient. This was also 
the fault of another cross-over study by Kristensen (339), 
but in this study a range of treatment periods between 
8 - 7 9  months was used, and 80% of the group also 
received concurrent thiazide diuretic therapy. Eliasson 
et al (83), found no change in HDL cholesterol after 32 
weeks of atenolol therapy. The latter authors, however, 
reported increased VLDL and LDL triglyceride concentrations. 
England (85) also measured apoproteins by electroimmuno­
diffusion and found no change in Apo B, but a fall in 
Apo A .
The presence of cardioselectivity therefore, does 
not seem to produce more consistent changes than those 
found with non-selective beta blockers. Where 
significant changes were found, they were similar to those
reported with non selective agents i e . a rise in plasma 
triglyceride and a fall in total HDL cholesterol. As 
with nonselective drugs, there is a paucity of long-term 
studies, only one being conducted for more than six months.
In summary the literature concerning the effect of 
beta blockers and plasma lipoproteins is conflicting.
No consistent differences arise from the presence of 
cardioselectivity or ISA. In this regard it is relevant 
that the one study involving the cardioselective drug 
practolol, (which also possesses ISA) (340), showed no 
significant changes in plasma lipids following 12 months 
treatment.
5.7. POSSIBLE MECHANISMS OF CHANGES IN .LIPO­
PROTEIN PROFILE IN RESPONSE TO BETA BLOCKERS.
The most consistent changes in serum lipoproteins 
induced by beta blockers are an elevation of total 
triglyceride and reduction in total HDL cholesterol 
(Table 5.9). The reasons for these changes are speculative 
with several hypotheses suggested. The increased levels 
of triglyceride must be due to increased synthesis 
or reduced catabolism. Day et al (341), proposed that 
unopposed alpha stimulation in the face of beta blockade 
inhibits lipoprotein lipase with a subsequent rise in 
plasma triglyceride and fall in HDL concentration.
Their finding of a reduction in free fatty acid concen­
tration during therapy argues against there being an 
increased rate of synthesis of triglycerides. In response 
to this suggestion, Lehtonen (342) pointed out that this 
would not be consistent with his own findings of no change 
in adipose tissue lipoprotein lipase activity (88) during 
treatment with beta blockers. However, the latter report 
did observe a significant increase in lecithin cholesterol 
acetyl transferase activity during treatment with pindolol 
and a decrease when pindolol was discontinued. This 
enzyme, catalyzes the transfer of fatty acids from HDL 
lecithin to HDL cholesterol during HDL formation. (343)
This finding may explain changes in HDL concentrations 
experienced by Lehtonen (82,88) and others. (81,85,326,328)
The stimulating effect of catecholamines on 
lipolysis is probably mediated by their beta receptor
stimulating property. Their importance in regulating 
lipolysis is evidenced by the fact that beta blockers 
will reduce plasma free fatty acid concentrations during 
different lipolysis conditions such as fasting, exercise 
and following hypoglycaemia. (344) Pindolol has not been 
found to reduce concentrations of free fatty acids under 
resting conditions (88), and is therefore probably not 
antilipolytic. The resultant lipoprotein effects 
reflecting the balance between partial stimulation of 
the beta receptor and beta blockade.
However, the hypothesis that increases in 
triglyceride may be linked to a reduction in lipoprotein 
lipase activity also finds favour with Tanaka (77), who 
noted a 40% reduction in post heparin lipase during 
treatment with propranolol although a reduction of only 
7% was observed by Schauer. (326) This would cause a 
reduced rate of removal of circulatory triglyceride.
Such a change could explain the previously described 
elevation of triglyceride and the reduction in total HDL 
cholesterol as this enzyme is also involved with HDL 
cholesterol metabolism. (345) Inhibition of lipoprotein 
lipase could be mediated through a direct inhibitory 
action by the beta-adrenergic blockers or secondary to 
unopposed alpha adrenergic stimulation. During adrenergic 
blockade, plasma catecholamine concentrations may be 
increased and in vitro catecholamines appear to inactivate 
lipoprotein lipase. (346) Alpha adrenergic stimulation may 
have an important role in suppressing adipose tissue 
lipoprotein lipase, with a secondary reduction in plasma
HDL cholesterol and rise of triglyceride concentrations. 
Both Betax and 2 adrenoceptor stimulation activates 
lipolysis (347), by stimulating adenylate cyclase activity 
Thus, if propranolol is a powerful inhibitor of lipolysis 
then a reduction in total triglyceride (rather than the 
frequently reported increase) would be expected - similar 
to that produced by nicotinic acid and other antilipolytic 
agents. (348) Therefore beta blockers by inhibiting both 
lipolysis and lipoprotein lipase have "divergent activity" 
with the resultant change in the lipoprotein profile being 
related to the pharmacological properties of the agent 
used. This may help explain the differences in response 
noted with beta blockers possessing ISA (88,329), as one 
could argue that stimulation of the adrenoceptor is 
maintained, and thus, despite a reduction in lipoprotein 
lipase activity, lipolysis is maintained, sufficient to 
prevent a significant increase in plasma triglyceride.
Day et al (341) suggested that individuals with 
low basal concentrations of HDL cholesterol were liable 
to excessive alpha stimulation which impaired the 
production of HDL cholesterol but the present study was 
not able to confirm this and in fact showed a significant 
rise in HDL cholesterol after six weeks treatment with 
pindolol, but not propranolol when the initial value was 
<1.2 mmols/l. The cause of this discrepancy is 
speculative, but is probably related to the ISA effect of 
pindolol on lipolysis.
Alternative, but less likely mechanisms liable to 
cause disturbance in the lipoprotein profile include a 
direct effect on hepatic triglyceride synthesis which may 
be increased - this aspect has not so far been the subject 
of investigation. In addition, as most studies have been 
performed in hypertension it is possible that the hypo­
tensive action of the beta blocker in some way causes 
lipoprotein disturbances. This unfashionable suggestion 
was presented in an earlier study of a thiazide diuretic 
(349), but could not be substantiated by Day et al. (79)
In summary, the changes in lipoproteins caused by 
beta blockers are not fully understood but are probably 
related to activity of lipoprotein lipase and intracellular 
lipolysis - it is probable that the more stable lipoprotein 
profiles experienced when using pindolol, are the result 
of a balance between increased lipolysis and diminished 
lipoprotein lipase activity.
In the present study the highly significant fall 
in cholesterol experienced in those taking Pindolol with 
basal values >7mmols/l., cannot be explained by the 
foregoing hypotheses and must remain a matter for 
speculation. Likewise,the cause of a significant increase 
in HDL 2 after 52 weeks of treatment with propranolol 
following a significant reduction at 26 weeks is unknown.
5.8. CONCLUSIONS.
The results of the present study suggest that 
pindolol is less likely to upset the lipoprotein profile 
compared to propranolol, but not all changes associated 
with the latter drug are potentially harmful ie. the rise 
in HDL2 after 52 weeks treatment, in association with a 
rise in VLDL and Apo B and fall in total HDL cholesterol 
over the same time scale.
Further useful information was derived from the 
data by separating the subjects into groups according 
to their initial lipoprotein concentrations. In this way 
a highly significant reduction in total serum cholesterol 
was observed during therapy with pindolol in those with 
initially elevated levels ( > 7.0 mmols/1.). No such 
benefit was observed with propranolol. Total HDL 
cholesterol also fell significantly with both drugs for 
those with initial values >1.2 mmols/1. Although 
elevation of total triglyceride is the most frequent 
change noted in other investigations. I was unable to 
show significant increases using either drug although a 
13.5% increase occurred after 12 weeks treatment with 
propranolol, this deviation gradually declined thereafter 
The only significant change in triglyceride was observed 
in those with initial values of <2.0 mmols/1., treated 
with propranolol, but not pindolol.
In conclusion I would suggest that pindolol is 
less likely to upset lipoprotein metabolism and in those
in whom this occurs there is a favourable change in 
comparison to propranolol apart from the latters ability 
to raise H D L 2 levels significantly after a year of 
treatment.
It is not immediately clear why there is such 
inconsistency in reported findings of beta blocker therapy 
and serum lipoproteins. It is possible that different 
characteristics of study population are important. Most 
studies reporting an increase in serum triglycerides or 
other significant change in lipoproteins were performed 
in patients with hypertension (78,81,82,88,328,329,338) 
although some have been performed in those recovering from 
a cerebrovascular accident (350) or myocardial infarction. 
(325) No significant changes in plasma cholesterol or 
triglycerides have been demonstrated in a group requiring 
beta blockade exclusively for CAD, either because of 
angina or as part of secondary prevention (351,352), 
although Murphy et al (321) studied a group containing 
some subjects with angina pectoris.
Another reason for discrepancy in results is the 
methodology of lipoprotein analysis and quality assurance 
in individual laboratories and differing experimental 
conditions in relation to diet, smoking, levels of 
exertion, changes in plasma volume which may be important 
in long-term studies (353), drug compliance, duration of 
treatment period and concurrent drug therapy. In the 
present study strenuous efforts were made to ensure that 
all these variables remained constant and that no other
drug therapy was administered.
It is possible that an elevation of plasma total 
triglyceride induced by beta blockers will enhance the 
risk of CAD. (296) Similarly a reduction in HDL 
cholesterol (300) and Apo B concentration (322) may 
result in an increased risk. Hypercholesterolaemia has 
long been recognised as having a role in the genesis of 
atherosclerosis (354) and in this respect the fall in 
cholesterol observed in those with elevated levels taking 
pindolol in this study is potentially beneficial. It is 
possible that even subtle changes in the lipoprotein 
profile may substantially influence atherosclerotic risk 
in the large population taking beta blockers for long 
periods of time. With this view, it would seem prudent 
to use drugs with the least effect on lipoprotein 
metabolism, and current evidence suggests that pindolol 
may be the safest drug in this respect. However, where 
beta-adrenoceptor blockade is necessary in the presence 
of established atherosclerosis it is possible that small 
changes in lipoproteins are of less importance than 
effective beta blockade.
5.9. THE EFFECT OF SOTALOL ON PLASMA LIPOPROTEINS.
Introduction.
Lehtonen and Viikari (82) examined the effect of 
sotalol on plasma lipids in hypertensive subjects over a 
one year period. The authors found a significant elevation 
of plasma total triglycerides and cholesterol and LDL with 
a fall in total HDL cholesterol. All of these changes 
reaching statistical significance after six months of 
treatment. These results are in conflict with similar 
investigations on non-cardioselective beta blockers 
without ISA, as described previously in this thesis, but 
none have observed a significant change in total 
cholesterol. Likewise, VLDL and LDL concentrations do 
not change, although studies have shown an increase in 
VLDL. (77,336)
Sotalol is a non-cardioselective beta-adrenoceptor
/
blocking agent without ISA, and one might expect it to 
influence plasma lipids in a similar way to propranolol. 
This study was undertaken in view of the discrepancy in 
results between studies investigating propranolol (78-81, 
321,326,328,335) and sotalol (82) (Table 5.9a). As this 
drug is a frequently prescribed B-blocker, it is important 
to confirm any adverse influence on plasma lipids, which 
may exert an atherogenic effect.
Methods and Subjects.
Thirteen previously untreated hypertensive subjects 
were commenced on sotalol hydrochloride 80 mg.bd 
increasing to 160 mg.bd after two weeks. Three subjects 
developed intolerance to the drug and were removed from 
the study (two subjects developed a metallic taste and 
one developed mild left ventricular failure). The remaning
ten patients had a mean age of 51 ± 11.2 years (mean - SD)
• ... , • , 180 ± 25.9 ,and an initial supine blood pressure of (mean of
three readings). The study protocol was designed to
reproduce that of Lehtonen and Viikari (82), and blood
sampling was timed to coincide with the times at which
Lehtonen and Viikari (82) found significant lipoprotein
changes. Blood pressure, haematocrit and fasting plasma
lipoproteins were recorded following an overnight fast
before treatment commenced and then six weeks and six
months later. All patients were normolipaemic at the
beginning of the study, and did not alter their diets
or mean body weight significantly during the study period.
Lipoproteins and apolipoproteins were analysed as 
described previously.
Statistical Analysis.
Comparison of results was made using a two-way 
analysis of variance followed by a Student's paired t-test 
and Wilcoxan signed rank test. The most conservative 
significance values are reported.
Results.
Heart rate fell sequentially throughout the study, 
reaching a highly significant difference between basal and 
six month visits (p < 0.01). There was a similar fall in 
blood pressure, but this did not reach statistical 
significance for either systolic or diatolic values. 
Throughout the study there was no significant change in 
the haematocrit. Changes in serum lpoproteins are shown 
in Table 5.10. There was a sequential rise in plasma 
triglyceride from a basal value of 1.87 - 1.064 to 
2.5 ± 0.877 (p < 0.005) at six months. There was no
significant change in total plasma cholesterol and 
although there was a rise of VLDL cholesterol this did 
not reach statistical significance. An insignificant 
fall in HDL cholesterol also occurred. There was no 
significant change in plasma apolipoproteins.
Discussion.
As previously discussed, many conflicting reports 
have been published concerning the effect of beta- 
adrenoceptor blocking agents on plasma lipoproteins. Of 
particular relevance to this study is the report by 
Lehtonen and Viikari (82) which demonstrated significant 
increases in plasma total cholesterol and LDL cholesterol 
while at the same time causing a fall in HDL cholesterol. 
All of these changes could be regarded as detrimental in 
terms of CAD. (89,90) That study contrasts with others on
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non-selective B-blockers in which the predominant, but not 
consistent findings' have been an increase in plasma 
triglycerides and fall in HDL cholesterol (Table 5.9a). 
Lehtonen and Viikari (82) used a precipitation method to 
analyse HDL cholesterol and (VLDL + LDL) cholesterol 
concentrations. The present study, used the more 
generally accepted combination of ultra-centrifugation 
and precipitation to separate the individual lipoprotein 
classes. In addition, the mean dose of sotalol used by 
Lehtonen and Viikari was 80 mg. per day higher than the 
present investigation. Other possible causes of 
discrepancy between such studies may be difficulties with 
quality assurance or in differences with patient compliance.
Apolipoproteins are now thought to be useful 
discriminators in determining risk for future coronary 
events (304), and it was felt relevant to estimate these 
substances inthis study, although I found no significant 
change.
The fact that this was an uncontrolled study 
detracts from i t ’s merit. However, the objective was 
to reproduce the circumstances of the study by Lehtonen 
and Viikari. (82) Thus, I conclude that sotalol has 
similar effects on serum triglycerides as other non­
car dioselective beta blockers without ISA and is not 
likely to exert an increased atherogenic influence as 
previously suggested when compared to other beta blockers. 
(82)
Conclusions.
Plasma lipoproteins were estimated in ten 
hypertensive subjects (mean age 51 ± 11.2 years), before 
and six weeks and six months following treatment with 
sotalol 320 mg. per day. Heart rate fell sequentially 
throughout the study (p < 0.01) and although there was 
a sequential fall in mean blood pressure this did not 
reach statistical significance. There was a significant 
increase in plasma triglyceride concentration from a 
basal value of 1.87 ± 1.064 to 2.50 ± 0.877 mmol/1.
(p < 0.005) at six months. No significant change was 
found in VLDL, LDL and HDL cholesterol or apolipoprotein 
concentrations (Apo-I, ApoA-II, ApoB). I conclude that 
sotalol exerts a similar influence on plasma lipoproteins 
as other non-cardioseletive beta-adrenoceptor blockers 
without ISA and its use does not constitute an increased 
risk of developing atherosclerosis, when compared with 
other B-blockers
SECTION 6.
THE INFLUENCE OF BETA-BLOCKADE ON HEART R A T E . 
ARRHYTHMIAS AND ST SEGMENTS: COMPARISON OF 
PROPRANOLOL AND PINDOLOL IN PATIENTS WITH CHRONIC
STABLE ANGINA PECTORIS.
6.1. INTRODUCTION.
Beta blockers are now established for the 
symptomatic relief of angina pectoris (66), and their 
beneficial effects are well described. (357-359) Their 
effect on asymptomatic myocardial ischaemia has only 
recently come under scrutiny.
Beta blockers were introduced to antagonise the 
cardiac effects of sympathetic stimulation (360), which 
can, through i t ’s beta adrenergic actions cause markedly 
increased myocardial oxygen requirements by increasing 
heart rate and enhancing myocardial contractility. There 
appear to be four main factors which influence myocardial 
oxygen demand. (361) The most important of these are heart 
rate and ventricular systolic pressure, but the rate of 
rise of left ventricular pressure and left ventricular 
size are also of importance. Beta blockers reduce 
myocardial oxygen requirements mainly by reducing heart 
rate and blood pressure increments with exercise, and 
therefore allowing a longer time for diastolic filling 
of the coronary arteries. In addition there is a reduction 
in the velocity of contraction and oxygen consumption at 
a given workload. (359,362) Other possible metabolic 
effects and effects on platelet aggregation may also 
contribute to the anti-anginal action. (363,364)
The anti-anginal efficacy of pindolol has been 
confirmed in several reports (8,32,58,365-367), and 
comparative studies have failed to find any significant
difference with beta blockers not possessing ISA. (365,367) 
However, because of ISA, pindolol produces little or no 
reduction in resting heart rate (5) and i t ’s antagonistic 
effects only become apparent during periods of increased 
sympathetic activity (eg. during exercise). This effect 
is potentially harmful in those with rest or nocturnal 
angina who are dependant on a reduction in resting heart 
rate for relief of symptoms. Quyyumi et al (65) have 
recently compared the effect of pindolol and atenolol in 
15 patients with severe angina pectoris (including rest or 
nocturnal angina) on symptoms and ambulatory ST segment 
responses. They found that heart rate, frequency of 
angina, and the frequency and magnitude of episodes of ST 
depression were reduced significantly more by atenolol 
than by pindolol. They conclude that a reduction in 
resting heart rate is important in the treatment of rest 
angina, and therefore pindolol is not a suitable agent in 
this group. This was the first report to utilise the 
technique of ambulatory electrocardiography to assess the 
efficacy of beta blockers, in terms of ST segment changes.
The present study was undertaken to assess the 
effect of pindolol on heart rate, arrhythmias, and 
ST segments in a group of middle aged men with stable 
exertional angina pectoris in comparison to propranolol, 
and was already in progress when Q u y y u m i ’s paper was 
published.
Improvements in the recording and reproduction of 
low frequency signals by ambulatory electrocardiography
systems have provided an opportunity to study ST changes. 
(368) and this has now provided a useful aid in the 
detection of painful and painless ST segment deviation in 
several recent studies of patients with CAD. (65,369,370)
6.2. PATIENTS AND METHODS.
Study Group .
Seventeen males with a mean age of 54 i 9.1 years 
(range 38-68 years), were recruited into the study. Their 
characteristics are summarised in Table 6.1. All the 
patients had a diagnosis of chronic stable angina pectoris 
- describing typical exertional symptoms and having an 
abnormal exercise electrocardiogram. Each subject 
underwent a maximal symptom limited treadmill exercise 
test in the run-in period using a modified Bruce Protocol. 
(125) In all cases, ST segment depression of > 1  mm. for 
0.08 seconds after the J point developed and persisted for 
at least three consecutive complexes. Patients who showed 
some ST segment depression before exercise were included 
only if the ST segment depression became deeper by > 1 mm. 
at peak exercise and if a previously normal lead showed 
ST segment depression. The subjects had a mean duration 
of symptoms of 30 + 28.6 months (range 6-84 months), and 
seven had a previous history of myocardial infarction. 
Written informed consent was obtained from all patients 
and the protocol was approved by the local Ethical 
Committee .
Study Pro tocol.
After a diagnosis of chronic stable angina 
pectoris was made, characterised by a typical history of 
exertional chest pain and positive exercise electro-
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cardiogram, all anti-anginal medication was withdrawn for 
at least two weeks before investigation. Glyceryl 
trinitrate was permitted for pain. Patients were randomised 
to treatment with propranolol 80 mg. t.i.d. or pindolol 
5 mg. t.i.d. for a period of 14 days each, then 
cross-over took place onto the alternative medication 
for a further period of 14 days (Double Blind). During 
the last 48 hours of each treatment period, ambulatory 
electrocardiography was performed.
Ambulatory Electrocardiography.
The Medilog 4000 (MARS) ambulatory ECG recorder 
(Oxford Medical Systems Ltd., Oxford) was used to perform 
ECG recording. This apparatus performs real-time ECG 
analysis and includes cassette tape storage of the resultant 
ECG and analysis results. Previous systems have analysed 
ECG recordings at replay time, but such an analyser needs 
to be able to work at high speeds to make this practicable. 
This limits the processing capacity available to analyse 
each beat. In addition, several systems employ an audio­
visual playback of the recording with a human operator 
identifying abnormalities on an ECG running at X60 normal 
speed. Thus, over or under reporting of abnormalities is 
liable to occur. In the present study, ECG analysis data 
was retrieved from the cassette tape by the Medilog MARS 
replay system (Oxford Medical Systems Ltd., Oxford).
The importance of real-time ECG analysis using this 
system lies in the ability of the system to analyse each
beat more thoroughly than systems dependent on analysis at 
replay time. Thus the processing capacity is greater.
To permit subsequent verification of the analysis 
the system stores both the ECG and results which can be 
reproduced in full disclosure form.
In all, four channels are recorded on the cassette - 
two for analcgie ECG, one for the results of the analysis 
in digital form on a beat-by-beat basis and one for time 
code.
Analysis is performed by recorder based electronics, 
which compares each beat against a template and records the 
template number and the timing of the beat on a digital 
track. The templates are classified by the replay system. 
Arrhythmia sequences are identified during high speed 
scanning through the recorded digital information.
The timing and the template number of each beat are 
recorded in digital form, together with ST information 
averaged over 30 second periods. At the end of the 
recording, a data dump consisting of each template shape is 
recorded digitally with a number indicating how many 
matches were obtained.
On replay, the data dump is read and each template 
is classified by feature or extraction measurements, as 
dominant, supraventricular, ventricular or artefact. This 
information is used to build up a table of arrhythmia
combinations with times and durations of each episode. The 
times of occurence are listed in the report and searches 
are made to provide analogue examples of each type. The 
report also includes trends of heart rate, ST level and 
ventricular ectopy, as well as examples of each template. 
The templates may be edited manually if required and a 
further report generated, based on this classification.
The ST segment is defined 100 ms after the peak of 
the R wave and the system calculates the differences between 
this segment and the isoelectric line, as defined 60 ms 
before the peak of the R wave. The ability of the apparatus 
to measure changes in the ST segment has previously been 
compared to a standard ECG during an exercise test. (371)
Mean sensitivity was 87%, specificity was 95% for detection 
of ST-shift, and correlation coefficient for ST segment 
level was 0.94. Thus, this system provides a valid means 
of recording ST segment changes.
The system provides a report including maximum and 
minimum HR and ST level and mean ST level. For each of 
these results, a corresponding section of ECG is produced 
at the precise time when these events occurred. This 
allowed the author to verify all individual results and 
reject any which were artefactual. From the ST segment level 
trend, ST segment elevation ( < 1 mm. over baseline) or 
depression ( > 1 mm. under baseline) could be measured in 
terms of frequency, duration and depth. These changes were 
verified by correlating the ST segment changes produced by 
the full disclosure. Thus any potential for artefact to
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FIGURE 6.1
Placement of electrodes on the chest wall. 
Electrodes 1 and 3 provides CM5 recording and 
electrodes 2 and 4 record lead I.
/
influence the results was removed.
to ensure optimum performance of-the equipment the 
recording head and tape transport mechanism were cleaned 
before each recording, a new set of batteries was used for 
each 24 hour recording and the cassette tapes were 
demagnetised using a bulk demagnetiser (Oxford Medical 
Systems Limited, Type 26). After careful skin preparation 
using an abrasive paste and shaving if necessary, five 
electrodes (Medicotest) were applied to the chest wall 
as shown in Figure 6.1, thus producing a recording of lead 
CM5 and a modified lead II. Careful skin preparation 
and siting of the electrodes helps minimise baseline 
instability. An impedence meter was then used to ensure 
that the resistance between each electrode was <5 kilohms, 
and surgical tape was used to attach the leads to the 
patient incorporating stress loops to reduce artefact 
caused by electrode movement. The recorder was worn at 
the patient’s side and supported by a belt. A 1 mv. 
calibration test signal was then recorded and was 
subsequently used by the system to calibrate analysed 
data. The patient was instructed to follow his normal 
daily habits and to record any symptoms or activities in 
a diary, particular attention was paid to the occurance 
of any chest pain. Before leaving the laboratory the 
ECG waveform and magnitude being recorded was checked on 
a conventional ECG writer to ensure a satisfactory 
recording.
Mean nocturnal heart rate was derived from the
mean of the hourly heart rates between 24.00 - 06.00 hours 
when the patients were in bed. Significant ST segment 
depression was defined as planar or downsloping shift 
of the ST segment of >1 mm. in magnitude measured 
100 milliseconds after the peak of the R wave and 
persisting for at least 30 seconds.
Maximum and minimum heart rates refer to rates 
recorded over the average R-R interval over four complexes. 
A sinus pause is defined as asystole greater than 1.5 
seconds and 1.9 times greater than the average R-R 
interval of the four previous complexes. Ventricular 
tachycardia is regarded as three or more consecutive 
premature ventricular contractions (PVC’s) during which 
two R-R intervals exceed 110 bpm and if less than 110 bpm 
this is regarded as idioventricular rhythm.
At the end of each recording the cassette was 
transferred to the Medilog Mars replay system which 
generates a comprehensive report and offers a search 
or full 24 hour disclosure, via a Microdot Printer, for 
verification of the analysis.
Statistical Analysis.
Results are expressed as mean + standard 
deviation. Data was analysed using S t u d e n t ’s paired 
t-test and W i l c o x o n ’s signed rank test for paired 
observations. The most conservative significance 
values obtained are reported.
6.3. RESULTS.
Heart R a t e .
The 24 hour trend of mean heart rate per hour 
is shown in Figure 6.2, for each drug. Propranolol 
resulted in a significantly lower mean hourly (p < 0.001), 
mean 24 hour, (p < 0.001), minimum (p < 0.001) and lower 
maximum heart rate (p = NS). Likewise, propranolol caused 
a lower mean daytime (p < 0.001) and nocturnal heart 
rate (p < 0.025). These results are shown in Table 6.2.
Frequency of Angina and ST C h a n g e s .
Fifteen episodes of angina occurred during the 
last 48 hours of treatment with pindolol compared to 12 
with propranolol (p = NS), and although the mean number 
of attacks rose from 1.79 - 3.94 per 48 hours (range 0-14) 
propranolol to 2.12 ± 4.74 (range 0-20), this was also not 
significant. In all, five patients developed pain during 
the treatment periods, and with the exception of one case, 
all of these subjects noted more frequent angina during 
treatment with pindolol. The remaining 12 patients were 
symptom free on both drugs. During ambulatory electro­
cardiography the total number of episodes of ST segment 
depression increased from 59 on propranolol to 85 on 
pindolol (p = NS). Both the mean 24 hour ST level and 
the mean maximum ST segment depression were lower during 
treatment with pindolol, but this failed to reach 
statistical significance. (See Table 6.3)
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Heart Rhythm.
During 48 hour ambulatory electrocardiography 
a total of 117 nocturnal pauses or episodes of asystole 
occurred in three patients during treatment with 
propranolol, ranging in length from 1.5 - 2.8 seconds.
(See Figure 6.3a) During treatment with Pindolol no pause 
was noted in these patients, although one other patient 
had one episode lasting 1.7 seconds.
All patients exhibited PVC’s during treatment with 
both propranolol and pindolol although only six had more 
than 100 PVC’s in any one 24 hour period. The total 
number of PVC’s occurring during treatment with pindolol 
(1316 beats) was less than on propranolol (2010 beats) 
and the mean hourly frequency of PVC’s was significantly 
lower during pindolol administration (p < 0.02). (Figure 
6.4)
One subject (A.S.) developed one episode of 
ventricular tachycardia while on propranolol and pindolol 
(Figure 6.3b), and one subject (J.M.) had 42 episodes of 
ventricular bigemeny while taking propranolol, but only 
five episodes occurred in the last 48 hours of treatment 
with pindolol. (Figure 6.3c)
In general, the VPC’s were unifocal in origin, 
but in two subjects (A.S. and J.M.), multifocal VPC’s 
were identified together with occurrence of couplets.
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6.4 DISCUSSION
Previous studies evaluating the use of pindolol 
in the treatment of angina pectoris have confirmed 
its efficacy in reducing anginal symptoms in 42-85% of 
patients and increasing exercise tolerance by 12-21%. A 
greater improvement being observed in short-term or 
uncontrolled studies. (See Table 6.4) However, in a 
double blind cross-over comparative study with atenolol 
Quyyumi et al (65) drew attention to the deliterious 
effects of pindolol in subjects with severe effort angina 
and nocturnal angina. They studied 15 subjects with 
documented CAD and severe symptoms and randomised them to 
treatment with pindolol 5 mgs. t.i.d. or atenolol 100 mgs. 
daily in a cross-over study of five days treatment with 
each drug. They found that atenolol caused a greater 
reduction in the frequency and magnitude of day-time and 
nocturnal episodes of ST depression and attributed this 
to the ability of atenolol to reduce resting heart rate 
more than pindolol. Their study differed substantially 
from the present in several ways: the patients investigated
had more severe CAD; there was a very short withdrawal 
period for patients already on beta blockers before 
entry into the study, which could have resulted in rebound 
effects in the first treatment phase and the method of 
analysis of ambulant ECGs was different. It is difficult 
to place their findings in clinical perspective as it is 
unlikely that the subject with severe rest or nocturnal 
angina would be treated with beta blockers alone - being 
liable to require additional therapy such as nitrates or
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calcium antagonists. As this group will probably have 
more marked deterioration in cardiac contractility than 
those with chronic stable angina, it is possible that the 
benefits of a beta blocker with ISA will outweigh the 
disadvantages. I chose to study patients with stable 
angina who had been observed for at least one year, and 
compare the effects of pindolol with another nonselective 
beta blocker which does not possess ISA (propranolol).
The withdrawal phase before entry into the study was longer, 
as were the treatment periods. Ambulatory electro­
cardiography was performed using recently introduced 
automatic equipment, thus removing any possiblity of 
observor error which could have been a factor in Quyyumi’s 
study (65), as they utilised a visual playback system at 
60 times normal speed to analyse the ECGs. This method 
is fraught with difficulty and may lead to under or over 
reporting of abnoralities.
Using cruder methods of assessment, other workers 
have reported variable findings using pindolol in angina.
In a randomised control study, Harston and Friesinger (366) 
reported a reduction in the HR x BP product and increased 
exercise tolerance in 12 patients treated with pindolol. 
However, in the long-term, pindolol did not cause a 
significant reduction in attacks of angina or an enhanced 
exercise tolerance in comparison to placebo. Erikssen 
et al (372), in a study comparing pindolol with atenolol 
and metoprolol noted that pindolol was more effective in 
suppressing heart rate and blood pressure in a group of 
males aged 19-25 years, but extrapolation of this finding
to the diseased patient is not appropriate. Using 
high doses of pindolol (40 mgs) against moderate daily 
doses of propranolol (160 mgs) in patients with angina, 
Frishman et al (58) demonstrated a significant reduction 
in the frequency of angina and increased exercise tolerance 
with both drugs, but did not compare the difference in 
effect. In the present study a daily dose of 15 mg. per 
day in three divided doses was administered. This is the 
dose most frequently used in clinical practice, and 
previous studies have shown adequate beta blockade using 
this dosage with no additional haemodynamic benefit being 
observed with higher doses. (32) In another cross-over 
comparative study in stable angina pectoris with atenolol, 
lasting six weeks with each drug, both drugs reduced 
anginal attacks and increased exercise tolerance. But, 
atenolol was superior to pindolol in both these effects. (5)
It appears, that although pindolol is effective 
in terms of suppression of anginal symptoms, it is 
possibly inferior to other agents without ISA. During 
exercise, several investigators including Quyyumi (65) 
have observed effective beta blockade with pindolol 
suggesting that patients with effort angina will derive 
sufficient benefit from this drug. In the present study, 
although frequency of angina was greater during treatment 
with pindolol, this failed to reach significance.
Heart Rate.
The present study confirmed that pindolol 
suppresses resting heart rate to a lesser extent than 
propranolol (figure 6.2), but maximum heart rate achieved 
during treatment with these drugs was not significantly 
different, suggesting a similar beta blocking effect 
during periods of increased sympathetic tone. Pindolol 
protected the individual from severe bradycardia with 
a significantly higher minimum heart rate (p < 0.001). 
Three subjects exhibited asystolic episodes of 1.5-2.8 
seconds during sleep while taking propranolol, but not 
pindolol. These findings are similar to those observed 
with atenolol vs pindolol previously. (65) However, in 
this study, the circadian rhythm of heart rate was 
maintained, there being no significant difference between 
each drugs effect on daytime and nocturnal heart rates. 
These results are virtually identical to another study 
examining circadian heart rate. (44) The failure of beta- 
blockers with ISA to effectively reduce resting heart 
rate has been noted by others (58,9,65), but in stable 
effort angina pectoris, it is probably more important 
to suppress exercise induced tachycardia than reduce 
resting heart rate. The relative impact of pindolol on 
resting heart rate is probably dependant on the 
pretreatment level of sympathetic tone as it has been 
found to reduce heart rate in subjects with pretreatment 
heart rates of greater than 80 bpm and increase heart 
rate in those with initial rates less than 80 bpm. (373) 
Thus, at rest, when sympathetic tone is low, beta blockers
with ISA will cause little change in heart rate, but 
during exercise an attenuation of heart rate will occur 
which is probably of equal potency to beta blockers 
without ISA, as shown by Finch et al (374) in a comparison 
with propranolol.
Ambulatory Electrocardiography.
The equipment used in the present study is one of 
a new generation of systems which are capable of faithfully 
reproducing the ST segment. This is an improvement on 
the form of analysis used by Quyyumi et al (19) and several 
other investigators who have studied ST segments using the 
audio-visual superimposed electrocardiographic presentation 
(AVSEP) method at 60 times normal speed. A recent review 
has suggested that these older systems are essentially 
outmoded. (375) The newer systems now incorporate analogue 
to digital convertors and electronic memories allowing real 
time ECG strip analysis and printout that can provide a 
real time, trend, graph or digital display of data. These 
systems have been shown to provide reproducible results 
and have removed observor error or bias from analysis 
of continuous ECG recordings.
In addition the poor low range frequency response 
of older monitoring equipment rendered assessment of 
ST changes unreliable. (376,377).
ST Segment Analysis.
This study found that 59 episodes of significant 
ST segment depression occurred during 48 hours monitoring 
while the patients were taking propranolol, and 85 
episodes while taking pindolol. Only 12 and 15 episodes 
respectively were accompanied by pain. This is a similar 
proportion to that described by Quyyumi et al (65), but in 
this study no significant difference was observed between 
the number, duration or magnitude of ST depressions 
comparing the two drugs, although ST segment depression 
was more frequent, longer in duration and deeper during 
treatment with pindolol. It is possible that the 
episodes of painless ST depression do not represent 
ischaemia, but other influences which can disturb the 
ST segment such as changes in patient posture. (378)
In addition, ST segment depression has been shown to 
occur in healthy individuals. (379) However, recently, 
Deanfield et al (380) have shown that planar ST 
depression during ambulatory electrocardiography, in 
patients with normal coronary arteriograms is rare, and 
in a separate report (381) they have correlated the 
results of positron tomography and ST segment recording 
and conclude that ST segment depression during continuous 
monitoring is a useful and reliable method of assessing 
the activity of CAD, but only in those with typical angina 
and proved CAD. Similarly, symptomatic and asymptomatic 
attacks of ST depression have been correlated with the 
results of stress testing (371,382), and there seems to 
be a concensus that asymptomatic ST depression is a more
frequent phenomenon than ST segment depression with angina 
and does in fact represent myocardial ischaemia in these 
patients. In this study, many of the ST segment 
depressions occurred at times when the heart rate was not 
significantly elevated. It has previously been suggested 
by Quyyumi et al (383) that ST depression is usually 
preceded by elevation of heart rate. Under resting 
conditions,- in those with severe CAD, nocturnal resting 
ischaemia would be more liable to occur as myocardial 
oxygen demand may still be high. However, this hypothesis 
has recently been refuted by Chierchia et al (384) who 
demonstrated that ST depression could occur irrespective 
of resting heart rate, and further, that tachycardia 
could occur in the absence of ST depression. They suggest 
that myocardial oxygen demand is not the only, or the most 
common cause of acute ischaemia in chronic stable angina. 
These findings suggest that a suppression of heart rate 
alone need not indicate an advantage to a beta blocker 
without ISA, in chronic stable effort angina.
It is possible that future therapy aimed at 
morbidity and mortality in CAD may have to relieve 
asymptomatic as well as symptomatic ST depression, to have 
a desirable result.
Arrhythmias.
In this study, the mean hourly frequency of 
PVCs in the last 48 hours of monitoring during treatment 
with pindolol was significantly lower than during treatment
with propranolol (p < 0.02). The reason for such a 
difference is not clear. It has previously been shown 
that a diurnal variation of VPC frequency occurs in 
patients with CAD - with a fall in frequency during sleep. 
(385) This suggests that PVCs are more common at times of 
increased neural activity with resultant high sympathetic 
tone. If this were true, one would expect fewer VPCs to 
occur during treatment with propranolol. It is possible 
that the sustained, but suboptimal stimulation of 
B-receptors by pindolol is capable of suppressing 
ventricular ectopic foci already present and if a pure 
beta blocker is administered, this control is lost and 
ectopic foci are "released” from sympathetic influence.
A number of studies have supported the hypothesis that the 
presence of VPCs in patients with CAD is a risk indicator 
of sudden death. (386,387) Thus, the 35% reduction in VPC 
frequency observed during pindolol treatment may be of 
some importance. However, according to Morganroth (388), 
a reduction of more than 65% would be required for 95% 
confidence of a drug effect and even then, 72 hour periods 
of monitoring would be required because of the spontaneous 
variability in frequency of VPCs.
In one study examining the electrophysiological 
effects of beta blockade (389), both propranolol and 
oxprenolol increased the threshold for ventricular 
fibrillation by 42 and 56% respectively, but pindolol 
resulted in an elevation of only 25%, suggesting that 
ISA alters myocardial excitability. Thus, the reason 
for my finding of a fall in VPCs during treatment
with pindolol is not consistent with previous findings 
and may be related to spontaneous variability of 
frequency alone, although no formal investigation using 
the techniques utilised in this study has been performed.
6.5. CONCLUSIONS.
Treatment with propranolol (80 mg. t.d.s.) and 
pindolol (5 mg. t.d.s.) resulted in significantly lower 
mean 24 hour, minimal, maximal, nocturnal and daytime 
heart rates with propranolol in patients with chronic 
stable effort angina. Although the number, duration and 
magnitude of both symptomatic and asymptomatic ST 
depression was greater during treatment with pindolol, 
none of these differences reached statistical significance. 
The mean hourly frequency of VPCs fell by 35% (p < 0.02)
during treatment with pindolol compared to propranolol, 
the cause of this is unclear. Pindolol is a useful drug 
in the treatment of chronic stable angina pectoris and was 
not shown to be significantly inferior to propranolol, 
but may have less benefit in the treatment of severe 
or rest angina.
SECTION 7.
THE EFFECT OF CHRONIC BETA BLOCKER THERAPY
ON RESPIRATORY FUNCTION: INFLUENCE OF ISA.
7.1. INTRODUCTION.
Soon after their introduction, it was appreciated 
that B-blockers could have a deliterious effect on 
respiratory function. This was due to blockade of the 
beta-adrenoceptors in the lung which are responsible for 
bronchomotor tone. Stimulation of the B 2 receptors 
results in bronchodilation - a situation which occurs 
when a sympathomimetic (or B2 agonist) is administered 
eg. salbutamol. Blockade of these receptors may result 
in significant bronchoconstriction in susceptible 
individuals, such as those with pre-existing chronic 
obstructive airways disease (COAD), in whom the use of 
beta blockers may be restricted (395,396), or in 
ashtmatics in whom beta blockers are contra-indicated 
because of the risk of bronchospasm (397), and even acute 
asthmatic attacks. (396,398) In patients with fixed 
irreversible bronchial obstruction this is thought to be 
less likely (397,399), but has nevertheless been reported. 
(400) Further, it is recognised that acute bronchospasm 
can occur in some with no previous history of asthma, COAD 
or allergic disorders, following case reports by Froley 
et al (401) and Schwarz et al. (402) In healthy subjects 
some beta blockers have been shown to cause an increase in 
airways resistance in a proportion of individuals. (403) 
Using the body plethysmograph MacDonald et al (404) and 
McNeill and Ingram (405) have shown that a single dose of 
intravenous propranolol can increase airway resistance 
although Singh et al (406) failed to confirm these findings 
in norma1 subjects following a single oral dose of
propranolol (80 mg). The beta blocker most frequently 
incriminated in such respiratory effects is propranolol 
(396,398) (non-selective, without ISA). With the 
introduction of Beta 1 selective blockers such as atenolol 
and metoprolol it was hoped that the risk of bronchospasm 
would be reduced and although these agents are also known 
to produce a broncho-constrictive effect (407), studies 
comparing the effect of oral metoprolol with propranolol 
have shown that the former agent has less adverse effects 
on pulmonary function than equivalent doses of propranolol. 
(408-410) The fact that relatively selective beta blockers 
can cause bronchoconstriction, is probably because they are 
not exclusively selective and that besides beta2 receptors, 
beta i receptors may also be present in the bronchi. (411)
Beta blockers possessing ISA are also thought to 
result in a less detrimental effect on ventilation 
compared to "pure” beta blockers, such as propranolol. 
However, it has not been established whether these agents 
can be safely administered to patients with COAD. Few 
studies report the effect of propranolol on patients with 
nonasthmatic COAD and the results are often conflicting. 
(399,412,413) This may be due to differences in 
methodology and study population involved. The results of 
most controlled studies are based on single doses of 
beta blocker of either the intravenous or oral formulation. 
(414-416) Data for chronic administration has usually 
resulted from open, uncontrolled investigations (417,418), 
and so the effect of chronic therapy in subjects with 
hypertension or angina pectoris has not been established.
In addition, the role of ISA in moderating beta blocker 
induced bronchoconstriction is not clear (419), although 
both oxprenolol and pindolol were found by Kumana et al 
(420) to have less effect on airways resistance when 
compared to propranolol in normal volunteers.
Since beta blockers are commonly prescribed to 
patients with angina pectoris or hypertension who may 
suffer from a degree of COAD, this study was undertaken 
to establish the effect of chronic oral beta blocker 
administration on respiratory function in a group of 
patients with angina pectoris, and to assess the potential 
benefits of ISA in this respect.
7.2. PATIENTS AND METHODS
Forty male patients with chronic stable angina 
were recruited to the study. Prior to inclusion these 
subjects were either untreated or responding inadequately 
to previous therapy. After at least two weeks without 
any medication the subjects were randomly allocated to 
treatment with propranolol 40 mgs. t.i.d. (n = 21) or 
pindolol 2.5 mgs. t.i.d. (n = 19) for two weeks, 
thereafter increasing to 80 mgs. and 5 mgs. t.i.d. 
respectively as described in previous sections of this 
thesis. Respiratory function was assessed at intervals 
of 2, 6, 12, 26 and 52 weeks following commencement of 
therapy. No subject was admitted to the study who suffered 
from reversible airways obstruction, a known allergic 
disorder, diabetes mellitus, heart block or renal failure, 
and glyceryl trinitrate was the only other routine 
medication permitted throughout the study. Indirect 
estimation of airways diameter was made by measuring 
Forced Vital Capacity (FVC) and Forced Expiratory 
Volume in one second (FEVi). Expiratory Reserve Volume 
(ERV), Inspiratory Reserve Volume (IRV) and Inspiratory 
Capacity (IC) were also measured using a Morgan Rolling 
Seal Dry Spirometer (Model b), which has a reproducibility 
better than 2%. The calculation of these parameters is 
demonstrated in Figure 7.1. All measurements were taken 
after three minutes rest in the seated position after an 
overnight fast. Measurements were taken approximately 
2-3 hours after the last oral dose of beta blocker at 
between 09.30 - 11.00 hours, as peak blood levels have
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been demonstrated at this time. (421) On each occasion 
the subject had been present in the laboratory for at 
least 45 minutes to allow for equilibration to occur.
There is no concensus concerning the number of measure­
ments of each parameter that need be taken when measuring 
respiratory function. (422) In the present study I used 
the mean of three satisfactory attempts after a single 
training attempt, each attempt being separated by a period 
of one minute. All testing and analysis was carried out 
by the author and the spirometer was calibrated daily, 
prior to any measurement. As a dry spirometer was used, 
the volumes indicated on the chart paper were corrected 
to standard temperature and pressure according to the 
ambient temperature.
Statistical Analysis.
Two way analysis of variance was carried out for 
each measurement, if this indicated a significant change, 
then Student’s paired t-test and a Wilcoxan signed rank 
test (for non parametric data) was applied with each 
comparison to the basal measurment. The most conservative 
significance values from these tests are reported.
Between drug differences were tested using a Student’s 
paired t-test and Wilcoxan signed rank test.
7.3. RESULTS
The groups of patients were not significantly 
different in terms of age, body weight, height or mass 
index (Table 3.1). The results of respiratory function 
testing are shown in tables 7.1 (pindolol) and 7.2 
(propranolol). Basal respiratory function was similar 
in the two groups, although those taking propranolol had 
a slightly lower FEV lv Heart rate and blood pressure 
changes are recorded on Figure 5.3.
In those treated with pindolol there was a fall 
in the mean FEVi of 120 mis. after 52 weeks treatment 
(p < 0.05) and a fall of up to 270 mis. in IC. at 
12 weeks (p < 0.05). If results are expressed as a 
percentage of that predicted for age (using nomograms 
of Kamburoff and Woitowitz (423)), there was a highly 
significant fall in the FEV i from a mean of 89.5% to 
85.6% (p < 0.01) at 52 weeks. No significant changes 
occurred in other parameters, although a slight fall in 
the FEVi/FVC ratio occurred which reflects the fall in 
FEV i.
In those treated with propranolol there was a fall 
in FEVi, first significant after two weeks (p < 0.05) and 
falling sequentially by 240 mis. at 52 weeks (p < 0.001) 
which was twice the fall recorded with pindolol (Figure 
7.2). A similar reduction in percentage of predicted 
value of FEVi occurred. In addition, a significant fall 
in VC occurred at 52 weeks (p < 0.05), and although no
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FIGURE 7.2
Changes in FEVi related to mean basal value.
Abbreviations: FEVi - Forced expiratory volume in
one second.
•p < 0.05; «»p < 0.01; •••p < 0.001.
change occurred in FEVi/FVC ratio, this reflected a 
similar fall in FEVX and VC. A significant rise occurred 
in ERV and falls in IRV and IC were also recorded.
To determine whether those with chronic airflow 
obstruction reacted differently to each drug the 
subjects were subdivided according to a basal FEVi/FVC 
ratio of less than, or greater than 70%.
Pindolol caused a significant reduction of FEVi 
and FEVi/FVC at 52 weeks only when the basal FEVi/FVC 
was greater than 70% (Table 7.3). Propranolol caused 
a similar reduction in FEVi regardless of the basal 
value although this became more significant at 12 and 52 
weeks in those with basal ratios greater than 70%
(Table 7.4), compared with those who had values less than 
70%.
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7.4 DISCUSSION
The most important finding of this study is 
the progressive deterioration in respiratory function 
during chronic beta blockade in subjects with no history 
of reversible airways disease. This phenomena was most 
marked with propranolol which had a significantly 
greater effect on FEVl than pindolol. In addition VC 
became progressively smaller during treatment with 
propranolol, but no change, occurred during treatment with 
pindolol. There was no significant difference in 
an individuals response to each beta blocker according 
to basal values of FEVi/FVC, propranolol being shown to 
have a consistently detrimental effect, while pindolol 
caused only small reductions in FEVX and the FEVX /FVC 
r a t i o .
Although propranolol caused a progressive and 
highly significant reduction in FEVi (Figure 7.2), it is 
unclear whether a reduction of 240 mis. in FEVX (at 52 
weeks) is of clinical significance as no subject reported 
increasing breathlessness or wheeze with this drug. It is 
also possible that the deterioration in respiratory 
function will progress beyond one year in a cummulative 
fashion, thus precipitating symptomatic deterioration.
In addition the effect of chronic oral administration of 
propranolol to patients with COAD might have been an 
adverse progressive effect on pulmonary function which 
could lead to deterioration in a previously compensated 
patient. While the drug did not cause a rapid and
dramatic clinial exacerbation in these patients, it 
did cause a definite and sustained increase in airways 
obstruction compared to pindolol.
The significantly greater deterioration in 
respiratory function indices presumed to reflect changes 
in large airway calibre after propranolol administration 
compared to an agent with ISA, has been referred to by 
others. (407,424) However, Patakas et al (425), when 
studying respiratory function after single oral doses of 
propranolol (40 mgs.) and pindolol (2.5 mgs.)in asthmatics 
confirmed a bronchoconstrictive effect on large and small 
airways after propranolol, but pindolol, although causing 
no significant effect on large airway calibre, caused a 
significant bronchoconstriction of the small airways.
They suggest that pindolol remains potentially dangerous 
in asthmatics because of the small airway effects.
7.5. PREVIOUS STUDIES
Most studies have examined the effect of single 
dose oral or intravenous administration of beta blockers. 
Usually these experiments have been carried out in 
subjects with reversible airways obstruction, and most 
have evaluated respiratory effects on the basis of FEVi , 
peak expiratory flow rate (PEFR) or airways resistance 
(Raw). Studies evaluating the effect of beta blockers 
on respiratory function, in subjects being treated for 
hypertension or angina pectoris on a chronic basis, are 
rare. (426) Of the studies exclusively examining non- 
selective agents without ISA, Nordstrom et al (399) 
administered intravenous propranolol to 10 patients with 
COAD, and found an increase in airways resistance after 
only 10 minutes. In a similar study, using intravenous 
administration Ryo and Tomnley (427) found a significant 
reduction of FEVi after 3 mgs. propranolol. Using a single 
oral dose of propranolol (80 mgs.) Kumana and Ruffin (428) 
reported a reduction in FEVi and PEFR, and during chronic 
administration, Horvath et al (429) reported increased 
airways obstruction during chronic administration with 
propranolol (320 mgs./day).
In contrast, Trembath et al (430), found no change 
in FEVi or VC following a single oral dose of propranolol 
(80 mgs.), although only five patients were included in 
that study. In one of the few studies examining the 
effects of propranolol on respiratory function in non­
asthmatic subjects with angina pectoris, Jebavy et al (426), 
found a significant reduction in total ventilation and 
tidal volume after 10 mgs. intravenous propranolol, but 
no bronchoconstriction was observed. Other single dose 
studies have confirmed the finding of a minor, but 
significant reduction in FEVj following propranolol. 
(431.432) In healthy subjects, both Campbell et al (433) 
and Warren et al (434), failed to find any deterioration 
in respiratory function after oral propranolol, but in 
those with non-asthmatic COAD, Chester et al (435), in a 
double blind cross-over comparison of propranolol and 
placebo found a deterioration after propranolol only and 
concluded that this beta blocker may exacerbate symptoms 
in these individuals.
With the introduction of Bi selective blockers, 
it was hoped that they would have a less damaging effect 
on respiratory function. Svedmyr and Thiringer (410) 
reported a slight and similar reduction in FEVl after 
oral administration of propranolol (40 mgs) and metoprolol 
(50 and 100 mgs.).
In healthy subjects, Singh et al (406), failed to 
show any significant effect on respiratory function after 
oral metoprolol (100 mg.), but this dose caused an increase 
in airways resistance in 12 asthmatic subjects although 
less pronounced than following propranolol. In contrast,
Mue et al (436) observed no change in FEVi or VC in a 
placebo controlled study of metoprolol in 33 asthmatic 
patients. Skinner et al (437) have shown that although
8 mgs. intravenous metoprolol given to 12 stable asthmatics
had a minimal effect on FEVi, in two subjects, FEVi fell
by more than 500 mis. and this was felt to be clinically
#
significant. Again, using single dose iv. administration, 
Johnsson (438) found that an equipotent dose of metoprolol 
had less effect on FEVi than propranolol. In seven 
subjects with chronic, stable obstructive airways disease, 
Abraham et al (439) administered increasing doses of 
intravenous metoprolol until a reduction of FEVi occurred 
at 0.15 mg./kg. body weight - thus demonstrating that 
cardioselectivity was lost at high dosage, but might 
be useful in preventing bronchospasm if used in smaller 
doses. In more recent studies, Butland et al (440) found 
a reduction of FEV i and VC during therapy with metoprolol 
(intravenous and oral administration) in 10 patients with 
emphysema. During chronic administration of atenolol 
and metoprolol in a cross-over study in 14 hypertensive 
subjects with asthma, Lawrence et al (441) found that 
Atenolol caused significantly less bronchospasm (p < 0.05) 
in terms of fewer asthmatic attacks and less effect of PEFR. 
However, they also found that after a single dose, both 
atenolol and metoprolol caused similar, significant falls 
in FEVi and FVC.
A new Bi adrenoceptor blocker, pafenolol, which is 
more selective for Bi adrenoceptors than metoprolol, has 
been studied by Lofdahl et al (442), in eight asthmatic 
subjects in a cross-over study with metoprolol. There 
was no difference between the treatments on FEVi, but 
following inhaled terbutaline (B2 stimulant) it was found
that there was a greater response in those treated with 
pafenolol, thus indicating that less blockade of B2 
adrenoceptors had occurred with this drug.
Several studies have evaluated the role of ISA 
on respiratory function. Benson et al (408) carried out 
a study in 12 asthmatic subjects who received placebo, 
propranolol (100 mgs.), Pindolol (5 mgs.), acebutalol 
(300 mgs.) and atenolol (100 mgs.) and showed that 
propranolol caused the greatest reduction in F E V 1 and this 
was less marked with the other drugs. In eight normal 
subjects, Folgering and Braakhekke (443) carried out a 
double blind cross-over trial of propranolol, metoprolol 
and oxprenolol in normal subjects and found no effect 
with any drug on PEFR. England, however, found that only 
propranolol caused a significant reduction in FEV 1 , in 
a study of 18 non-asthmatic hypertensives taking 
propranolol, atenolol and pindolol. (119) Using a 
different approach, Dorow (444), in a group of 10 
asthmatics, determined the pretreatment histamine 
concentration necessary to produce a 20% fall in FEVi 
Histamine provocation was repeated after equipotent doses 
of propranolol, pindolol and metoprolol. Although the 
amount of histamine required to induce bronchospasm fell 
slightly following pindolol or metoprolol, this was not 
significant. After propranolol, however, very small 
quantities of histamine were required to produce a 20% 
reduction in F E V i .
One disadvantage of agents with ISA compared to 
cardioselective drugs was demonstrated by Greefhorst (445), 
who studied the effect of metoprolol and acebutolol on 
eight asthmatic subjects. FEVi and PEFR were reduced 
significantly by both drugs, but following a terbutaline 
infusion a dose dependent increase in FEVi and PEFR 
occurred, although the increase in these indices was 
partly inhibited by acebutolol compared to atenolol.
Thus, if airways obstruction does occur, it is less 
likely to be reversed by a B 2 agonist if the beta blocker 
is not relatively Bi selective. Patakas et al (425) found 
that pindolol was more likely to cause bronchoconstriction 
in the small airways only compared to the broncho- 
constrictor effect of propranolol which affects both large 
and small airways, and they concluded that pindolol may 
still be potentially dangerous in asthmatic patients 
because of this.
Thus, there is agreement that non-selective agents 
without ISA cause potentially harmful changes in 
respiratory function in asthmatics and possibly also in 
those with irreversible chronic obstructive airways 
disease and even in healthy subjects. Cardioselectivity 
tends to reduce the bronchoconstrictive effect as does ISA, 
but if bronchoconstriction is induced it is less likely 
to be reversed by a B2 agonist compared with a cardio- 
selective agent.
The present study is the first to evaluate the 
effect of chronic beta blocker therapy in individuals
being treated for angina pectoris and has shown a clear 
advantage of pindolol compared to propranolol.
The available evidence suggests that no beta 
blocker is entirely safe in patients with chronic 
obstructive airways disease. If possible, an alternative 
medication should first be considered. Bronchoconstrietion 
following beta blocker administration is most marked in 
those with reversible bronchial obstruction and less 
pronounced in those with irreversible bronchial obstruction. 
Beta blockers with ISA or cardioselectivity have a less 
marked effect on pulmonary function and so should be 
considered in preference to those noncardioselective agents 
without ISA in situations 'where a beta blocker is felt 
desirable despite the presence of respiratory impairment.
In such an instance in patients with angina pectoris 
requiring additional antianginal agents, the most 
appropriate drug could be nifedipine, which has been shown 
to have a slightly more beneficial effect on beta blocker 
induced bronchoconstriction than that achieved by 
nitrates. (446)
Ideally, it would be advantageous to develop a 
beta blocker with no adverse effects on respiratory 
function ie. a completely cardioselective agent. However, 
in view of present knowledge of beta receptors, this 
would not be possible, as it has been established that 
an absolute separation of B x and B 2 receptors in different 
organs, as postulated by Lands et al (447) is incorrect. 
Radioligand studies and pharmacodynamic experiments have
shown that the airways possess, besides mainly B 2 , also Bi 
receptors (411,448), and further, that stimulation of both 
of these receptors may cause bronchodilation. (449,450)
This may explain why a selective beta blocker can induce 
a limited increase in bronchoconstriction which can be 
counteracted by a B 2 stimulant.
7.6. CONCLUSIONS
It is firmly established that beta blockers can 
have a bronchoconstrictive effect, especially in 
asthmatic subjects and possibly also in those with 
irreversible airways obstruction and those with normal 
respiratory function. Most studies evaluating the 
effect of beta blockers have used a single oral or 
intravenous dose of drug in small numbers of subjects, 
who usually have had a degree of obstructive airways 
disease. The present study evaluated the effect of 
chronic oral administration of propranolol and pindolol 
in subjects with angina pectoris. Propranolol caused 
a progressive and highly significant deterioration in 
respiratory function when compared to pindolol. It is 
suggested that pindolol may be a more suitable drug in 
subjects with respiratory disease in whom beta blockade 
is thought to be desirable although respiratory function 
should be monitored from time to time regardless of the 
beta blocker employed.
SECTION 8.
Final Commentary
Refere nces.
8.1. FINAL COMMENTARY.
The medical management of angina pectoris has been 
enhanced by beta-adrenoceptor blockers, with the result 
that many hundreds of thousands of individuals are 
currently being treated on a long-term basis with these 
drugs. Thus, it is vitally important to establish the 
chronic effects of beta blockers and the role of any 
inherent pharmacological property. Despite this, there 
is a paucity of long-term studies evaluating the use of 
beta blockers in angina pectoris. In addition, the 
effect of different pharmacological properties has not 
been fully established.
In this thesis the effects of beta blockers with 
and without ISA have been evaluated. The prototype of a 
beta blocker with ISA was pindolol and that of a pure 
beta blocker, propranolol.
Treatment with propranolol was associated with 
improved left ventricular function, both at rest and 
during exercise at intervals throughout treatment, but no 
significant improvement occurred during treatment with 
pindolol. This result contradicts the findings of 
short-term studies which have suggested improved left 
ventricular performance with beta blockers possessing 
ISA. However, there are no other long-term studies of 
either pure beta blockers or those with ISA with which 
to compare these results. Thus, the work in this thesis
indicates that ISA does not represent an advantage in 
terms of left ventricular performance. It is probable 
that propranolol reduced myocardial oxygen demand at 
rest and during exercise to a greater extent than pindolol, 
and by lowering heart rate by a greater degree, allowed 
more time for diastolic filling of the coronary arteries. 
This may result in improved left ventricular function, 
causing the possible inotropic effect of ISA to be 
undetectable over the long-term.
By assessing the effect of propranolol and 
pindolol in a short-term study using ambulatory electro­
cardiography, I found that there was no significant 
difference between the drugs in their ability to prevent 
symptomatic and asymptomatic myocardial ischaemia judged 
by changes in the ST-segment, although pindolol was 
associated with more episodes of ST-segment depression.
This result, in chronic stable angina, differed from an 
earlier study which found pindolol to be less effective 
in controlling ischaemia, but in subjects with severe, 
or rest angina pectoris.
There are few long-term studies examining the 
effect of beta blockers on plasma lipids, despite several 
short-term studies suggesting possible harmful effects.
In the present studies, I found that pindolol was less 
likely to upset the lipoprotein profile than propranolol, 
and if the pre-treatment total cholesterol level was 
elevated, only pindolol caused a significant fall.
However, the potentially harmful effects of propranolol 
observed in short-term studies were not confirmed. In 
particular, propranolol was found to increase H D L 2 after 
12 months treatment, despite there being a fall in total 
HDL. This effect is potentially beneficial with respect 
to coronary artery disease risk. Pindolol also caused an 
increase in H D L 2 . No other study has carried out such an 
analysis and the results require confirmation. It is 
possible that the failure to reduce cardiovascular 
mortality in several large antihypertension studies is 
a result of the detrimental effect of pure beta blockers 
on plasma lipids. If an alternative beta blocker were to 
prevent these changes, or minimise them, this would be of 
considerable value.
Respiratory function was found to deteriorate in a 
sequential manner during treatment with propranolol - 
this was significantly greater than during treatment with 
pindolol suggesting an advantage of ISA in subjects with 
obstructive airways disease when a beta blocker is felt 
desirable for treatment of angina pectoris.
Finally, the use of radionuclide ventriculography 
and the value of cold pressor testing and sustained 
isometric handgrip exercise were assessed as an integral 
part of this thesis. Previous work has shown inconsistent 
results using these techniques in the detection of coronary 
artery disease, and in our laboratory they proved to be of
only moderate sensitivity. However, their value in the 
serial assessment of left ventricular performance has not 
previously been assessed, and in this respect they were 
useful, easily applied and reproducible interventions.
In summary, although ISA has been found to be., 
potentially useful in terms of respiratory function and, 
plasma lipoprotein responses to beta blockade, it is not 
a useful property in the long-term, when compared to pure 
beta blockade in the control of myocardial ischaemia and 
improvement in left ventricular performance.
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